<!DOCTYPE html><html lang="en" class="bg-surface-base antialiased"><head><meta charSet="utf-8"/><meta name="viewport" content="width=device-width, initial-scale=1, interactive-widget=resizes-content"/><link rel="stylesheet" href="/_next/static/css/62c4caba71dfda84.css" nonce="NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/eb3d87f98fe1565f.css" nonce="NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/1b5e561215938d4d.css" nonce="NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/0227d069a630d414.css" nonce="NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/f87fff2ab93d05a7.css" nonce="NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh" data-precedence="next"/><link rel="preload" as="script" fetchPriority="low" nonce="NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh" href="/_next/static/chunks/webpack-e121ed42680f327e.js"/><script src="/_next/static/chunks/78a669d9-e7993486b22c4915.js" async="" nonce="NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh"></script><script src="/_next/static/chunks/40c4a5a7-abdabb07419d1cfc.js" async="" nonce="NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh"></script><script src="/_next/static/chunks/2230-f7c87dc9fa57c408.js" async="" nonce="NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh"></script><script src="/_next/static/chunks/main-app-536d4b8fca62396a.js" async="" nonce="NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh"></script><script src="/_next/static/chunks/63f0ec43-8ee6a76d70472249.js" async="" nonce="NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh"></script><script src="/_next/static/chunks/7670-7326298c9856172b.js" async="" nonce="NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh"></script><script src="/_next/static/chunks/282-691fffb366e24ca5.js" async="" nonce="NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh"></script><script src="/_next/static/chunks/7515-336759ef5dad2b52.js" async="" nonce="NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh"></script><script src="/_next/static/chunks/927-34e2a6da3e15e26b.js" async="" nonce="NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh"></script><script src="/_next/static/chunks/5855-243eeca8f0e4cabd.js" async="" nonce="NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh"></script><script src="/_next/static/chunks/4393-1c8dff25ec904469.js" async="" nonce="NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh"></script><script src="/_next/static/chunks/2225-454cf9f44775e7ce.js" async="" nonce="NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh"></script><script src="/_next/static/chunks/7618-43536a8fb0dd3bfe.js" async="" nonce="NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js" async="" nonce="NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh"></script><script src="/_next/static/chunks/7720-3a1e7e411adba2d3.js" async="" nonce="NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh"></script><script src="/_next/static/chunks/7086-1f1c4891d766e04f.js" async="" nonce="NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/not-found-69a3edc7db5749d6.js" async="" nonce="NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh"></script><script src="/_next/static/chunks/app/global-error-4d07d20223cd4b4c.js" async="" nonce="NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh"></script><script src="/_next/static/chunks/8208b75a-a48e5a4507a0de91.js" async="" nonce="NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh"></script><script src="/_next/static/chunks/5497-ab85ef3ea59dd353.js" async="" nonce="NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh"></script><script src="/_next/static/chunks/6281-c6e84786dade3614.js" async="" nonce="NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh"></script><script src="/_next/static/chunks/2660-d983a7f287e89f18.js" async="" nonce="NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh"></script><script src="/_next/static/chunks/5002-9735c25beda556ba.js" async="" nonce="NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh"></script><script src="/_next/static/chunks/3655-6717081f7512305a.js" async="" nonce="NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh"></script><script src="/_next/static/chunks/8945-e4e3cf487f5e27c7.js" async="" nonce="NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh"></script><script src="/_next/static/chunks/9214-a10614844a67ba31.js" async="" nonce="NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh"></script><script src="/_next/static/chunks/4789-2080f6497f78b5b6.js" async="" nonce="NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh"></script><script src="/_next/static/chunks/app/layout-226f2bd71acf9f9e.js" async="" nonce="NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh"></script><script src="/_next/static/chunks/24cf1b50-159cca90b09285e0.js" async="" nonce="NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh"></script><script src="/_next/static/chunks/9ffa21ba-c069766d809bd4c7.js" async="" nonce="NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh"></script><script src="/_next/static/chunks/600-9a9fcafaaa6c1c4c.js" async="" nonce="NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh"></script><script src="/_next/static/chunks/5448-2a3cfd853d899c9a.js" async="" nonce="NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh"></script><script src="/_next/static/chunks/8-8ca70ca619d8e099.js" async="" nonce="NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js" async="" nonce="NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh"></script><script src="/_next/static/chunks/app/error-4a29e9399afba038.js" async="" nonce="NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh"></script><script src="/_next/static/chunks/app/not-found-dd95690acf732f18.js" async="" nonce="NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh"></script><meta name="next-size-adjust" content=""/><title>Grokipedia</title><meta name="description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><link rel="icon" type="image/x-icon" href="/favicon.ico" sizes="48x48"/><link rel="icon" href="/images/icon-dark.png" media="(prefers-color-scheme: light)" type="image/png"/><link rel="icon" href="/images/icon-light.png" media="(prefers-color-scheme: dark)" type="image/png"/><link rel="apple-touch-icon" href="/icon-192x192.png"/><link rel="manifest" href="/manifest.webmanifest"/><meta name="robots" content="index, follow"/><meta name="googlebot" content="index, follow, max-snippet:-1"/><meta property="og:title" content="Grokipedia"/><meta property="og:description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><meta property="og:url" content="https://grokipedia.com"/><meta property="og:site_name" content="Grokipedia"/><meta property="og:locale" content="en_US"/><meta property="og:type" content="website"/><meta property="og:image" content="https://grokipedia.com/icon-512x512.png"/><meta property="og:image:width" content="512"/><meta property="og:image:height" content="512"/><meta property="og:image:alt" content="Grokipedia"/><meta name="twitter:card" content="summary"/><meta name="twitter:creator" content="@Grokipedia"/><meta name="twitter:title" content="Grokipedia"/><meta name="twitter:description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><meta name="twitter:image" content="https://grokipedia.com/icon-512x512.png"/><title>Bard (company)</title><meta name="description" content="C. R. Bard, Inc. was a medical technology company specializing in the development, manufacture, and marketing of devices for vascular, urology, oncology, and surgical applications. Founded in 1907 in Covington, Georgia, the company grew to become a leader in products such as catheters, stents, and soft tissue repair meshes, serving hospitals and healthcare professionals worldwide. Headquartered in Murray Hill, New Jersey, Bard employed over 14,000 people and generated significant revenue from..."/><meta name="author" content="system"/><link rel="manifest" href="/manifest.webmanifest"/><meta name="keywords" content="C. R. Bard, C.R. Bard, Inc., CR Bard, Bard Inc."/><meta name="robots" content="index, follow"/><meta name="googlebot" content="index, follow, max-snippet:-1"/><link rel="canonical" href="https://grokipedia.com/page/Bard_(company)"/><meta property="og:title" content="Bard (company)"/><meta property="og:description" content="C. R. Bard, Inc. was a medical technology company specializing in the development, manufacture, and marketing of devices for vascular, urology, oncology, and surgical applications. Founded in 1907 in Covington, Georgia, the company grew to become a leader in products such as catheters, stents, and soft tissue repair meshes, serving hospitals and healthcare professionals worldwide. Headquartered in Murray Hill, New Jersey, Bard employed over 14,000 people and generated significant revenue from..."/><meta property="og:url" content="https://grokipedia.com/page/Bard_(company)"/><meta property="og:site_name" content="Grokipedia"/><meta property="og:locale" content="en"/><meta property="og:image" content="https://grokipedia.com/icon-512x512.png"/><meta property="og:image:width" content="512"/><meta property="og:image:height" content="512"/><meta property="og:image:alt" content="Bard (company)"/><meta property="og:type" content="article"/><meta property="article:modified_time" content="1970-01-21T09:19:44.819Z"/><meta name="twitter:card" content="summary"/><meta name="twitter:creator" content="@Grokipedia"/><meta name="twitter:title" content="Bard (company)"/><meta name="twitter:description" content="C. R. Bard, Inc. was a medical technology company specializing in the development, manufacture, and marketing of devices for vascular, urology, oncology, and surgical applications. Founded in 1907 in Covington, Georgia, the company grew to become a leader in products such as catheters, stents, and soft tissue repair meshes, serving hospitals and healthcare professionals worldwide. Headquartered in Murray Hill, New Jersey, Bard employed over 14,000 people and generated significant revenue from..."/><meta name="twitter:image" content="https://grokipedia.com/icon-512x512.png"/><link rel="icon" href="/favicon.ico" type="image/x-icon" sizes="16x16"/><meta name="sentry-trace" content="026f6221d7abc6fda2e5daeee0abed2b-d71f615e1ebd772f-1"/><meta name="baggage" content="sentry-environment=production,sentry-public_key=5f2258f71198ee26a355127af230c3a6,sentry-trace_id=026f6221d7abc6fda2e5daeee0abed2b,sentry-org_id=4508179396558848,sentry-transaction=GET%20%2Fpage%2F%5Bslug%5D,sentry-sampled=true,sentry-sample_rand=0.006240995526385573,sentry-sample_rate=1"/><script src="/_next/static/chunks/polyfills-42372ed130431b0a.js" noModule="" nonce="NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh"></script></head><body class="flex h-[100svh] w-full flex-col __variable_13c637 __variable_8a0ba0 __variable_779740 __variable_2484fd __variable_525cc3 __variable_13486b"><div hidden=""><!--$--><!--/$--></div><script nonce="NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh">((a,b,c,d,e,f,g,h)=>{let i=document.documentElement,j=["light","dark"];function k(b){var c;(Array.isArray(a)?a:[a]).forEach(a=>{let c="class"===a,d=c&&f?e.map(a=>f[a]||a):e;c?(i.classList.remove(...d),i.classList.add(f&&f[b]?f[b]:b)):i.setAttribute(a,b)}),c=b,h&&j.includes(c)&&(i.style.colorScheme=c)}if(d)k(d);else try{let a=localStorage.getItem(b)||c,d=g&&"system"===a?window.matchMedia("(prefers-color-scheme: dark)").matches?"dark":"light":a;k(d)}catch(a){}})("class","theme","dark",null,["light","dark"],null,true,true)</script><header class="h-16 bg-surface-base fixed top-0 z-50 w-full"><div class="hidden h-full grid-cols-[1fr_3fr_1fr] items-center gap-4 !py-0 md:grid max-w-full py-6 px-4 w-full mx-auto"><div class="-ml-2 justify-self-start"><a class="cursor-pointer" href="/"><svg width="200" height="auto" viewBox="0 0 955 225" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M99.6937 159.214C90.008 159.214 81.5652 157.414 74.3652 153.814C67.1652 150.214 61.5509 144.986 57.5223 138.129C53.5794 131.271 51.608 123.043 51.608 113.443C51.608 103.843 53.5794 95.4857 57.5223 88.3714C61.5509 81.2572 67.1652 75.7286 74.3652 71.7857C81.6509 67.8429 90.1794 65.8714 99.9509 65.8714C103.208 65.8714 106.679 66.1286 110.365 66.6429C114.051 67.0714 117.222 67.6714 119.879 68.4429C121.508 68.8714 123.008 69.2572 124.379 69.6C125.751 69.9429 127.122 70.1143 128.494 70.1143C129.522 70.1143 130.551 69.9857 131.579 69.7286C131.751 73.5 131.922 77.4 132.094 81.4286C132.265 85.4572 132.522 89.6572 132.865 94.0286C131.065 94.2857 129.565 94.3714 128.365 94.2857C126.651 86.4 123.522 80.5714 118.979 76.8C114.437 72.9429 108.394 71.0143 100.851 71.0143C94.8509 71.0143 89.708 72.1286 85.4223 74.3572C81.2223 76.5 77.7937 79.4572 75.1366 83.2286C72.5652 87 70.6794 91.3714 69.4794 96.3429C68.2794 101.229 67.6794 106.457 67.6794 112.029C67.6794 120.171 68.9223 127.371 71.408 133.629C73.8937 139.886 77.6652 144.814 82.7223 148.414C87.8652 151.929 94.2937 153.686 102.008 153.686C104.408 153.686 107.065 153.471 109.979 153.043C112.894 152.529 115.679 151.757 118.337 150.729V134.529C118.337 131.871 118.208 129.814 117.951 128.357C117.779 126.814 117.222 125.7 116.279 125.014C115.422 124.329 114.008 123.857 112.037 123.6C110.151 123.257 107.537 122.957 104.194 122.7C103.937 121.329 103.937 119.957 104.194 118.586C105.994 118.586 108.179 118.629 110.751 118.714C113.322 118.714 115.894 118.757 118.465 118.843C121.122 118.843 123.308 118.843 125.022 118.843C127.679 118.843 130.722 118.8 134.151 118.714C137.665 118.629 140.665 118.586 143.151 118.586C143.322 119.871 143.322 121.2 143.151 122.571C139.637 123 137.108 123.429 135.565 123.857C134.022 124.286 133.079 125.143 132.737 126.429C132.394 127.714 132.222 129.9 132.222 132.986V137.1C132.222 141.129 132.308 144.514 132.479 147.257C132.737 150 132.951 151.971 133.122 153.171C121.208 157.2 110.065 159.214 99.6937 159.214ZM148.19 157.414C147.933 156.043 147.933 154.714 148.19 153.429C151.105 153.257 153.248 153 154.619 152.657C155.99 152.229 156.89 151.371 157.319 150.086C157.748 148.8 157.962 146.743 157.962 143.914V115.114C157.962 111.771 157.79 109.286 157.448 107.657C157.19 106.029 156.376 104.914 155.005 104.314C153.719 103.629 151.49 103.071 148.319 102.643C148.062 101.443 148.062 100.329 148.319 99.3C151.748 98.6143 155.09 97.8429 158.348 96.9857C161.605 96.0429 165.033 94.8429 168.633 93.3857L170.819 94.1572V105.471C176.819 97.8429 182.948 94.0286 189.205 94.0286C192.205 94.0286 194.433 94.8429 195.89 96.4714C197.348 98.0143 198.076 99.7714 198.076 101.743C198.076 104.057 197.305 105.857 195.762 107.143C194.219 108.343 192.462 108.943 190.49 108.943C188.862 108.943 187.233 108.514 185.605 107.657C184.062 106.8 182.905 105.471 182.133 103.671C179.219 103.671 176.605 104.829 174.29 107.143C172.062 109.371 170.948 111.986 170.948 114.986V142.629C170.948 145.971 171.119 148.371 171.462 149.829C171.89 151.286 172.919 152.229 174.548 152.657C176.262 153 179.005 153.257 182.776 153.429C182.948 154.629 182.948 155.957 182.776 157.414C179.862 157.414 176.862 157.371 173.776 157.286C170.69 157.2 167.519 157.157 164.262 157.157C161.09 157.157 158.262 157.2 155.776 157.286C153.376 157.371 150.848 157.414 148.19 157.414ZM229.285 158.829C223.028 158.829 217.542 157.5 212.828 154.843C208.199 152.1 204.599 148.371 202.028 143.657C199.457 138.857 198.171 133.371 198.171 127.2C198.171 120.514 199.499 114.686 202.157 109.714C204.899 104.743 208.714 100.886 213.599 98.1429C218.485 95.4 224.099 94.0286 230.442 94.0286C236.699 94.0286 242.142 95.4 246.771 98.1429C251.399 100.886 254.999 104.657 257.571 109.457C260.142 114.257 261.428 119.7 261.428 125.786C261.428 132.043 260.057 137.7 257.314 142.757C254.657 147.729 250.928 151.671 246.128 154.586C241.328 157.414 235.714 158.829 229.285 158.829ZM212.699 125.657C212.699 134.4 214.114 141.343 216.942 146.486C219.857 151.543 224.185 154.071 229.928 154.071C235.414 154.071 239.614 151.671 242.528 146.871C245.442 141.986 246.899 135.471 246.899 127.329C246.899 118.671 245.442 111.771 242.528 106.629C239.614 101.486 235.371 98.9143 229.799 98.9143C224.314 98.9143 220.071 101.271 217.071 105.986C214.157 110.7 212.699 117.257 212.699 125.657ZM267.394 157.414C267.308 157.071 267.265 156.729 267.265 156.386C267.265 156.043 267.265 155.7 267.265 155.357C267.265 155.014 267.265 154.714 267.265 154.457C267.265 154.114 267.308 153.771 267.394 153.429C270.308 153.257 272.451 153 273.822 152.657C275.194 152.229 276.094 151.371 276.522 150.086C276.951 148.8 277.165 146.743 277.165 143.914V79.5C277.165 76.8429 276.908 74.8714 276.394 73.5857C275.965 72.2143 274.979 71.2714 273.437 70.7572C271.979 70.1572 269.751 69.7286 266.751 69.4714C266.665 69.1286 266.622 68.8286 266.622 68.5714C266.622 68.3143 266.622 68.0572 266.622 67.8C266.622 67.4572 266.622 67.1572 266.622 66.9C266.622 66.6429 266.665 66.3429 266.751 66C270.179 65.5714 273.694 64.9286 277.294 64.0714C280.894 63.1286 284.579 61.8429 288.351 60.2143L290.537 60.9857C290.451 62.8714 290.365 65.0143 290.279 67.4143C290.279 69.8143 290.279 72.4286 290.279 75.2572V122.957C291.308 122.957 292.165 122.786 292.851 122.443C293.537 122.1 294.094 121.757 294.522 121.414C294.694 121.243 295.037 120.943 295.551 120.514C296.065 120 296.965 119.1 298.251 117.814C299.537 116.529 301.379 114.6 303.779 112.029C306.008 109.543 307.765 107.614 309.051 106.243C310.422 104.786 311.108 103.586 311.108 102.643C311.108 101.957 310.508 101.4 309.308 100.971C308.194 100.457 306.651 100.157 304.679 100.071C304.594 99.7286 304.551 99.3857 304.551 99.0429C304.551 98.7 304.551 98.3572 304.551 98.0143C304.551 97.6714 304.551 97.3286 304.551 96.9857C304.551 96.6429 304.594 96.3 304.679 95.9572C306.394 95.9572 308.537 96 311.108 96.0857C313.765 96.1714 316.122 96.2143 318.179 96.2143C319.208 96.2143 320.665 96.2143 322.551 96.2143C324.522 96.1286 326.494 96.0857 328.465 96.0857C330.437 96.0857 331.894 96.0857 332.837 96.0857C332.922 96.4286 332.965 96.7714 332.965 97.1143C333.051 97.4572 333.094 97.8 333.094 98.1429C333.094 98.4857 333.051 98.8286 332.965 99.1714C332.965 99.4286 332.922 99.7286 332.837 100.071C328.379 100.157 324.608 101.271 321.522 103.414C318.437 105.471 315.479 107.914 312.651 110.743L303.394 120L321.137 143.4C323.022 145.886 324.565 147.857 325.765 149.314C327.051 150.686 328.422 151.671 329.879 152.271C331.337 152.871 333.351 153.257 335.922 153.429C336.094 154.629 336.094 155.957 335.922 157.414C334.808 157.414 333.137 157.371 330.908 157.286C328.765 157.2 325.379 157.157 320.751 157.157C320.065 157.157 319.037 157.157 317.665 157.157C316.294 157.157 315.008 157.243 313.808 157.414C313.808 156.471 313.294 155.186 312.265 153.557C311.237 151.843 310.422 150.6 309.822 149.829C309.565 149.4 308.922 148.5 307.894 147.129C306.865 145.671 305.622 144 304.165 142.114C302.794 140.143 301.379 138.171 299.922 136.2C298.465 134.143 297.137 132.343 295.937 130.8C294.994 129.514 294.094 128.529 293.237 127.843C292.465 127.071 291.479 126.686 290.279 126.686V142.629C290.279 145.971 290.408 148.371 290.665 149.829C291.008 151.286 291.737 152.229 292.851 152.657C294.051 153 295.851 153.257 298.251 153.429C298.422 154.714 298.422 156.043 298.251 157.414C296.022 157.414 293.665 157.371 291.179 157.286C288.779 157.2 286.165 157.157 283.337 157.157C280.594 157.157 277.894 157.2 275.237 157.286C272.579 157.371 269.965 157.414 267.394 157.414ZM369.34 157.414C366.94 157.414 364.454 157.371 361.883 157.286C359.311 157.2 356.526 157.157 353.526 157.157C350.783 157.157 347.997 157.2 345.169 157.286C342.426 157.371 339.769 157.414 337.197 157.414C336.94 156.043 336.94 154.714 337.197 153.429C340.111 153.257 342.254 153 343.626 152.657C344.997 152.229 345.897 151.371 346.326 150.086C346.754 148.8 346.969 146.743 346.969 143.914V115.114C346.969 111.771 346.84 109.286 346.583 107.657C346.326 106.029 345.511 104.914 344.14 104.314C342.854 103.629 340.583 103.071 337.326 102.643C337.069 101.443 337.069 100.329 337.326 99.3C341.097 98.6143 344.697 97.7572 348.126 96.7286C351.554 95.7 354.854 94.5857 358.026 93.3857L360.211 94.1572C360.126 96.8143 360.04 99.3 359.954 101.614C359.954 103.929 359.954 106.114 359.954 108.171V142.629C359.954 145.971 360.126 148.371 360.469 149.829C360.897 151.286 361.754 152.229 363.04 152.657C364.411 153 366.511 153.257 369.34 153.429C369.597 154.714 369.597 156.043 369.34 157.414ZM343.626 71.5286C343.626 69.0429 344.483 66.9429 346.197 65.2286C347.997 63.5143 350.14 62.6572 352.626 62.6572C355.026 62.6572 357.083 63.5143 358.797 65.2286C360.597 66.9429 361.497 69 361.497 71.4C361.497 73.6286 360.64 75.6857 358.926 77.5715C357.211 79.3714 355.026 80.2714 352.369 80.2714C349.969 80.2714 347.911 79.4143 346.197 77.7C344.483 75.9857 343.626 73.9286 343.626 71.5286ZM372.678 188.914C372.592 187.543 372.592 186.214 372.678 184.929C375.678 184.757 377.864 184.457 379.235 184.029C380.607 183.6 381.464 182.743 381.807 181.457C382.235 180.257 382.45 178.286 382.45 175.543V115.114C382.45 111.771 382.278 109.286 381.935 107.657C381.678 106.029 380.864 104.914 379.492 104.314C378.207 103.629 375.978 103.071 372.807 102.643C372.635 101.443 372.635 100.329 372.807 99.3C376.321 98.6143 379.75 97.8 383.092 96.8572C386.435 95.9143 389.907 94.7572 393.507 93.3857L395.307 94.2857C395.221 96.4286 395.178 98.2714 395.178 99.8143C395.178 101.271 395.178 102.686 395.178 104.057C398.521 100.543 401.821 98.0143 405.078 96.4714C408.335 94.8429 411.807 94.0286 415.492 94.0286C420.892 94.0286 425.435 95.4429 429.121 98.2714C432.892 101.1 435.764 104.786 437.735 109.329C439.707 113.871 440.692 118.8 440.692 124.114C440.692 130.371 439.321 136.157 436.578 141.471C433.921 146.7 430.192 150.9 425.392 154.071C420.592 157.243 415.021 158.829 408.678 158.829C406.192 158.829 403.835 158.614 401.607 158.186C399.378 157.843 397.278 157.329 395.307 156.643V174C395.307 177.343 395.564 179.743 396.078 181.2C396.592 182.657 397.707 183.557 399.421 183.9C401.135 184.329 403.835 184.629 407.521 184.8C407.607 186.171 407.607 187.543 407.521 188.914C404.607 188.914 401.65 188.871 398.65 188.786C395.735 188.7 392.521 188.657 389.007 188.657C385.664 188.657 382.792 188.7 380.392 188.786C377.992 188.871 375.421 188.914 372.678 188.914ZM395.178 146.1C398.864 151.414 403.75 154.071 409.835 154.071C414.121 154.071 417.507 152.871 419.992 150.471C422.564 148.071 424.407 144.943 425.521 141.086C426.721 137.229 427.321 133.157 427.321 128.871C427.321 124.586 426.764 120.386 425.65 116.271C424.535 112.157 422.692 108.771 420.121 106.114C417.635 103.371 414.207 102 409.835 102C404.607 102 399.721 104.529 395.178 109.586V146.1ZM477.335 158.829C471.25 158.829 466.107 157.414 461.907 154.586C457.707 151.757 454.493 147.986 452.264 143.271C450.121 138.471 449.05 133.2 449.05 127.457C449.05 121.543 450.164 116.057 452.393 111C454.707 105.943 458.05 101.871 462.421 98.7857C466.793 95.6143 472.107 94.0286 478.364 94.0286C485.907 94.0286 491.778 96.3 495.978 100.843C500.264 105.3 502.407 111.086 502.407 118.2C502.407 119.057 502.364 119.829 502.278 120.514C502.278 121.114 502.235 121.629 502.15 122.057L461.65 121.671C461.65 122.014 461.65 122.314 461.65 122.571C461.65 130.971 463.578 137.571 467.435 142.371C471.293 147.171 476.693 149.571 483.635 149.571C489.464 149.571 495.207 147.686 500.864 143.914C501.721 144.943 502.364 145.929 502.793 146.871C495.507 154.843 487.021 158.829 477.335 158.829ZM462.035 116.914L488.65 116.4C488.735 116.229 488.778 116.014 488.778 115.757C488.778 115.414 488.778 115.2 488.778 115.114C488.778 110.486 487.75 106.629 485.693 103.543C483.721 100.457 480.764 98.9143 476.821 98.9143C473.135 98.9143 469.921 100.414 467.178 103.414C464.435 106.414 462.721 110.914 462.035 116.914ZM559.644 158.957L557.587 158.057L557.073 149.186C554.073 152.443 550.987 154.886 547.816 156.514C544.73 158.057 541.302 158.829 537.53 158.829C532.216 158.829 527.544 157.414 523.516 154.586C519.573 151.671 516.53 147.9 514.387 143.271C512.244 138.643 511.173 133.629 511.173 128.229C511.173 121.971 512.502 116.271 515.159 111.129C517.902 105.986 521.716 101.871 526.602 98.7857C531.573 95.6143 537.359 94.0286 543.959 94.0286C545.93 94.0286 547.987 94.2 550.13 94.5429C552.273 94.8 554.502 95.2714 556.816 95.9572V79.5C556.816 76.8429 556.559 74.8714 556.044 73.5857C555.53 72.2143 554.502 71.2714 552.959 70.7572C551.502 70.1572 549.273 69.7286 546.273 69.4714C546.016 68.3572 546.016 67.2 546.273 66C549.702 65.5714 553.216 64.9286 556.816 64.0714C560.416 63.1286 564.102 61.8429 567.873 60.2143L570.059 60.9857C569.973 62.8714 569.887 65.0143 569.802 67.4143C569.802 69.8143 569.802 72.4286 569.802 75.2572V139.029C569.802 142.286 569.93 144.729 570.187 146.357C570.445 147.986 571.216 149.143 572.502 149.829C573.787 150.429 575.973 150.986 579.059 151.5C579.316 152.614 579.316 153.771 579.059 154.971C575.63 155.486 572.287 156.043 569.03 156.643C565.773 157.243 562.644 158.014 559.644 158.957ZM556.944 106.886C553.259 101.829 548.416 99.3 542.416 99.3C536.502 99.3 532.044 101.486 529.044 105.857C526.044 110.143 524.544 116.1 524.544 123.729C524.544 128.186 525.144 132.471 526.344 136.586C527.544 140.7 529.516 144.086 532.259 146.743C535.002 149.4 538.644 150.729 543.187 150.729C548.93 150.729 553.516 148.243 556.944 143.271V106.886ZM615.699 157.414C613.299 157.414 610.813 157.371 608.242 157.286C605.67 157.2 602.885 157.157 599.885 157.157C597.142 157.157 594.356 157.2 591.527 157.286C588.785 157.371 586.127 157.414 583.556 157.414C583.299 156.043 583.299 154.714 583.556 153.429C586.47 153.257 588.613 153 589.985 152.657C591.356 152.229 592.256 151.371 592.685 150.086C593.113 148.8 593.327 146.743 593.327 143.914V115.114C593.327 111.771 593.199 109.286 592.942 107.657C592.685 106.029 591.87 104.914 590.499 104.314C589.213 103.629 586.942 103.071 583.685 102.643C583.427 101.443 583.427 100.329 583.685 99.3C587.456 98.6143 591.056 97.7572 594.485 96.7286C597.913 95.7 601.213 94.5857 604.385 93.3857L606.57 94.1572C606.485 96.8143 606.399 99.3 606.313 101.614C606.313 103.929 606.313 106.114 606.313 108.171V142.629C606.313 145.971 606.485 148.371 606.827 149.829C607.256 151.286 608.113 152.229 609.399 152.657C610.77 153 612.87 153.257 615.699 153.429C615.956 154.714 615.956 156.043 615.699 157.414ZM589.985 71.5286C589.985 69.0429 590.842 66.9429 592.556 65.2286C594.356 63.5143 596.499 62.6572 598.985 62.6572C601.385 62.6572 603.442 63.5143 605.156 65.2286C606.956 66.9429 607.856 69 607.856 71.4C607.856 73.6286 606.999 75.6857 605.285 77.5715C603.57 79.3714 601.385 80.2714 598.727 80.2714C596.327 80.2714 594.27 79.4143 592.556 77.7C590.842 75.9857 589.985 73.9286 589.985 71.5286ZM665.837 158.571C660.18 158.571 656.623 155.743 655.165 150.086C649.08 155.914 642.865 158.829 636.523 158.829C632.151 158.829 628.423 157.543 625.337 154.971C622.337 152.314 620.837 148.671 620.837 144.043C620.837 132.729 632.365 125.614 655.423 122.7C655.423 120.643 655.423 118.543 655.423 116.4C655.508 114.257 655.551 111.986 655.551 109.586C655.551 106.586 654.437 104.271 652.208 102.643C650.065 100.929 647.451 100.071 644.365 100.071C642.137 100.071 640.251 100.414 638.708 101.1C638.708 103.071 638.28 105.086 637.423 107.143C636.565 109.2 635.365 110.957 633.823 112.414C632.365 113.786 630.565 114.471 628.423 114.471C626.537 114.471 625.037 113.957 623.923 112.929C622.894 111.814 622.38 110.486 622.38 108.943C622.38 106.886 623.323 104.957 625.208 103.157C627.18 101.271 629.665 99.6857 632.665 98.4C635.665 97.0286 638.794 95.9572 642.051 95.1857C645.308 94.4143 648.223 94.0286 650.794 94.0286C653.965 94.0286 656.88 94.6286 659.537 95.8286C662.28 96.9429 664.465 98.6572 666.094 100.971C667.808 103.2 668.665 105.986 668.665 109.329C668.665 111.386 668.623 114.086 668.537 117.429C668.451 120.686 668.365 124.2 668.28 127.971C668.28 131.657 668.237 135.171 668.151 138.514C668.065 141.857 668.023 144.557 668.023 146.614C668.023 149.357 669.223 150.729 671.623 150.729C673.165 150.729 675.523 150.214 678.694 149.186C679.037 149.614 679.251 150.086 679.337 150.6C679.508 151.114 679.637 151.586 679.723 152.014C677.58 154.329 675.308 156 672.908 157.029C670.594 158.057 668.237 158.571 665.837 158.571ZM655.165 146.614L655.423 127.329C647.537 128.357 642.094 130.029 639.094 132.343C636.18 134.657 634.723 137.614 634.723 141.214C634.723 144.214 635.494 146.529 637.037 148.157C638.665 149.7 640.68 150.471 643.08 150.471C644.623 150.471 646.337 150.129 648.223 149.443C650.194 148.757 652.508 147.814 655.165 146.614Z" fill="currentColor"></path><rect x="715" y="65" width="195" height="105" rx="52.5" fill="currentColor" fill-opacity="0.05"></rect><path d="M767.529 142.875L754.049 107.938H762.552L769.309 127.582C769.705 128.812 770.078 130.032 770.43 131.24C770.781 132.449 771.078 133.559 771.32 134.569H771.616C771.858 133.559 772.144 132.449 772.473 131.24C772.825 130.032 773.198 128.812 773.594 127.582L780.186 107.938H788.689L775.472 142.875H767.529ZM810.856 143.633C806.901 143.633 803.528 142.71 800.737 140.865C797.969 138.997 795.871 136.305 794.442 132.79C793.014 129.252 792.3 124.989 792.3 120.001V118.255C792.3 113.245 793.014 108.982 794.442 105.467C795.871 101.929 797.969 99.2373 800.737 97.3916C803.528 95.5239 806.901 94.5901 810.856 94.5901C814.789 94.5901 818.129 95.5129 820.875 97.3586C823.644 99.2043 825.731 101.907 827.138 105.467C828.566 109.004 829.28 113.267 829.28 118.255V120.001C829.28 124.989 828.577 129.252 827.171 132.79C825.764 136.327 823.677 139.019 820.908 140.865C818.162 142.71 814.811 143.633 810.856 143.633ZM810.889 136.382C813.064 136.382 814.877 135.789 816.327 134.602C817.799 133.416 818.898 131.658 819.623 129.329C820.348 126.978 820.711 124.066 820.711 120.595V117.694C820.711 114.223 820.337 111.311 819.59 108.96C818.865 106.609 817.777 104.84 816.327 103.654C814.877 102.445 813.064 101.841 810.889 101.841C808.714 101.841 806.879 102.434 805.385 103.621C803.912 104.785 802.792 106.554 802.023 108.927C801.276 111.278 800.902 114.201 800.902 117.694V120.595C800.902 124.044 801.287 126.945 802.056 129.296C802.825 131.647 803.945 133.416 805.418 134.602C806.89 135.789 808.714 136.382 810.889 136.382ZM838.988 143.205C838 143.205 837.099 142.985 836.286 142.545C835.495 142.106 834.879 141.491 834.44 140.7C834.001 139.909 833.781 139.019 833.781 138.03C833.781 137.019 834.001 136.118 834.44 135.327C834.879 134.536 835.495 133.921 836.286 133.482C837.099 133.042 838 132.823 838.988 132.823C839.977 132.823 840.867 133.042 841.658 133.482C842.449 133.921 843.064 134.536 843.504 135.327C843.943 136.118 844.163 137.019 844.163 138.03C844.163 139.019 843.943 139.909 843.504 140.7C843.064 141.491 842.449 142.106 841.658 142.545C840.867 142.985 839.977 143.205 838.988 143.205ZM857.365 142.875V104.511L846.39 111.663V103.357L858.453 95.3481H865.802V142.875H857.365Z" fill="currentColor"></path></svg></a></div><div class="mx-auto flex w-full"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 border-input text-primary hover:border-primary/15 border hover:bg-overlay-hover py-2 max-w-full px-3 shadow-none sm:w-80 focus-visible:z-1 mx-auto h-full w-full rounded-full bg-surface-l1" type="button"><div class="flex items-center justify-between sm:w-full gap-4"><div class="flex items-center justify-start gap-2"><span class="inline-flex items-center justify-center p-0 m-0 w-4 h-4 text-muted" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-4 h-4" focusable="false" style="fill:currentColor"><path d="m18.031 16.617 4.283 4.282-1.415 1.415-4.282-4.283A8.96 8.96 0 0 1 11 20c-4.968 0-9-4.032-9-9s4.032-9 9-9 9 4.032 9 9a8.96 8.96 0 0 1-1.969 5.617m-2.006-.742A6.98 6.98 0 0 0 18 11c0-3.867-3.133-7-7-7s-7 3.133-7 7 3.133 7 7 7a6.98 6.98 0 0 0 4.875-1.975z"></path></svg></span><p class="text-sm text-muted hidden sm:block">Search</p></div><span class="hidden sm:block"><div class="bg-foreground/10 text-muted inline-flex items-center rounded-md px-1 py-0.5 text-center font-sans text-xs font-normal tracking-widest rtl:space-x-reverse"><span>âŒ˜</span><span class="text-xs">K</span></div></span></div></button></div><div class="flex items-center gap-2 justify-self-end"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover px-4 py-2 w-9 h-9 flex-shrink-0" type="button" id="radix-_R_7apfiumdb_" aria-haspopup="menu" aria-expanded="false" data-state="closed"><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 rotate-0 scale-100 transition-all dark:-rotate-90 dark:scale-0" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M12 18a6 6 0 1 1 0-12 6 6 0 0 1 0 12m0-2a4 4 0 1 0 0-8 4 4 0 0 0 0 8M11 1h2v3h-2zm0 19h2v3h-2zM3.515 4.929l1.414-1.414L7.05 5.636 5.636 7.05zM16.95 18.364l1.414-1.414 2.121 2.121-1.414 1.414zm2.121-14.85 1.414 1.415-2.121 2.121-1.414-1.414zM5.636 16.95l1.414 1.414-2.121 2.121-1.414-1.414zM23 11v2h-3v-2zM4 11v2H1v-2z"></path></svg></span><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 absolute rotate-90 scale-0 transition-all dark:rotate-0 dark:scale-100" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M10 7a7 7 0 0 0 12 4.9v.1c0 5.523-4.477 10-10 10S2 17.523 2 12 6.477 2 12 2h.1A6.98 6.98 0 0 0 10 7m-6 5a8 8 0 0 0 15.062 3.762A9 9 0 0 1 8.238 4.938 8 8 0 0 0 4 12"></path></svg></span><span class="sr-only">Toggle theme</span></button></div></div><div class="flex h-full items-center md:hidden justify-between max-w-full py-6 px-4 w-full mx-auto pt-8"><div class="flex items-center"><div class="-ml-2"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover h-9 w-9" type="button" aria-label="Toggle table of contents"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-list h-6 w-6"><path d="M3 12h.01"></path><path d="M3 18h.01"></path><path d="M3 6h.01"></path><path d="M8 12h13"></path><path d="M8 18h13"></path><path d="M8 6h13"></path></svg></button></div><a class="cursor-pointer" href="/"><svg width="160" height="auto" viewBox="0 0 955 225" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M99.6937 159.214C90.008 159.214 81.5652 157.414 74.3652 153.814C67.1652 150.214 61.5509 144.986 57.5223 138.129C53.5794 131.271 51.608 123.043 51.608 113.443C51.608 103.843 53.5794 95.4857 57.5223 88.3714C61.5509 81.2572 67.1652 75.7286 74.3652 71.7857C81.6509 67.8429 90.1794 65.8714 99.9509 65.8714C103.208 65.8714 106.679 66.1286 110.365 66.6429C114.051 67.0714 117.222 67.6714 119.879 68.4429C121.508 68.8714 123.008 69.2572 124.379 69.6C125.751 69.9429 127.122 70.1143 128.494 70.1143C129.522 70.1143 130.551 69.9857 131.579 69.7286C131.751 73.5 131.922 77.4 132.094 81.4286C132.265 85.4572 132.522 89.6572 132.865 94.0286C131.065 94.2857 129.565 94.3714 128.365 94.2857C126.651 86.4 123.522 80.5714 118.979 76.8C114.437 72.9429 108.394 71.0143 100.851 71.0143C94.8509 71.0143 89.708 72.1286 85.4223 74.3572C81.2223 76.5 77.7937 79.4572 75.1366 83.2286C72.5652 87 70.6794 91.3714 69.4794 96.3429C68.2794 101.229 67.6794 106.457 67.6794 112.029C67.6794 120.171 68.9223 127.371 71.408 133.629C73.8937 139.886 77.6652 144.814 82.7223 148.414C87.8652 151.929 94.2937 153.686 102.008 153.686C104.408 153.686 107.065 153.471 109.979 153.043C112.894 152.529 115.679 151.757 118.337 150.729V134.529C118.337 131.871 118.208 129.814 117.951 128.357C117.779 126.814 117.222 125.7 116.279 125.014C115.422 124.329 114.008 123.857 112.037 123.6C110.151 123.257 107.537 122.957 104.194 122.7C103.937 121.329 103.937 119.957 104.194 118.586C105.994 118.586 108.179 118.629 110.751 118.714C113.322 118.714 115.894 118.757 118.465 118.843C121.122 118.843 123.308 118.843 125.022 118.843C127.679 118.843 130.722 118.8 134.151 118.714C137.665 118.629 140.665 118.586 143.151 118.586C143.322 119.871 143.322 121.2 143.151 122.571C139.637 123 137.108 123.429 135.565 123.857C134.022 124.286 133.079 125.143 132.737 126.429C132.394 127.714 132.222 129.9 132.222 132.986V137.1C132.222 141.129 132.308 144.514 132.479 147.257C132.737 150 132.951 151.971 133.122 153.171C121.208 157.2 110.065 159.214 99.6937 159.214ZM148.19 157.414C147.933 156.043 147.933 154.714 148.19 153.429C151.105 153.257 153.248 153 154.619 152.657C155.99 152.229 156.89 151.371 157.319 150.086C157.748 148.8 157.962 146.743 157.962 143.914V115.114C157.962 111.771 157.79 109.286 157.448 107.657C157.19 106.029 156.376 104.914 155.005 104.314C153.719 103.629 151.49 103.071 148.319 102.643C148.062 101.443 148.062 100.329 148.319 99.3C151.748 98.6143 155.09 97.8429 158.348 96.9857C161.605 96.0429 165.033 94.8429 168.633 93.3857L170.819 94.1572V105.471C176.819 97.8429 182.948 94.0286 189.205 94.0286C192.205 94.0286 194.433 94.8429 195.89 96.4714C197.348 98.0143 198.076 99.7714 198.076 101.743C198.076 104.057 197.305 105.857 195.762 107.143C194.219 108.343 192.462 108.943 190.49 108.943C188.862 108.943 187.233 108.514 185.605 107.657C184.062 106.8 182.905 105.471 182.133 103.671C179.219 103.671 176.605 104.829 174.29 107.143C172.062 109.371 170.948 111.986 170.948 114.986V142.629C170.948 145.971 171.119 148.371 171.462 149.829C171.89 151.286 172.919 152.229 174.548 152.657C176.262 153 179.005 153.257 182.776 153.429C182.948 154.629 182.948 155.957 182.776 157.414C179.862 157.414 176.862 157.371 173.776 157.286C170.69 157.2 167.519 157.157 164.262 157.157C161.09 157.157 158.262 157.2 155.776 157.286C153.376 157.371 150.848 157.414 148.19 157.414ZM229.285 158.829C223.028 158.829 217.542 157.5 212.828 154.843C208.199 152.1 204.599 148.371 202.028 143.657C199.457 138.857 198.171 133.371 198.171 127.2C198.171 120.514 199.499 114.686 202.157 109.714C204.899 104.743 208.714 100.886 213.599 98.1429C218.485 95.4 224.099 94.0286 230.442 94.0286C236.699 94.0286 242.142 95.4 246.771 98.1429C251.399 100.886 254.999 104.657 257.571 109.457C260.142 114.257 261.428 119.7 261.428 125.786C261.428 132.043 260.057 137.7 257.314 142.757C254.657 147.729 250.928 151.671 246.128 154.586C241.328 157.414 235.714 158.829 229.285 158.829ZM212.699 125.657C212.699 134.4 214.114 141.343 216.942 146.486C219.857 151.543 224.185 154.071 229.928 154.071C235.414 154.071 239.614 151.671 242.528 146.871C245.442 141.986 246.899 135.471 246.899 127.329C246.899 118.671 245.442 111.771 242.528 106.629C239.614 101.486 235.371 98.9143 229.799 98.9143C224.314 98.9143 220.071 101.271 217.071 105.986C214.157 110.7 212.699 117.257 212.699 125.657ZM267.394 157.414C267.308 157.071 267.265 156.729 267.265 156.386C267.265 156.043 267.265 155.7 267.265 155.357C267.265 155.014 267.265 154.714 267.265 154.457C267.265 154.114 267.308 153.771 267.394 153.429C270.308 153.257 272.451 153 273.822 152.657C275.194 152.229 276.094 151.371 276.522 150.086C276.951 148.8 277.165 146.743 277.165 143.914V79.5C277.165 76.8429 276.908 74.8714 276.394 73.5857C275.965 72.2143 274.979 71.2714 273.437 70.7572C271.979 70.1572 269.751 69.7286 266.751 69.4714C266.665 69.1286 266.622 68.8286 266.622 68.5714C266.622 68.3143 266.622 68.0572 266.622 67.8C266.622 67.4572 266.622 67.1572 266.622 66.9C266.622 66.6429 266.665 66.3429 266.751 66C270.179 65.5714 273.694 64.9286 277.294 64.0714C280.894 63.1286 284.579 61.8429 288.351 60.2143L290.537 60.9857C290.451 62.8714 290.365 65.0143 290.279 67.4143C290.279 69.8143 290.279 72.4286 290.279 75.2572V122.957C291.308 122.957 292.165 122.786 292.851 122.443C293.537 122.1 294.094 121.757 294.522 121.414C294.694 121.243 295.037 120.943 295.551 120.514C296.065 120 296.965 119.1 298.251 117.814C299.537 116.529 301.379 114.6 303.779 112.029C306.008 109.543 307.765 107.614 309.051 106.243C310.422 104.786 311.108 103.586 311.108 102.643C311.108 101.957 310.508 101.4 309.308 100.971C308.194 100.457 306.651 100.157 304.679 100.071C304.594 99.7286 304.551 99.3857 304.551 99.0429C304.551 98.7 304.551 98.3572 304.551 98.0143C304.551 97.6714 304.551 97.3286 304.551 96.9857C304.551 96.6429 304.594 96.3 304.679 95.9572C306.394 95.9572 308.537 96 311.108 96.0857C313.765 96.1714 316.122 96.2143 318.179 96.2143C319.208 96.2143 320.665 96.2143 322.551 96.2143C324.522 96.1286 326.494 96.0857 328.465 96.0857C330.437 96.0857 331.894 96.0857 332.837 96.0857C332.922 96.4286 332.965 96.7714 332.965 97.1143C333.051 97.4572 333.094 97.8 333.094 98.1429C333.094 98.4857 333.051 98.8286 332.965 99.1714C332.965 99.4286 332.922 99.7286 332.837 100.071C328.379 100.157 324.608 101.271 321.522 103.414C318.437 105.471 315.479 107.914 312.651 110.743L303.394 120L321.137 143.4C323.022 145.886 324.565 147.857 325.765 149.314C327.051 150.686 328.422 151.671 329.879 152.271C331.337 152.871 333.351 153.257 335.922 153.429C336.094 154.629 336.094 155.957 335.922 157.414C334.808 157.414 333.137 157.371 330.908 157.286C328.765 157.2 325.379 157.157 320.751 157.157C320.065 157.157 319.037 157.157 317.665 157.157C316.294 157.157 315.008 157.243 313.808 157.414C313.808 156.471 313.294 155.186 312.265 153.557C311.237 151.843 310.422 150.6 309.822 149.829C309.565 149.4 308.922 148.5 307.894 147.129C306.865 145.671 305.622 144 304.165 142.114C302.794 140.143 301.379 138.171 299.922 136.2C298.465 134.143 297.137 132.343 295.937 130.8C294.994 129.514 294.094 128.529 293.237 127.843C292.465 127.071 291.479 126.686 290.279 126.686V142.629C290.279 145.971 290.408 148.371 290.665 149.829C291.008 151.286 291.737 152.229 292.851 152.657C294.051 153 295.851 153.257 298.251 153.429C298.422 154.714 298.422 156.043 298.251 157.414C296.022 157.414 293.665 157.371 291.179 157.286C288.779 157.2 286.165 157.157 283.337 157.157C280.594 157.157 277.894 157.2 275.237 157.286C272.579 157.371 269.965 157.414 267.394 157.414ZM369.34 157.414C366.94 157.414 364.454 157.371 361.883 157.286C359.311 157.2 356.526 157.157 353.526 157.157C350.783 157.157 347.997 157.2 345.169 157.286C342.426 157.371 339.769 157.414 337.197 157.414C336.94 156.043 336.94 154.714 337.197 153.429C340.111 153.257 342.254 153 343.626 152.657C344.997 152.229 345.897 151.371 346.326 150.086C346.754 148.8 346.969 146.743 346.969 143.914V115.114C346.969 111.771 346.84 109.286 346.583 107.657C346.326 106.029 345.511 104.914 344.14 104.314C342.854 103.629 340.583 103.071 337.326 102.643C337.069 101.443 337.069 100.329 337.326 99.3C341.097 98.6143 344.697 97.7572 348.126 96.7286C351.554 95.7 354.854 94.5857 358.026 93.3857L360.211 94.1572C360.126 96.8143 360.04 99.3 359.954 101.614C359.954 103.929 359.954 106.114 359.954 108.171V142.629C359.954 145.971 360.126 148.371 360.469 149.829C360.897 151.286 361.754 152.229 363.04 152.657C364.411 153 366.511 153.257 369.34 153.429C369.597 154.714 369.597 156.043 369.34 157.414ZM343.626 71.5286C343.626 69.0429 344.483 66.9429 346.197 65.2286C347.997 63.5143 350.14 62.6572 352.626 62.6572C355.026 62.6572 357.083 63.5143 358.797 65.2286C360.597 66.9429 361.497 69 361.497 71.4C361.497 73.6286 360.64 75.6857 358.926 77.5715C357.211 79.3714 355.026 80.2714 352.369 80.2714C349.969 80.2714 347.911 79.4143 346.197 77.7C344.483 75.9857 343.626 73.9286 343.626 71.5286ZM372.678 188.914C372.592 187.543 372.592 186.214 372.678 184.929C375.678 184.757 377.864 184.457 379.235 184.029C380.607 183.6 381.464 182.743 381.807 181.457C382.235 180.257 382.45 178.286 382.45 175.543V115.114C382.45 111.771 382.278 109.286 381.935 107.657C381.678 106.029 380.864 104.914 379.492 104.314C378.207 103.629 375.978 103.071 372.807 102.643C372.635 101.443 372.635 100.329 372.807 99.3C376.321 98.6143 379.75 97.8 383.092 96.8572C386.435 95.9143 389.907 94.7572 393.507 93.3857L395.307 94.2857C395.221 96.4286 395.178 98.2714 395.178 99.8143C395.178 101.271 395.178 102.686 395.178 104.057C398.521 100.543 401.821 98.0143 405.078 96.4714C408.335 94.8429 411.807 94.0286 415.492 94.0286C420.892 94.0286 425.435 95.4429 429.121 98.2714C432.892 101.1 435.764 104.786 437.735 109.329C439.707 113.871 440.692 118.8 440.692 124.114C440.692 130.371 439.321 136.157 436.578 141.471C433.921 146.7 430.192 150.9 425.392 154.071C420.592 157.243 415.021 158.829 408.678 158.829C406.192 158.829 403.835 158.614 401.607 158.186C399.378 157.843 397.278 157.329 395.307 156.643V174C395.307 177.343 395.564 179.743 396.078 181.2C396.592 182.657 397.707 183.557 399.421 183.9C401.135 184.329 403.835 184.629 407.521 184.8C407.607 186.171 407.607 187.543 407.521 188.914C404.607 188.914 401.65 188.871 398.65 188.786C395.735 188.7 392.521 188.657 389.007 188.657C385.664 188.657 382.792 188.7 380.392 188.786C377.992 188.871 375.421 188.914 372.678 188.914ZM395.178 146.1C398.864 151.414 403.75 154.071 409.835 154.071C414.121 154.071 417.507 152.871 419.992 150.471C422.564 148.071 424.407 144.943 425.521 141.086C426.721 137.229 427.321 133.157 427.321 128.871C427.321 124.586 426.764 120.386 425.65 116.271C424.535 112.157 422.692 108.771 420.121 106.114C417.635 103.371 414.207 102 409.835 102C404.607 102 399.721 104.529 395.178 109.586V146.1ZM477.335 158.829C471.25 158.829 466.107 157.414 461.907 154.586C457.707 151.757 454.493 147.986 452.264 143.271C450.121 138.471 449.05 133.2 449.05 127.457C449.05 121.543 450.164 116.057 452.393 111C454.707 105.943 458.05 101.871 462.421 98.7857C466.793 95.6143 472.107 94.0286 478.364 94.0286C485.907 94.0286 491.778 96.3 495.978 100.843C500.264 105.3 502.407 111.086 502.407 118.2C502.407 119.057 502.364 119.829 502.278 120.514C502.278 121.114 502.235 121.629 502.15 122.057L461.65 121.671C461.65 122.014 461.65 122.314 461.65 122.571C461.65 130.971 463.578 137.571 467.435 142.371C471.293 147.171 476.693 149.571 483.635 149.571C489.464 149.571 495.207 147.686 500.864 143.914C501.721 144.943 502.364 145.929 502.793 146.871C495.507 154.843 487.021 158.829 477.335 158.829ZM462.035 116.914L488.65 116.4C488.735 116.229 488.778 116.014 488.778 115.757C488.778 115.414 488.778 115.2 488.778 115.114C488.778 110.486 487.75 106.629 485.693 103.543C483.721 100.457 480.764 98.9143 476.821 98.9143C473.135 98.9143 469.921 100.414 467.178 103.414C464.435 106.414 462.721 110.914 462.035 116.914ZM559.644 158.957L557.587 158.057L557.073 149.186C554.073 152.443 550.987 154.886 547.816 156.514C544.73 158.057 541.302 158.829 537.53 158.829C532.216 158.829 527.544 157.414 523.516 154.586C519.573 151.671 516.53 147.9 514.387 143.271C512.244 138.643 511.173 133.629 511.173 128.229C511.173 121.971 512.502 116.271 515.159 111.129C517.902 105.986 521.716 101.871 526.602 98.7857C531.573 95.6143 537.359 94.0286 543.959 94.0286C545.93 94.0286 547.987 94.2 550.13 94.5429C552.273 94.8 554.502 95.2714 556.816 95.9572V79.5C556.816 76.8429 556.559 74.8714 556.044 73.5857C555.53 72.2143 554.502 71.2714 552.959 70.7572C551.502 70.1572 549.273 69.7286 546.273 69.4714C546.016 68.3572 546.016 67.2 546.273 66C549.702 65.5714 553.216 64.9286 556.816 64.0714C560.416 63.1286 564.102 61.8429 567.873 60.2143L570.059 60.9857C569.973 62.8714 569.887 65.0143 569.802 67.4143C569.802 69.8143 569.802 72.4286 569.802 75.2572V139.029C569.802 142.286 569.93 144.729 570.187 146.357C570.445 147.986 571.216 149.143 572.502 149.829C573.787 150.429 575.973 150.986 579.059 151.5C579.316 152.614 579.316 153.771 579.059 154.971C575.63 155.486 572.287 156.043 569.03 156.643C565.773 157.243 562.644 158.014 559.644 158.957ZM556.944 106.886C553.259 101.829 548.416 99.3 542.416 99.3C536.502 99.3 532.044 101.486 529.044 105.857C526.044 110.143 524.544 116.1 524.544 123.729C524.544 128.186 525.144 132.471 526.344 136.586C527.544 140.7 529.516 144.086 532.259 146.743C535.002 149.4 538.644 150.729 543.187 150.729C548.93 150.729 553.516 148.243 556.944 143.271V106.886ZM615.699 157.414C613.299 157.414 610.813 157.371 608.242 157.286C605.67 157.2 602.885 157.157 599.885 157.157C597.142 157.157 594.356 157.2 591.527 157.286C588.785 157.371 586.127 157.414 583.556 157.414C583.299 156.043 583.299 154.714 583.556 153.429C586.47 153.257 588.613 153 589.985 152.657C591.356 152.229 592.256 151.371 592.685 150.086C593.113 148.8 593.327 146.743 593.327 143.914V115.114C593.327 111.771 593.199 109.286 592.942 107.657C592.685 106.029 591.87 104.914 590.499 104.314C589.213 103.629 586.942 103.071 583.685 102.643C583.427 101.443 583.427 100.329 583.685 99.3C587.456 98.6143 591.056 97.7572 594.485 96.7286C597.913 95.7 601.213 94.5857 604.385 93.3857L606.57 94.1572C606.485 96.8143 606.399 99.3 606.313 101.614C606.313 103.929 606.313 106.114 606.313 108.171V142.629C606.313 145.971 606.485 148.371 606.827 149.829C607.256 151.286 608.113 152.229 609.399 152.657C610.77 153 612.87 153.257 615.699 153.429C615.956 154.714 615.956 156.043 615.699 157.414ZM589.985 71.5286C589.985 69.0429 590.842 66.9429 592.556 65.2286C594.356 63.5143 596.499 62.6572 598.985 62.6572C601.385 62.6572 603.442 63.5143 605.156 65.2286C606.956 66.9429 607.856 69 607.856 71.4C607.856 73.6286 606.999 75.6857 605.285 77.5715C603.57 79.3714 601.385 80.2714 598.727 80.2714C596.327 80.2714 594.27 79.4143 592.556 77.7C590.842 75.9857 589.985 73.9286 589.985 71.5286ZM665.837 158.571C660.18 158.571 656.623 155.743 655.165 150.086C649.08 155.914 642.865 158.829 636.523 158.829C632.151 158.829 628.423 157.543 625.337 154.971C622.337 152.314 620.837 148.671 620.837 144.043C620.837 132.729 632.365 125.614 655.423 122.7C655.423 120.643 655.423 118.543 655.423 116.4C655.508 114.257 655.551 111.986 655.551 109.586C655.551 106.586 654.437 104.271 652.208 102.643C650.065 100.929 647.451 100.071 644.365 100.071C642.137 100.071 640.251 100.414 638.708 101.1C638.708 103.071 638.28 105.086 637.423 107.143C636.565 109.2 635.365 110.957 633.823 112.414C632.365 113.786 630.565 114.471 628.423 114.471C626.537 114.471 625.037 113.957 623.923 112.929C622.894 111.814 622.38 110.486 622.38 108.943C622.38 106.886 623.323 104.957 625.208 103.157C627.18 101.271 629.665 99.6857 632.665 98.4C635.665 97.0286 638.794 95.9572 642.051 95.1857C645.308 94.4143 648.223 94.0286 650.794 94.0286C653.965 94.0286 656.88 94.6286 659.537 95.8286C662.28 96.9429 664.465 98.6572 666.094 100.971C667.808 103.2 668.665 105.986 668.665 109.329C668.665 111.386 668.623 114.086 668.537 117.429C668.451 120.686 668.365 124.2 668.28 127.971C668.28 131.657 668.237 135.171 668.151 138.514C668.065 141.857 668.023 144.557 668.023 146.614C668.023 149.357 669.223 150.729 671.623 150.729C673.165 150.729 675.523 150.214 678.694 149.186C679.037 149.614 679.251 150.086 679.337 150.6C679.508 151.114 679.637 151.586 679.723 152.014C677.58 154.329 675.308 156 672.908 157.029C670.594 158.057 668.237 158.571 665.837 158.571ZM655.165 146.614L655.423 127.329C647.537 128.357 642.094 130.029 639.094 132.343C636.18 134.657 634.723 137.614 634.723 141.214C634.723 144.214 635.494 146.529 637.037 148.157C638.665 149.7 640.68 150.471 643.08 150.471C644.623 150.471 646.337 150.129 648.223 149.443C650.194 148.757 652.508 147.814 655.165 146.614Z" fill="currentColor"></path><rect x="715" y="65" width="195" height="105" rx="52.5" fill="currentColor" fill-opacity="0.05"></rect><path d="M767.529 142.875L754.049 107.938H762.552L769.309 127.582C769.705 128.812 770.078 130.032 770.43 131.24C770.781 132.449 771.078 133.559 771.32 134.569H771.616C771.858 133.559 772.144 132.449 772.473 131.24C772.825 130.032 773.198 128.812 773.594 127.582L780.186 107.938H788.689L775.472 142.875H767.529ZM810.856 143.633C806.901 143.633 803.528 142.71 800.737 140.865C797.969 138.997 795.871 136.305 794.442 132.79C793.014 129.252 792.3 124.989 792.3 120.001V118.255C792.3 113.245 793.014 108.982 794.442 105.467C795.871 101.929 797.969 99.2373 800.737 97.3916C803.528 95.5239 806.901 94.5901 810.856 94.5901C814.789 94.5901 818.129 95.5129 820.875 97.3586C823.644 99.2043 825.731 101.907 827.138 105.467C828.566 109.004 829.28 113.267 829.28 118.255V120.001C829.28 124.989 828.577 129.252 827.171 132.79C825.764 136.327 823.677 139.019 820.908 140.865C818.162 142.71 814.811 143.633 810.856 143.633ZM810.889 136.382C813.064 136.382 814.877 135.789 816.327 134.602C817.799 133.416 818.898 131.658 819.623 129.329C820.348 126.978 820.711 124.066 820.711 120.595V117.694C820.711 114.223 820.337 111.311 819.59 108.96C818.865 106.609 817.777 104.84 816.327 103.654C814.877 102.445 813.064 101.841 810.889 101.841C808.714 101.841 806.879 102.434 805.385 103.621C803.912 104.785 802.792 106.554 802.023 108.927C801.276 111.278 800.902 114.201 800.902 117.694V120.595C800.902 124.044 801.287 126.945 802.056 129.296C802.825 131.647 803.945 133.416 805.418 134.602C806.89 135.789 808.714 136.382 810.889 136.382ZM838.988 143.205C838 143.205 837.099 142.985 836.286 142.545C835.495 142.106 834.879 141.491 834.44 140.7C834.001 139.909 833.781 139.019 833.781 138.03C833.781 137.019 834.001 136.118 834.44 135.327C834.879 134.536 835.495 133.921 836.286 133.482C837.099 133.042 838 132.823 838.988 132.823C839.977 132.823 840.867 133.042 841.658 133.482C842.449 133.921 843.064 134.536 843.504 135.327C843.943 136.118 844.163 137.019 844.163 138.03C844.163 139.019 843.943 139.909 843.504 140.7C843.064 141.491 842.449 142.106 841.658 142.545C840.867 142.985 839.977 143.205 838.988 143.205ZM857.365 142.875V104.511L846.39 111.663V103.357L858.453 95.3481H865.802V142.875H857.365Z" fill="currentColor"></path></svg></a></div><div class="flex items-center gap-1"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover px-4 py-2 w-9 h-9 flex-shrink-0 [&amp;_svg]:!w-5" type="button" id="radix-_R_aipfiumdb_" aria-haspopup="menu" aria-expanded="false" data-state="closed"><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 rotate-0 scale-100 transition-all dark:-rotate-90 dark:scale-0" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M12 18a6 6 0 1 1 0-12 6 6 0 0 1 0 12m0-2a4 4 0 1 0 0-8 4 4 0 0 0 0 8M11 1h2v3h-2zm0 19h2v3h-2zM3.515 4.929l1.414-1.414L7.05 5.636 5.636 7.05zM16.95 18.364l1.414-1.414 2.121 2.121-1.414 1.414zm2.121-14.85 1.414 1.415-2.121 2.121-1.414-1.414zM5.636 16.95l1.414 1.414-2.121 2.121-1.414-1.414zM23 11v2h-3v-2zM4 11v2H1v-2z"></path></svg></span><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 absolute rotate-90 scale-0 transition-all dark:rotate-0 dark:scale-100" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M10 7a7 7 0 0 0 12 4.9v.1c0 5.523-4.477 10-10 10S2 17.523 2 12 6.477 2 12 2h.1A6.98 6.98 0 0 0 10 7m-6 5a8 8 0 0 0 15.062 3.762A9 9 0 0 1 8.238 4.938 8 8 0 0 0 4 12"></path></svg></span><span class="sr-only">Toggle theme</span></button><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover h-9 w-9" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-search h-5 w-5"><circle cx="11" cy="11" r="8"></circle><path d="m21 21-4.3-4.3"></path></svg></button></div></div></header><div class="bg-surface-base fixed right-0 top-16 z-50 h-[calc(100vh-4rem)] w-full transform border-l transition-transform duration-300 ease-in-out sm:w-1/2 md:hidden translate-x-full"><div class="flex flex-col gap-4 p-4"><div class="flex flex-row gap-2"><button class="focus-visible:ring-ring inline-flex items-center gap-x-2 whitespace-nowrap text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 border-input text-primary hover:border-primary/15 border hover:bg-overlay-hover py-2 max-w-full shadow-none sm:w-80 h-10 w-full justify-start rounded-full bg-surface-l1 px-4" type="button"><div class="flex items-center justify-between sm:w-full gap-4"><div class="flex items-center justify-start gap-2"><span class="inline-flex items-center justify-center p-0 m-0 w-4 h-4 text-muted" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-4 h-4" focusable="false" style="fill:currentColor"><path d="m18.031 16.617 4.283 4.282-1.415 1.415-4.282-4.283A8.96 8.96 0 0 1 11 20c-4.968 0-9-4.032-9-9s4.032-9 9-9 9 4.032 9 9a8.96 8.96 0 0 1-1.969 5.617m-2.006-.742A6.98 6.98 0 0 0 18 11c0-3.867-3.133-7-7-7s-7 3.133-7 7 3.133 7 7 7a6.98 6.98 0 0 0 4.875-1.975z"></path></svg></span><p class="text-sm text-muted hidden sm:block">Search</p></div><span class="hidden sm:block"><div class="bg-foreground/10 text-muted inline-flex items-center rounded-md px-1 py-0.5 text-center font-sans text-xs font-normal tracking-widest rtl:space-x-reverse"><span>âŒ˜</span><span class="text-xs">K</span></div></span></div></button></div></div></div><div><div class="min-[1350px]:grid min-[1350px]:grid-cols-[1fr_3fr_1fr]"><nav class="bg-surface-base hidden h-[calc(100vh-4rem)] overflow-y-auto px-6 pb-32 min-[1350px]:sticky min-[1350px]:top-16 min-[1350px]:block scrollbar-none [-ms-overflow-style:none] [scrollbar-width:none] [&amp;::-webkit-scrollbar]:hidden [overscroll-behavior:contain] pt-8"><ul class="space-y-2 text-sm"><li style="padding-left:0rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#bard-company" class="transition-opacity hover:opacity-100 opacity-50">Bard (company)</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#history" class="transition-opacity hover:opacity-100 opacity-50">History</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#founding-and-early-development" class="transition-opacity hover:opacity-100 opacity-50">Founding and Early Development</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#mid-20th-century-growth-and-diversification" class="transition-opacity hover:opacity-100 opacity-50">Mid-20th Century Growth and Diversification</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#late-20th-and-early-21st-century-acquisitions" class="transition-opacity hover:opacity-100 opacity-50">Late 20th and Early 21st Century Acquisitions</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#acquisition-by-becton-dickinson" class="transition-opacity hover:opacity-100 opacity-50">Acquisition by Becton Dickinson</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#products-and-technologies" class="transition-opacity hover:opacity-100 opacity-50">Products and Technologies</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#urology-and-urological-devices" class="transition-opacity hover:opacity-100 opacity-50">Urology and Urological Devices</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#vascular-access-and-intervention-devices" class="transition-opacity hover:opacity-100 opacity-50">Vascular Access and Intervention Devices</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#oncology-and-radiation-therapy-products" class="transition-opacity hover:opacity-100 opacity-50">Oncology and Radiation Therapy Products</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#surgical-and-hernia-repair-devices" class="transition-opacity hover:opacity-100 opacity-50">Surgical and Hernia Repair Devices</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#innovations-and-contributions" class="transition-opacity hover:opacity-100 opacity-50">Innovations and Contributions</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#key-technological-breakthroughs" class="transition-opacity hover:opacity-100 opacity-50">Key Technological Breakthroughs</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#clinical-impact-and-patient-outcomes-data" class="transition-opacity hover:opacity-100 opacity-50">Clinical Impact and Patient Outcomes Data</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#legal-and-regulatory-issues" class="transition-opacity hover:opacity-100 opacity-50">Legal and Regulatory Issues</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#anti-kickback-settlements" class="transition-opacity hover:opacity-100 opacity-50">Anti-Kickback Settlements</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#transvaginal-mesh-litigation" class="transition-opacity hover:opacity-100 opacity-50">Transvaginal Mesh Litigation</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#inferior-vena-cava-ivc-filter-cases" class="transition-opacity hover:opacity-100 opacity-50">Inferior Vena Cava (IVC) Filter Cases</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#hernia-mesh-disputes" class="transition-opacity hover:opacity-100 opacity-50">Hernia Mesh Disputes</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#fda-warnings-recalls-and-compliance" class="transition-opacity hover:opacity-100 opacity-50">FDA Warnings, Recalls, and Compliance</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#references" class="transition-opacity hover:opacity-100 opacity-50">References</a></li></ul></nav><div class="relative top-16 pb-32 pt-8 px-4 md:px-8"><div class="mx-auto max-w-[850px]"><button data-state="closed" type="button" class="flex items-center"><div class="text-fg-tertiary mb-2 flex cursor-help items-center gap-2 text-sm"><span class="inline-flex items-center justify-center p-0 m-0" data-namespace="@xai/icons" data-slot="icon" style="height:16px;width:16px"><svg xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 33 33" aria-hidden="true" class="" focusable="false" style="fill:currentColor;height:16px;width:16px"><path fill="currentColor" d="m13.237 21.04 11.082-8.19c.543-.4 1.32-.244 1.578.38 1.363 3.288.754 7.241-1.957 9.955-2.71 2.714-6.482 3.31-9.93 1.954l-3.765 1.745c5.401 3.697 11.96 2.782 16.059-1.324 3.251-3.255 4.258-7.692 3.317-11.693l.008.009c-1.365-5.878.336-8.227 3.82-13.031q.123-.17.247-.345l-4.585 4.59v-.014L13.234 21.044M10.95 23.031c-3.877-3.707-3.208-9.446.1-12.755 2.446-2.449 6.454-3.448 9.952-1.979L24.76 6.56c-.677-.49-1.545-1.017-2.54-1.387A12.465 12.465 0 0 0 8.675 7.901c-3.519 3.523-4.625 8.94-2.725 13.561 1.42 3.454-.907 5.898-3.251 8.364-.83.874-1.664 1.749-2.335 2.674l10.583-9.466"></path></svg></span><span>Fact-checked by Grok<!-- --> <!-- -->4 days ago</span></div></button><article class="text-[16px]"><h1 id="bard-company" class="group relative mb-2 scroll-mt-24 font-serif text-[2.125em] font-semibold tracking-[-1px] [&amp;:not(:first-child)]:mt-14" node="[object Object]">Bard (company)<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h1>
<span class="mb-4 block break-words text-[1em] leading-7"></span>
<span class="mb-4 block break-words text-[1em] leading-7">C. R. Bard, Inc. was a medical technology company specializing in the development, manufacture, and marketing of devices for vascular, urology, oncology, and surgical applications.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_41abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> Founded in 1907 in Covington, Georgia, the company grew to become a leader in products such as catheters, stents, and soft tissue repair meshes, serving hospitals and healthcare professionals worldwide.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_81abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> Headquartered in Murray Hill, New Jersey, Bard employed over 14,000 people and generated significant revenue from its specialized medical solutions prior to its acquisition.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In 2017, Becton, Dickinson and Company (BD) completed the acquisition of C. R. Bard for approximately $24 billion, integrating Bard&#x27;s portfolio into BD&#x27;s broader offerings in diagnostics, medical devices, and biosciences, thereby creating a combined entity with enhanced capabilities in peripheral vascular disease, urology, and hernia repair.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_41qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_61qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup> Bard&#x27;s innovations, including its BardÂ® Mesh for tension-free hernia repairs with over 50 years of clinical use, underscored its contributions to minimally invasive procedures.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a1qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup> However, the company encountered major controversies involving product liability lawsuits, particularly over transvaginal mesh and hernia mesh devices alleged to cause injuries, resulting in multibillion-dollar settlements and highlighting risks in implantable medical technologies.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_e1qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[7]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_g1qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup></span>
<h2 id="history" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">History<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="founding-and-early-development" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Founding and Early Development<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Charles Russell Bard established the company in New York City in 1907, initially focusing on the U.S. distribution of a urethral catheter developed by the French firm J. Eynard.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_43abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup> This venture marked the beginnings of what would become a specialized medical device enterprise, emphasizing urological products imported from Europe.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_83abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In 1915, Bard partnered with inventor Morgan Parker to form Bard-Parker Co. Inc., which produced detachable-blade scalpels, expanding into surgical instruments.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_43qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup> Bard incorporated his primary business as C.R. Bard, Inc. in 1923, hiring James Vassar as its first full-time salesperson, though he sold his interest in the scalpel partnership to Parker that year for $23,000.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_83qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup> By 1926, facing operational challenges, Bard sold the incorporated company to John Frederick Willits and Edson L. Outwin for $18,000, with Willits assuming the role of president and Outwin serving as vice-president and treasurer.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c3qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_e3qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Under new ownership, C.R. Bard continued importing European catheters while beginning to distribute the Foley catheter in 1934, a significant advancement in urological drainage technology invented by Frederic Foley.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_44abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup> The company&#x27;s early growth relied on these imported and distributed devices, serving hospitals and medical professionals, though World War II disruptions in 1940 prompted a shift toward U.S.-sourced alternatives through partnerships like U.S. Catheter and Instrument Corporation (USCI).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_84abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup> This period laid the foundation for Bard&#x27;s focus on minimally invasive medical solutions, establishing its reputation in urology prior to broader diversification.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c4abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup></span>
<h3 id="mid-20th-century-growth-and-diversification" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Mid-20th Century Growth and Diversification<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Following World War II disruptions in European imports, C.R. Bard partnered with the United States Catheter and Instrument Corporation (USCI) in 1944 to distribute the first American-manufactured woven catheters, shifting production to domestic synthetics like nylon.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_45abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_65abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup> By 1945, net sales had risen 150% from 1935 levels, reflecting postwar demand for urological products.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup> In 1948, the company relocated its headquarters to a 5,400-square-foot facility in Summit, New Jersey, surpassing $1 million in annual sales and adding 18 employees.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_e5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The 1950s marked accelerated growth, with net sales expanding over 400% and workforce reaching 200 employees; by decade&#x27;s end, all products were manufactured in the United States, eliminating reliance on foreign suppliers.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_45qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_65qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup> A key innovation came in 1957â€“1958, when Bard introduced pre-sterilized, packaged Foley catheters, which reduced hospital preparation costs and infection risks by enabling direct use from packaging.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a5qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c5qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Entering the 1960s, Bard diversified beyond urology into cardiology, radiology, and anesthesiology, beginning manufacturing of additional medical devices in 1961.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_46abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup> Net sales climbed to $51 million by 1969, supported by workforce expansion to 2,200 employees and a new 50,000-square-foot headquarters in Murray Hill, New Jersey.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_86abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup> The company went public on the over-the-counter market in 1963 and initiated in-house production of medical plastic tubing in 1964, alongside establishing C.R. Bard Limited in Toronto to serve the Canadian market.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c6abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_e6abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup> Diversification accelerated through the 1966 acquisition of USCI, which broadened offerings in urological and cardiovascular products.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_i6abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_k6abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup> By 1968, Bard&#x27;s stock listed on the New York Stock Exchange, coinciding with a 172,000-square-foot manufacturing plant opening in Murray Hill.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_o6abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup></span>
<h3 id="late-20th-and-early-21st-century-acquisitions" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Late 20th and Early 21st Century Acquisitions<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">In the 1980s, C.R. Bard expanded its urology and vascular product lines through strategic purchases. In 1980, the company acquired Davol Inc. and its international subsidiary from International Paper Company, gaining control over the production of Foley catheters and other latex-based urinary products that had previously been supplied under a long-term relationship.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_47abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup> This move integrated manufacturing in-house and bolstered Bard&#x27;s position in disposable urological devices. Later in the decade, in 1989, Bard purchased Catheter Technology Corporation, adding specialized vascular access catheters to its portfolio.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_87abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The 1990s saw Bard pursue acquisitions to enter oncology diagnostics and advanced vascular interventions. In 1993, it acquired Bainbridge Sciences Inc., which provided diagnostic tests for early detection of prostate, bladder, cervical, and lung cancers, enhancing Bard&#x27;s oncology offerings.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_47qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup> The 1994 acquisition of Angiomed AG introduced self-expanding vascular stents and biliary stents, expanding Bard&#x27;s endovascular capabilities.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_87qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a7qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup> In 1995, Bard acquired MedChem Products, Inc. in a stock swap valued at approximately $100 million, incorporating neonatal and adult catheters along with surgical drainage products.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_e7qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup> The decade closed with the 1996 purchase of Impra, Inc. for about $143 million, securing vascular grafts used in blood vessel replacement surgeries, and the acquisition of Dymax, Inc., which added ultrasound guidance technology for catheter insertions.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_i7qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_k7qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Entering the 2000s, Bard focused on surgical repair and biopsy technologies amid growing demand for minimally invasive procedures. In 2001, it acquired Surgical Sense, Inc., obtaining the Kugel Hernia Patch, a composite mesh device for hernia repairs that later faced regulatory scrutiny for defects.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_48abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_68abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup> By 2003, Bard bought assets from Source Tech Medical, LLC for iodine-125 seeds used in prostate brachytherapy, as well as select assets from Prostate Services of America, Inc. and Imagyn Medical Technologies, Inc., strengthening its radiation therapy and women&#x27;s health segments.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a8abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> In 2004, the acquisition of Onux Medical, Inc. brought the Salute fixation system for securing prosthetic patches during hernia surgeries.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_e8abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup> Additional early 21st-century deals included Biomedical Instruments and Products GmbH for vacuum-assisted breast biopsy devices and the LifeStent product line from Edwards Lifesciences for peripheral vascular stenting.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_i8abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup> These moves diversified Bard&#x27;s technologies but also introduced products linked to subsequent litigation over safety issues.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_m8abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup></span>
<h3 id="acquisition-by-becton-dickinson" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Acquisition by Becton Dickinson<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">On April 23, 2017, Becton, Dickinson and Company (BD) announced its agreement to acquire C. R. Bard, Inc. for approximately $24 billion in a cash-and-stock transaction, representing a 25% premium over Bard&#x27;s closing share price on April 21, 2017.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_49abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_69abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[10]</sup> Under the terms, Bard shareholders received $222.93 in cash and 0.5077 shares of BD common stock per Bard share, valuing each Bard share at $317.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a9abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[10]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c9abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup> The deal aimed to combine BD&#x27;s expertise in medication delivery and diagnostics with Bard&#x27;s strengths in vascular, urology, and oncology devices, projecting $300 million in annual pre-tax cost synergies by fiscal year 2020.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_g9abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Bard shareholders approved the merger on August 8, 2017, with approximately 99% of votes cast in favor.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_49qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[12]</sup> Regulatory scrutiny followed, including second requests from the U.S. Federal Trade Commission (FTC) in June 2017 under the Hart-Scott-Rodino Act, European Commission clearance on October 18, 2017, and final approval from China&#x27;s Ministry of Commerce (MOFCOM) on December 28, 2017.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_89qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a9qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[14]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c9qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[15]</sup> The acquisition closed on December 29, 2017, after satisfying all customary closing conditions, resulting in Bard&#x27;s common stock ceasing to trade and being delisted from the New York Stock Exchange.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_g9qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_i9qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[16]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The merger created a combined entity with approximately $16 billion in annualized revenue, positioning BD as a leading global provider of medical technology solutions across vascular access, urological care, oncology interventions, and surgical devices.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4aabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6aabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[17]</sup> Vincent A. Forlenza, then BD&#x27;s chairman and CEO, described the integration as enhancing BD&#x27;s ability to address complex health care challenges through expanded innovation and scale.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_aaabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[15]</sup> Post-acquisition, BD reorganized its structure to incorporate Bard&#x27;s operations, focusing on realizing operational efficiencies while maintaining distinct product portfolios.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_eaabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup></span>
<h2 id="products-and-technologies" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Products and Technologies<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="urology-and-urological-devices" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Urology and Urological Devices<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">C.R. Bard&#x27;s urology division, now integrated into Becton Dickinson&#x27;s (BD) Acute Urology portfolio following the 2017 acquisition, specializes in devices for bladder management, urinary drainage, and endourological procedures. The company&#x27;s foundational contribution to urology was the introduction of the Foley indwelling catheter in 1934, which enabled continuous bladder drainage and marked a significant advancement in managing urinary retention and incontinence.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4bqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[18]</sup> By the 1950s, Bard had shifted to U.S.-based manufacturing of its urological products, and in 1958, it pioneered pre-sterilized, packaged Foley catheters to reduce infection risks associated with preparation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8bqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Key urological devices include a broad array of catheters designed to minimize complications such as catheter-associated urinary tract infections (CAUTIs). Indwelling options feature silicone-based Foley catheters, which are latex-free and provide enhanced patient comfort for long-term use, available in 2-way and 3-way configurations with balloon capacities from 3-30 cc.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4cabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[19]</sup> Intermittent catheters, such as the Bard Magic3, incorporate coatings like Micro-Hole Zone Technology for reduced friction and improved drainage.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8cabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[20]</sup> External catheters, including male and female variants like the PureWick system, offer non-invasive urine collection alternatives, supporting CAUTI prevention protocols.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ccabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[18]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In endourology, Bard developed ureteral stents and catheters for upper urinary tract drainage. The Bard Inlay and Inlay VerSaFit ureteral stents facilitate urine flow from the kidney to the bladder, with features like dual-durometer construction for flexibility and radiopaque markers for imaging guidance. The Urinary Diversion Stent supports drainage in uretero-intestinal diversion procedures post-surgery.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4cqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[21]</sup> Accessory products encompass urinary drainage bags, leg bags, and stabilization devices like the STATLOCK Foley Stabilization Device, which secure catheters to prevent migration and trauma.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8cqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[20]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Bard also innovated in infection-resistant technologies, with FDA approval in 1994 for urinary catheters incorporating hydrophilic coatings, such as those from Bactiguard partnerships, to lower bacterial adhesion.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4dabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[22]</sup> These devices collectively address acute and chronic urological needs, with Bard&#x27;s portfolio emphasizing biocompatibility, ease of insertion, and reduced healthcare-associated infections through material advancements like silicone and antimicrobial surfaces.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8dabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[18]</sup></span>
<h3 id="vascular-access-and-intervention-devices" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Vascular Access and Intervention Devices<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">C.R. Bard&#x27;s vascular access portfolio encompassed devices for short- and long-term intravenous access, including peripherally inserted central catheters (PICCs), midline catheters, central venous catheters, and implantable ports. These products facilitated the delivery of medications, fluids, nutrition, and contrast agents while aiming to minimize complications such as infection and thrombosis. The GroshongÂ® catheter, introduced with a slit valve mechanism at the distal tip, allowed passive flow control to reduce the need for heparin flushes and limit blood reflux, thereby potentially lowering occlusion rates compared to open-ended designs.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4eabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[23]</sup> Similarly, Bard&#x27;s PowerPICCÂ® catheters supported power injection for CT imaging, enabling rates up to 5 mL/second with pressures up to 300 psi, which expanded their utility in diagnostic procedures.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8eabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[24]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Implantable vascular access devices from Bard, such as the PowerPortÂ® implantable port, featured titanium construction and silicone septums rated for high-pressure power injection, accommodating up to 5 mL/second flows for contrast-enhanced imaging. This design addressed limitations of earlier ports by supporting radiopaque identification and catheter securement to prevent migration. Bard also developed guidance technologies, including the Site-RiteÂ® ultrasound systems with needle guides, to enhance first-insertion success rates and reduce arterial punctures during catheter placement.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4eqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[23]</sup> Care and maintenance products, like antimicrobial dressings and securement devices, complemented the access portfolio to extend dwell times and mitigate central line-associated bloodstream infections.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8eqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[24]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In vascular intervention, Bard&#x27;s Peripheral Vascular division produced stents and delivery systems for treating peripheral artery disease and other occlusive conditions. The LifeStentÂ® Vascular Stent System, a flexible nitinol self-expanding stent, was indicated for improving luminal diameter in symptomatic de novo or restenotic lesions up to 240 mm long in the superficial femoral and proximal popliteal arteries, with FDA approval granted in 2009 and subsequent expansions.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4fabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup> The COVERAâ„¢ Vascular Covered Stent, featuring ePTFE encapsulation over a nitinol frame, provided barrier properties against tissue ingrowth while maintaining flexibility for deployment in iliac and superficial femoral arteries. Bard further offered vascular access grafts, such as the V. AscendÂ® series, constructed from expanded polytetrafluoroethylene (ePTFE) for hemodialysis arteriovenous access, emphasizing kink resistance and reduced infection profiles through tissue ingrowth promotion.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8fabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[26]</sup> These intervention devices integrated with Bard&#x27;s introducer sets and sheaths to support minimally invasive endovascular procedures.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cfabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[27]</sup></span>
<h3 id="oncology-and-radiation-therapy-products" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Oncology and Radiation Therapy Products<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">C.R. Bard developed brachytherapy seeds for localized radiation delivery in prostate cancer treatment, utilizing iodine-125 (I-125) isotopes permanently implanted via needles to target tumor cells directly while sparing adjacent healthy tissue.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4gabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[28]</sup> The BrachySourceâ„¢ I-125 Seed Implant incorporates a polymer coating and embedded gold markers for radiopaque visualization under fluoroscopy, facilitating precise dosimetry and post-implant verification.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8gabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[29]</sup> These seeds, typically 4.5 mm in length and 0.8 mm in diameter, emit low-energy gamma radiation over a half-life of approximately 59.4 days, with indications for early-stage prostate cancer as monotherapy or adjunct to external beam radiation for residual or recurrent tumors.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cgabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[30]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Bard also produced implantable vascular access devices compatible with radiation therapy protocols, including the M.R.I.â„¢ Dual-Lumen Implantable Port, featuring large silicone septa and plastic construction to minimize imaging artifacts during MRI or radiotherapy sessions.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4gqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[31]</sup> The PowerPortâ„¢ ClearVUEâ„¢ ports employ a metal-free, clear silicone dome for power injection up to 5 mL/second at 300 psi, reducing radiation scatter in CT or fluoroscopy-guided procedures common in oncology.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8gqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[32]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">For intraoperative oncology applications, Bard&#x27;s Gamma FinderÂ® III wireless gamma probe detects emissions in the 20-512 keV range from technetium-99m radiotracers, enabling sentinel lymph node localization in breast cancer and melanoma surgeries with directional sensitivity and audio/visual feedback.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4habav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[33]</sup> The 2010 acquisition of SenoRx for $213 million integrated vacuum-assisted biopsy systems like EnCor Enspireâ„¢, which support stereotactic, ultrasound, and MRI-guided tissue sampling for breast oncology diagnostics prior to radiation planning.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8habav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[34]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ahabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[35]</sup></span>
<h3 id="surgical-and-hernia-repair-devices" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Surgical and Hernia Repair Devices<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">C.R. Bard developed and marketed a range of synthetic mesh implants and fixation devices for hernia repair, primarily targeting inguinal, ventral, incisional, and umbilical hernias. These products emphasized tension-free surgical techniques, utilizing materials such as monofilament polypropylene to reinforce abdominal walls while facilitating tissue integration and reducing recurrence risks. Bard&#x27;s hernia portfolio, managed through its Davol subsidiary, included both flat sheets and pre-shaped implants designed for open and laparoscopic procedures.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4iabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6iabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[36]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Key offerings encompassed Bard Mesh, a lightweight monofilament polypropylene sheet introduced as the standard for tension-free repairs, which promotes rapid tissue ingrowth due to its large pore structure and has been in clinical use for over 40 years.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4iqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup> The Ventralex ST Hernia Patch, cleared by the FDA for umbilical and epigastric hernias as well as trocar site closure, incorporates an absorbable hydrogel barrier on the visceral side to prevent unintended adhesions to bowel tissue during the critical healing phase.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8iqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[37]</sup> Plug-style devices like the PerFix Plug Mesh provided cone-shaped polypropylene implants for inguinal hernia occlusion, often combined with overlying patches for layered reinforcement in open repairs.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ciqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[38]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Bard also produced anatomically contoured meshes, such as the 3DMax Mesh and 3DMax Light variants, featuring macroporous polypropylene with pre-formed shapes to conform to pelvic anatomy, minimizing folding and improving fit in minimally invasive inguinal repairs.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4jabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[36]</sup> Composite products like Composix L/P Mesh integrated a low-profile polypropylene layer with an ePTFE barrier to reduce visceral attachments in ventral applications.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8jabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[38]</sup> These designs addressed biomechanical needs by balancing strength, flexibility, and porosity, with weights typically ranging from light (under 50 g/mÂ²) to standard grades for varying defect sizes.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cjabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[39]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In terms of technological advancements, Bard focused on enhancing deployment precision and biocompatibility. By 2019, the company secured FDA 510(k) clearance for a laparoscopic delivery system enabling tetherless mesh placement, which preclinical testing demonstrated improved accuracy and reduced operative time in minimally invasive hernia repairs compared to traditional methods.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4jqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[40]</sup> Earlier innovations included soft, large-pore variants like Bard Soft Mesh, engineered for reduced foreign body reaction through minimized material density while maintaining tensile strength exceeding 16 N/cm in both warp and weft directions.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8jqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[41]</sup> Following Bard&#x27;s acquisition by Becton Dickinson in December 2017, these products integrated into BD&#x27;s broader soft tissue repair lineup, sustaining emphasis on durable, non-absorbable synthetics over bioresorbable alternatives for long-term reinforcement.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cjqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[36]</sup></span>
<h2 id="innovations-and-contributions" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Innovations and Contributions<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="key-technological-breakthroughs" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Key Technological Breakthroughs<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">C. R. Bard&#x27;s early advancements in urological devices centered on the commercialization of the indwelling Foley catheter in 1934, which provided a self-retaining mechanism for continuous urinary drainage, significantly improving patient management for conditions requiring prolonged catheterization compared to prior intermittent methods.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4labav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[18]</sup> This innovation, originally designed by Frederic Foley, was scaled for market distribution by Bard, marking a pivotal shift toward reliable, balloon-retained catheters that reduced procedural frequency and complications like bladder spasms.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8labav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[42]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In the mid-20th century, Bard advanced catheter materials and designs to address infection risks and biocompatibility issues inherent in early latex models. By the late 1960s, the company introduced Teflon-coated latex catheters, which facilitated smoother insertion and limited bacterial adhesion, thereby decreasing urinary tract infection rates associated with indwelling devices.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4lqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[43]</sup> Concurrently, Bard pioneered in-house production of medical plastic tubing in 1964, enabling customized intravenous and drainage lines that enhanced sterility and precision in fluid management.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8lqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup> These developments laid the groundwork for disposable, single-patient-use products, a hallmark of Bard&#x27;s approach to minimizing cross-contamination in hospital settings.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_clqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[44]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In vascular access, Bard contributed to breakthroughs in central venous catheterization, particularly through the evolution of peripherally inserted central catheters (PICCs) optimized for power injection. The PowerPICC catheter, cleared by the FDA in 2016 for high-flow rates up to 5 mL/second, allowed safe administration of CT contrast media directly via peripheral insertion, reducing the need for more invasive central lines and improving imaging diagnostics for vascular and oncological conditions.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4mabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[45]</sup> This built on Bard&#x27;s broader expertise in antimicrobial coatings for PICCs, which incorporated technologies like chlorhexidine to combat catheter-related bloodstream infections, a leading cause of hospital-acquired morbidity.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8mabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[46]</sup></span>
<h3 id="clinical-impact-and-patient-outcomes-data" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Clinical Impact and Patient Outcomes Data<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Bard&#x27;s silver-alloy hydrogel-coated urinary catheters have shown significant reductions in catheter-associated urinary tract infections (CAUTIs) in clinical settings. In a multicenter before-after cohort study involving adult patients across seven acute care hospitals, implementation of these catheters resulted in a 47% relative reduction in symptomatic CAUTI rates (0.945 to 0.498 per 1000 patient days; odds ratio 0.53, P &lt; .0001) and a 58% reduction in National Healthcare Safety Network-defined CAUTIs (0.60 to 0.25 per 1000 patient days; odds ratio 0.42, P &lt; .0001), alongside decreased antimicrobial use for CAUTIs (1165 to 406 days).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4nabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[47]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In vascular access, Bard&#x27;s COVERAâ„¢ arteriovenous stent graft demonstrated high target lesion primary patency and safety in treating venous outflow stenoses in dialysis access circuits. The AVeNEW PAS prospective multicenter study reported 82.2% target lesion primary patency at 6 months (Kaplan-Meier estimate) among 93 patients, with 60.0% access circuit primary patency, 100% acute technical success, and 94.9% freedom from primary safety events at 30 days; complications were minimal, including no device-related deaths.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4nqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[48]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Bard stent grafts, such as the Fluencyâ„¢ system, have improved patency outcomes in dialysis circuits compared to percutaneous transluminal angioplasty (PTA). Randomized trials including FLAIR showed 51% treatment area patency at 6 months versus 23% with PTA (P &lt; .001) and 38% access circuit patency versus 20% (P = 0.008); RENOVA reported 47.6% versus 24.8% at 12 months (P &lt; .001); and RESCUE found 66.4% treatment area patency versus 12.3% at 6 months (P &lt; .001), with overall reductions in reintervention rates but no differences in complications or survival.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4oabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[49]</sup></span>





























<div class="border-border-l1 overflow-x-auto rounded-lg border my-6 w-full"><table node="[object Object]" class="w-full border-collapse text-sm"><thead node="[object Object]" class="border-border-l1 border-b bg-surface-l1"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Trial</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Device Comparison</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">6-Month Treatment Area Patency</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Clinical Impact</span></th></tr></thead><tbody node="[object Object]" class="divide-border-l1 divide-y"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">FLAIR</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Bard Fluency Stent Graft vs. PTA</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">51% vs. 23% (P &lt; .001)</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Reduced reinterventions; lower costs in some scenarios</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">RESCUE</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Stent Graft vs. PTA</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">66.4% vs. 12.3% (P &lt; .001)</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Extended time to next intervention</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">RENOVA</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Stent Graft vs. PTA</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Sustained benefits to 24 months (26.9% vs. 13.5%, P &lt; .001)</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Improved durability in high-risk grafts</span></td></tr></tbody></table></div>
<span class="mb-4 block break-words text-[1em] leading-7">For surgical hernia repair, Bard&#x27;s Phasixâ„¢ poly-4-hydroxybutyrate (P4HB) mesh has been associated with low complication rates and durable repairs in high-risk patients. A prospective multicenter study of ventral or incisional hernia repair with Phasix mesh reported favorable 3-year outcomes, including low recurrence and surgical site occurrences in cohorts at risk for complications, with improvements in quality of life metrics.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4pabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[50]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6pabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[51]</sup></span>
<h2 id="legal-and-regulatory-issues" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Legal and Regulatory Issues<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="anti-kickback-settlements" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Anti-Kickback Settlements<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">In January 2025, C.R. Bard, Inc., along with affiliates Liberator Medical Supply, Inc., Liberator Holdings, LLC, and Rochester Medical Corporation, agreed to pay $17 million to resolve allegations under the False Claims Act stemming from violations of the Anti-Kickback Statute.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4qqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[52]</sup> The U.S. Department of Justice claimed that from approximately 2016 to 2022, the companies provided unlawful remuneration, including free supplies, volume-based discounts, and other incentives, to urology practices to induce purchases and prescriptions of Bard&#x27;s intermittent catheters reimbursable by Medicare, Medicaid, and other federal healthcare programs.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8qqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[53]</sup> Bard did not admit liability in the settlement, which was initiated by a whistleblower qui tam action under the False Claims Act.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cqqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[52]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Earlier, in May 2013, C.R. Bard, Inc. settled False Claims Act allegations for $48.26 million related to Anti-Kickback Statute violations occurring between 1998 and 2006.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4rabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[28]</sup> The government alleged that Bard offered physicians and hospitals inducements such as unrestricted grant money, rebates, advertising support, and free equipment to encourage purchases of Bard&#x27;s products, including brachytherapy seeds used in prostate cancer treatment and other medical devices reimbursable by federal programs.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8rabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[54]</sup> These practices purportedly generated false claims submitted to Medicare and other programs; Bard again denied wrongdoing in the resolution.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_crabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[28]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In September 2025, Bard Peripheral Vascular, Inc.â€”a Bard subsidiaryâ€”and related entities settled for approximately $7.25 million as part of a broader $37 million False Claims Act resolution involving Semler Scientific, Inc., over kickback allegations tied to diagnostic testing devices.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4rqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[55]</sup> The claims centered on remuneration provided to physicians from 2017 to 2023 to promote orders of Bard-distributed FloChec and EverFlow tests for peripheral artery disease, leading to reimbursable claims under federal healthcare programs.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8rqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[55]</sup> No admission of liability occurred, and the settlement addressed inducements like speaker fees and consulting payments lacking fair market value.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_crqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[55]</sup></span>
<h3 id="transvaginal-mesh-litigation" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Transvaginal Mesh Litigation<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">C.R. Bard, Inc. faced thousands of lawsuits alleging that its transvaginal mesh products, particularly the Avaulta Solo and Avaulta Forte systems introduced in the mid-2000s for treating pelvic organ prolapse and stress urinary incontinence, caused severe complications including mesh erosion, chronic pain, organ perforation, and recurrent infections requiring multiple revision surgeries.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4sqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[56]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6sqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[57]</sup> Plaintiffs claimed the polypropylene mesh was defectively designed and inadequately tested, with Bard failing to warn adequately about risks despite internal knowledge of issues.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_asqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[58]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Litigation consolidated into multidistrict proceedings in the U.S. District Court for the Southern District of West Virginia, where bellwether trials tested claims; Bard defended by arguing the devices&#x27; benefits outweighed disclosed risks and that complications stemmed from surgical technique or patient factors rather than inherent defects.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4tabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[59]</sup> Early verdicts included a $5.5 million award in 2012 to a California plaintiff who underwent eight revision surgeries after Avaulta implantation, and a $2 million compensatory damages ruling in a Georgia state court case against Bard.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8tabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[60]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_atabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[61]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">To resolve mounting claims, Bard reached settlements totaling hundreds of millions; in October 2014, it agreed to pay over $21 million to resolve more than 500 Avaulta cases, averaging approximately $43,000 per claimant without admitting liability.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4tqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[56]</sup> This was followed by a $200 million global settlement in August 2015 covering about 3,000 additional pelvic mesh lawsuits, including Avaulta-related claims, amid ongoing trials and FDA scrutiny of transvaginal mesh risks.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8tqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[62]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_atqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[63]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Despite these resolutions, over 10,000 cases remained unresolved as of mid-decade, with some later trials yielding large plaintiff verdicts, such as $68 million in compensatory and punitive damages from a New Jersey jury in 2014 (upheld on appeal in part).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4uabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[64]</sup> Bard discontinued U.S. sales of its transvaginal mesh for prolapse in 2016, aligning with FDA reclassification of such devices as high-risk Class III requiring premarket approval, though no Bard-specific recall occurred.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8uabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[59]</sup> The litigation contributed to broader industry shifts, including the FDA&#x27;s 2019 order halting sales of transvaginal mesh for prolapse repair due to disproportionate risks versus benefits.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cuabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[65]</sup></span>
<h3 id="inferior-vena-cava-ivc-filter-cases" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Inferior Vena Cava (IVC) Filter Cases<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">The Inferior Vena Cava (IVC) filter products manufactured by C.R. Bard, including the Recovery, G2, G2X, Eclipse, and Meridian models, were designed to prevent pulmonary embolisms by capturing blood clots in patients at high risk for deep vein thrombosis.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4vabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[66]</sup> These retrievable filters faced allegations in lawsuits that they exhibited higher rates of complications such as strut fracture, migration, tilting, and perforation of the IVC wall or adjacent organs compared to predicate devices, leading to risks of embolization, hemorrhage, and death.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8vabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[67]</sup> Plaintiffs claimed Bard failed to adequately warn of these risks and continued marketing despite internal awareness of elevated adverse event reports, including data from the FDA&#x27;s MAUDE database showing Bard filters linked to 39 deaths as reported by NBC investigations.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cvabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[68]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Litigation consolidated into multidistrict proceedings (MDL No. 2185) in the U.S. District Court for the District of Arizona, where thousands of cases alleged design defects, manufacturing flaws, and inadequate testing under theories of strict liability, negligence, and failure to warn.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4vqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[66]</sup> Bellwether trials tested key issues: In October 2018, a jury awarded $3.6 million ($1.6 million compensatory and $2 million punitive) to a plaintiff injured by a fracturing G2 filter that migrated and perforated organs.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8vqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[69]</sup> A subsequent verdict in 2019 granted $926,000 to another plaintiff for similar G2 complications.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cvqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[66]</sup> In July 2021, verdicts included $386,250 for Recovery filter fracture causing embolization and $3.3 million (upheld on appeal) for a Meridian filter leg that embolized to the heart, as awarded to Natalie Johnson in Wisconsin federal court.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gvqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[70]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ivqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[71]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Bard defended the filters as safe and effective when used per instructions for short-term implantation in appropriately selected patients, arguing that complications often stemmed from off-label permanent use or patient factors rather than inherent defects, and citing FDA approval via 510(k) clearance.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_50abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[66]</sup> However, juries in multiple bellwether cases found Bard liable for defective design and punitive damages, with one Dallas firm securing verdicts totaling over $7 million across several Recovery and G2 filter injury claims by July 2021.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_90abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[72]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">By March 2024, the MDL remained active with ongoing settlements, though most cases had resolved confidentially, and lawyers continued filing new claims.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_50qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[66]</sup> As of October 2025, the Bard IVC filter MDL closed following agreements on major settlement terms, resolving remaining inventory cases without public disclosure of total amounts, while emphasizing Bard&#x27;s (now BD&#x27;s) position that the devices prevented countless emboli.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_90qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[73]</sup> An analysis of 557 Bard IVC filter cases in litigation reported common complications including 30% IVC penetration, 30% migration, and 26% fracture rates, with 45% requiring intervention.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d0qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[67]</sup></span>
<h3 id="hernia-mesh-disputes" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Hernia Mesh Disputes<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">C.R. Bard, Inc., through its Davol subsidiary, produced polypropylene-based hernia mesh devices such as the Ventralex, Ventralex ST, Composix, and PerFix Plug, intended for ventral and inguinal hernia repairs by providing tissue reinforcement and promoting integration.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_51qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[74]</sup> These products faced allegations in multidistrict litigation (MDL No. 2846) in the U.S. District Court for the Southern District of Ohio, where plaintiffs claimed defects including mesh contraction, degradation, and excessive inflammatory response caused complications like chronic pain, infections, adhesions, bowel obstructions, and recurrent hernias necessitating revision surgeries.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_91qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[75]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_b1qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[76]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">By mid-2025, over 25,000 federal lawsuits were pending against Bard in the MDL, with additional state claims, primarily asserting failure to warn of risks and inadequate pre-market testing despite known issues with polypropylene meshes eroding or migrating post-implantation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_52abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[77]</sup> Bard defended by arguing that individual surgeon technique and patient factors contributed more to adverse outcomes than device design, and that clinical data supported efficacy in most cases.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_92abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[78]</sup> Key bellwether trials highlighted disputes: in 2022, a Rhode Island jury awarded $4.8 million to a plaintiff alleging severe injuries from Ventralex mesh, including multiple corrective procedures; a subsequent Ohio verdict in 2023 reached $500,000 for PerFix Plug complications.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d2abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[75]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_f2abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[76]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The Kugel Hernia Patch, an earlier Bard product recalled in 2005 and 2007 due to ring breakage risks causing bowel perforations and deaths in rare instances, prompted a 2011 settlement of 2,600 claims for $184 million, resolving allegations of manufacturing flaws and inadequate disclosures.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_52qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[74]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_72qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[79]</sup> For non-recalled products like Ventralex and Composix, approximately 2,500 and thousands of suits respectively alleged similar polypropylene-related failures, though the FDA classified most as Class II devices with no broad recall, issuing only general safety communications on mesh risks in 2011 and 2018.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_b2qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[80]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d2qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[81]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In October 2024, Becton Dickinson (Bardâ€™s parent) approved a global resolution for roughly 38,000 claims across federal and state courts, with projected average payouts of $60,000â€“$100,000 per qualifying case based on injury severity, though weaker claims offered quick-pay options as low as $25,000; total value exceeded $1 billion in estimates, reflecting Bard&#x27;s strategy to avoid prolonged jury risks amid mounting evidence of revision rates up to 20% in some studies.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_53abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[82]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_73abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[83]</sup> This settlement did not admit liability, and remaining outlier cases continued, underscoring ongoing debates over mesh innovation benefits versus complication causality, with plaintiff experts citing peer-reviewed data on foreign body reactions while Bard referenced long-term success in population-level hernia recurrence reductions.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_b3abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[78]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d3abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[76]</sup></span>
<h3 id="fda-warnings-recalls-and-compliance" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">FDA Warnings, Recalls, and Compliance<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">In July 2015, the FDA issued a warning letter to C.R. Bard, Inc., citing multiple violations of the Federal Food, Drug, and Cosmetic Act and FDA regulations at its facilities in Tempe, Arizona, and Queensbury, New York. The letter identified marketing of the Recovery Cone Removal System (Model RC 15) and Model FBRC without required premarket approval or 510(k) clearance, inadequate complaint handling procedures that misclassified events such as patient deaths and serious injuries related to inferior vena cava (IVC) filters as mere malfunctions, failures to submit timely Medical Device Reports (MDRs) for events posing risks of death or serious injury, unvalidated manufacturing processes for IVC filter cleaning and dimensioning, and improper acceptance of incoming products without full inspection. Bard was required to respond within 15 business days outlining corrective actions, with the FDA warning of potential regulatory actions including seizures or injunctions if deficiencies persisted.</span>
<span class="mb-4 block break-words text-[1em] leading-7">C.R. Bard has initiated or been subject to numerous device recalls classified by the FDA, often Class II for potential temporary or reversible health risks, though some escalated to Class I indicating a reasonable probability of serious adverse health consequences or death. A prominent example is the 2005â€“2007 recalls of Composix Kugel hernia patch meshes, including large circle and oval models, classified as Class I in 2007 due to reports of the internal polypropylene ring breaking, which could lead to bowel perforation, abscesses, or other complications requiring surgical intervention.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_54qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[84]</sup> Initial recalls began in December 2005 after post-market complaints, expanding to affect thousands of units distributed domestically and internationally.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_94qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[85]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">More recent actions include a Class I recall in April 2025 for Bard Blakemore Esophageal-Nasogastric Tubes (adult size), prompted by risks of balloon deflation failure during esophagogastric tamponade for bleeding control, potentially causing life-threatening hemorrhage; BD (Bardâ€™s parent) updated instructions but did not remove devices from use.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_55abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[86]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_95abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[87]</sup> Class II recalls have addressed issues such as mislabeling in Ventralex ST hernia patches (2011), reduced flow in NG Sump Tubes with ENFit connectors (January 2024), and manufacturing defects in Magic3 GO catheters (2023).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[88]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_h5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[89]</sup> Additionally, FDA early alerts in 2025 highlighted risks with Bard Peripheral Vascular atherectomy catheters (potential for tip detachment) and BD PICC catheters (hub separation), urging immediate mitigation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_l5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[90]</sup> <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_p5abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[91]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Compliance efforts following these actions have included process validations, enhanced reporting, and facility corrections, though FDA inspections have repeatedly uncovered persistent quality system gaps, particularly in high-risk vascular and surgical devices. No further enforcement like import alerts or facility shutdowns have been publicly documented post-2015, but ongoing recalls suggest continued scrutiny of Bard&#x27;s (now BD&#x27;s) manufacturing and post-market surveillance.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_55qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[92]</sup></span></article><div id="references" class="min-w-0 scroll-mt-8 overflow-hidden"><div class="text-[16px]"><h2 id="references" node="[object Object]" class="mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden">References</h2></div><ol class="columns-1 gap-x-12 [counter-reset:item] md:columns-2"><li id="https://www.sec.gov/Archives/edgar/data/9892/000119312505038606/d10k1.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sec.gov/Archives/edgar/data/9892/000119312505038606/d10k1.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sec.gov/Archives/edgar/data/9892/000119312505038606/d10k1.pdf</a></span></div></li><li id="https://www.bd.com/en-us/about-bd/our-company" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.bd.com/en-us/about-bd/our-company" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.bd.com/en-us/about-bd/our-company</a></span></div></li><li id="https://www.companieshistory.com/cr-bard/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.companieshistory.com/cr-bard/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.companieshistory.com/cr-bard/</a></span></div></li><li id="https://news.bd.com/2017-12-29-BD-Completes-Bard-Acquisition-Creating-New-Global-Health-Care-Leader%2C1" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://news.bd.com/2017-12-29-BD-Completes-Bard-Acquisition-Creating-New-Global-Health-Care-Leader%2C1" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://news.bd.com/2017-12-29-BD-Completes-Bard-Acquisition-Creating-New-Global-Health-Care-Leader%2C1</a></span></div></li><li id="https://investors.bd.com/news-events/press-releases/detail/403/bd-to-acquire-bard-for-24-billion" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://investors.bd.com/news-events/press-releases/detail/403/bd-to-acquire-bard-for-24-billion" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://investors.bd.com/news-events/press-releases/detail/403/bd-to-acquire-bard-for-24-billion</a></span></div></li><li id="https://www.bd.com/en-us/products-and-solutions/products/product-families/bard-mesh" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.bd.com/en-us/products-and-solutions/products/product-families/bard-mesh" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.bd.com/en-us/products-and-solutions/products/product-families/bard-mesh</a></span></div></li><li id="https://www.drugwatch.com/manufacturers/bard/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.drugwatch.com/manufacturers/bard/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.drugwatch.com/manufacturers/bard/</a></span></div></li><li id="https://www.rxinjuryhelp.com/manufacturers/c-r-bard/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.rxinjuryhelp.com/manufacturers/c-r-bard/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.rxinjuryhelp.com/manufacturers/c-r-bard/</a></span></div></li><li id="https://www.company-histories.com/CR-Bard-Inc-Company-History.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.company-histories.com/CR-Bard-Inc-Company-History.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.company-histories.com/CR-Bard-Inc-Company-History.html</a></span></div></li><li id="https://www.reuters.com/article/business/becton-dickinson-to-acquire-bard-for-24-billion-idUSKBN17P0ZR/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.reuters.com/article/business/becton-dickinson-to-acquire-bard-for-24-billion-idUSKBN17P0ZR/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.reuters.com/article/business/becton-dickinson-to-acquire-bard-for-24-billion-idUSKBN17P0ZR/</a></span></div></li><li id="https://www.sec.gov/Archives/edgar/data/9892/000119312517220263/d420627ddefm14a.htm" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sec.gov/Archives/edgar/data/9892/000119312517220263/d420627ddefm14a.htm" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sec.gov/Archives/edgar/data/9892/000119312517220263/d420627ddefm14a.htm</a></span></div></li><li id="https://investors.bd.com/news-events/press-releases/detail/379/bard-shareholders-approve-proposed-merger-with-becton-dickinson" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://investors.bd.com/news-events/press-releases/detail/379/bard-shareholders-approve-proposed-merger-with-becton-dickinson" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://investors.bd.com/news-events/press-releases/detail/379/bard-shareholders-approve-proposed-merger-with-becton-dickinson</a></span></div></li><li id="https://investors.bd.com/news-events/press-releases/detail/388/bd-and-bard-receive-second-requests-from-ftc-under-hsr-act" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://investors.bd.com/news-events/press-releases/detail/388/bd-and-bard-receive-second-requests-from-ftc-under-hsr-act" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://investors.bd.com/news-events/press-releases/detail/388/bd-and-bard-receive-second-requests-from-ftc-under-hsr-act</a></span></div></li><li id="https://ec.europa.eu/competition/mergers/cases/decisions/m8523_1133_3.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://ec.europa.eu/competition/mergers/cases/decisions/m8523_1133_3.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://ec.europa.eu/competition/mergers/cases/decisions/m8523_1133_3.pdf</a></span></div></li><li id="https://investors.bd.com/news-events/press-releases/detail/355/bd-statement-on-mofcom-clearance-of-bard-acquisition" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://investors.bd.com/news-events/press-releases/detail/355/bd-statement-on-mofcom-clearance-of-bard-acquisition" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://investors.bd.com/news-events/press-releases/detail/355/bd-statement-on-mofcom-clearance-of-bard-acquisition</a></span></div></li><li id="https://www.sec.gov/Archives/edgar/data/10795/000119312517383523/d517273d8k.htm" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sec.gov/Archives/edgar/data/10795/000119312517383523/d517273d8k.htm" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sec.gov/Archives/edgar/data/10795/000119312517383523/d517273d8k.htm</a></span></div></li><li id="https://www.prnewswire.com/news-releases/bd-completes-bard-acquisition-creating-new-global-health-care-leader-300576098.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.prnewswire.com/news-releases/bd-completes-bard-acquisition-creating-new-global-health-care-leader-300576098.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.prnewswire.com/news-releases/bd-completes-bard-acquisition-creating-new-global-health-care-leader-300576098.html</a></span></div></li><li id="https://www.bd.com/en-us/products-and-solutions/solutions/bd-acute-urology" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.bd.com/en-us/products-and-solutions/solutions/bd-acute-urology" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.bd.com/en-us/products-and-solutions/solutions/bd-acute-urology</a></span></div></li><li id="https://pdf.medicalexpo.com/pdf/bard-medical/urological-catheters/78646-131364.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pdf.medicalexpo.com/pdf/bard-medical/urological-catheters/78646-131364.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pdf.medicalexpo.com/pdf/bard-medical/urological-catheters/78646-131364.html</a></span></div></li><li id="https://www.bd.com/en-us/products-and-solutions/products" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.bd.com/en-us/products-and-solutions/products" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.bd.com/en-us/products-and-solutions/products</a></span></div></li><li id="https://www.bd.com/en-us/products-and-solutions/products/product-families/urinary-diversion-stent" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.bd.com/en-us/products-and-solutions/products/product-families/urinary-diversion-stent" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.bd.com/en-us/products-and-solutions/products/product-families/urinary-diversion-stent</a></span></div></li><li id="https://www.bactiguard.com/about-us/history/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.bactiguard.com/about-us/history/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.bactiguard.com/about-us/history/</a></span></div></li><li id="https://www.bd.com/en-us/products-and-solutions/solutions/vascular-access-management" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.bd.com/en-us/products-and-solutions/solutions/vascular-access-management" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.bd.com/en-us/products-and-solutions/solutions/vascular-access-management</a></span></div></li><li id="https://www.bardaccess.com/catalog" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.bardaccess.com/catalog" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.bardaccess.com/catalog</a></span></div></li><li id="https://www.accessdata.fda.gov/cdrh_docs/pdf7/P070014S037d.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.accessdata.fda.gov/cdrh_docs/pdf7/P070014S037d.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.accessdata.fda.gov/cdrh_docs/pdf7/P070014S037d.pdf</a></span></div></li><li id="http://www.micromed.no/Userfiles/Sites/files/2014_Product_List_S120082_Rev2.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="http://www.micromed.no/Userfiles/Sites/files/2014_Product_List_S120082_Rev2.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">http://www.micromed.no/Userfiles/Sites/files/2014_Product_List_S120082_Rev2.pdf</a></span></div></li><li id="https://pdf.medicalexpo.com/pdf/bard-access-systems/introducer-sets/78824-181932.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pdf.medicalexpo.com/pdf/bard-access-systems/introducer-sets/78824-181932.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pdf.medicalexpo.com/pdf/bard-access-systems/introducer-sets/78824-181932.html</a></span></div></li><li id="https://www.justice.gov/archives/opa/pr/cr-bard-inc-pay-us-4826-million-resolve-false-claims-act-claims" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.justice.gov/archives/opa/pr/cr-bard-inc-pay-us-4826-million-resolve-false-claims-act-claims" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.justice.gov/archives/opa/pr/cr-bard-inc-pay-us-4826-million-resolve-false-claims-act-claims</a></span></div></li><li id="https://www.bd.com/en-us/products-and-solutions/products/product-page.ps1251l" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.bd.com/en-us/products-and-solutions/products/product-page.ps1251l" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.bd.com/en-us/products-and-solutions/products/product-page.ps1251l</a></span></div></li><li id="https://eu.bd.com/emea-peripheral-interventions/lib/asset/227.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://eu.bd.com/emea-peripheral-interventions/lib/asset/227.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://eu.bd.com/emea-peripheral-interventions/lib/asset/227.pdf</a></span></div></li><li id="https://www.bd.com/en-us/products-and-solutions/products/product-families/mri-dual-lumen-implantable-port" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.bd.com/en-us/products-and-solutions/products/product-families/mri-dual-lumen-implantable-port" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.bd.com/en-us/products-and-solutions/products/product-families/mri-dual-lumen-implantable-port</a></span></div></li><li id="https://www.bd.com/en-us/products-and-solutions/products/product-families/powerport-clearvue-implantable-ports" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.bd.com/en-us/products-and-solutions/products/product-families/powerport-clearvue-implantable-ports" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.bd.com/en-us/products-and-solutions/products/product-families/powerport-clearvue-implantable-ports</a></span></div></li><li id="https://www.bd.com/en-us/products-and-solutions/products/product-families/gamma-finder-iii-wireless-gamma-detector" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.bd.com/en-us/products-and-solutions/products/product-families/gamma-finder-iii-wireless-gamma-detector" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.bd.com/en-us/products-and-solutions/products/product-families/gamma-finder-iii-wireless-gamma-detector</a></span></div></li><li id="https://www.itnonline.com/content/c-r-bard-acquire-senorx-213-million" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.itnonline.com/content/c-r-bard-acquire-senorx-213-million" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.itnonline.com/content/c-r-bard-acquire-senorx-213-million</a></span></div></li><li id="https://www.bd.com/en-us/products-and-solutions/products/product-families/encor-enspire-breast-biopsy-system" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.bd.com/en-us/products-and-solutions/products/product-families/encor-enspire-breast-biopsy-system" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.bd.com/en-us/products-and-solutions/products/product-families/encor-enspire-breast-biopsy-system</a></span></div></li><li id="https://www.drugwatch.com/hernia-mesh/manufacturers/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.drugwatch.com/hernia-mesh/manufacturers/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.drugwatch.com/hernia-mesh/manufacturers/</a></span></div></li><li id="https://www.bd.com/en-us/products-and-solutions/products/product-families/ventralex-st-hernia-patch" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.bd.com/en-us/products-and-solutions/products/product-families/ventralex-st-hernia-patch" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.bd.com/en-us/products-and-solutions/products/product-families/ventralex-st-hernia-patch</a></span></div></li><li id="https://akinglobal.com.tr/uploads/subdir-182-4/BARD_catalogue.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://akinglobal.com.tr/uploads/subdir-182-4/BARD_catalogue.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://akinglobal.com.tr/uploads/subdir-182-4/BARD_catalogue.pdf</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC10672379/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10672379/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC10672379/</a></span></div></li><li id="https://idataresearch.com/c-r-bard-hernia-repair-device-fda-cleared/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://idataresearch.com/c-r-bard-hernia-repair-device-fda-cleared/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://idataresearch.com/c-r-bard-hernia-repair-device-fda-cleared/</a></span></div></li><li id="https://eu.bd.com/your-surgery/wp-content/uploads/2025/04/BD-107468-BDI-Surgery-Catalogue-October-2024.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://eu.bd.com/your-surgery/wp-content/uploads/2025/04/BD-107468-BDI-Surgery-Catalogue-October-2024.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://eu.bd.com/your-surgery/wp-content/uploads/2025/04/BD-107468-BDI-Surgery-Catalogue-October-2024.pdf</a></span></div></li><li id="https://activelifemed.com/catheter-resource/bard-catheters-facts-history-usage/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://activelifemed.com/catheter-resource/bard-catheters-facts-history-usage/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://activelifemed.com/catheter-resource/bard-catheters-facts-history-usage/</a></span></div></li><li id="https://www.liebertpub.com/doi/pdfplus/10.1089/end.2000.14.5" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.liebertpub.com/doi/pdfplus/10.1089/end.2000.14.5" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.liebertpub.com/doi/pdfplus/10.1089/end.2000.14.5</a></span></div></li><li id="https://www.mpo-mag.com/top-company-profile/c-r-bard/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.mpo-mag.com/top-company-profile/c-r-bard/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.mpo-mag.com/top-company-profile/c-r-bard/</a></span></div></li><li id="https://www.accessdata.fda.gov/cdrh_docs/pdf16/K162443.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.accessdata.fda.gov/cdrh_docs/pdf16/K162443.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.accessdata.fda.gov/cdrh_docs/pdf16/K162443.pdf</a></span></div></li><li id="https://www.prnewswire.com/news-releases/cr-bard-and-teleflex-benefit-from-new-antimicrobial-catheter-power-picc-and-tip-location-technologies-in-3-billion-vascular-access-market-119681574.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.prnewswire.com/news-releases/cr-bard-and-teleflex-benefit-from-new-antimicrobial-catheter-power-picc-and-tip-location-technologies-in-3-billion-vascular-access-market-119681574.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.prnewswire.com/news-releases/cr-bard-and-teleflex-benefit-from-new-antimicrobial-catheter-power-picc-and-tip-location-technologies-in-3-billion-vascular-access-market-119681574.html</a></span></div></li><li id="https://pubmed.ncbi.nlm.nih.gov/24922561/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pubmed.ncbi.nlm.nih.gov/24922561/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pubmed.ncbi.nlm.nih.gov/24922561/</a></span></div></li><li id="https://link.springer.com/article/10.1007/s00270-024-03930-7" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://link.springer.com/article/10.1007/s00270-024-03930-7" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://link.springer.com/article/10.1007/s00270-024-03930-7</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC8856768/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC8856768/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC8856768/</a></span></div></li><li id="https://pmc.ncbi.nlm.nih.gov/articles/PMC7750179/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC7750179/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://pmc.ncbi.nlm.nih.gov/articles/PMC7750179/</a></span></div></li><li id="https://www.researchgate.net/publication/347977018_Prospective_multicenter_study_of_P4HB_Phasix_mesh_for_hernia_repair_in_cohort_at_risk_for_complications_3-Year_follow-up" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.researchgate.net/publication/347977018_Prospective_multicenter_study_of_P4HB_Phasix_mesh_for_hernia_repair_in_cohort_at_risk_for_complications_3-Year_follow-up" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.researchgate.net/publication/347977018_Prospective_multicenter_study_of_P4HB_Phasix_mesh_for_hernia_repair_in_cohort_at_risk_for_complications_3-Year_follow-up</a></span></div></li><li id="https://www.justice.gov/usao-ndga/pr/cr-bard-inc-and-affiliates-pay-17-million-resolve-allegations-healthcare-kickbacks" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.justice.gov/usao-ndga/pr/cr-bard-inc-and-affiliates-pay-17-million-resolve-allegations-healthcare-kickbacks" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.justice.gov/usao-ndga/pr/cr-bard-inc-and-affiliates-pay-17-million-resolve-allegations-healthcare-kickbacks</a></span></div></li><li id="https://oig.hhs.gov/fraud/enforcement/cr-bard-inc-and-affiliates-pay-17-million-to-resolve-allegations-of-healthcare-kickbacks/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://oig.hhs.gov/fraud/enforcement/cr-bard-inc-and-affiliates-pay-17-million-to-resolve-allegations-of-healthcare-kickbacks/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://oig.hhs.gov/fraud/enforcement/cr-bard-inc-and-affiliates-pay-17-million-to-resolve-allegations-of-healthcare-kickbacks/</a></span></div></li><li id="https://www.fbi.gov/atlanta/press-releases/2013/c.r.-bard-inc.-to-pay-u.s.-48.26-million-to-resolve-false-claims-act-claims" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.fbi.gov/atlanta/press-releases/2013/c.r.-bard-inc.-to-pay-u.s.-48.26-million-to-resolve-false-claims-act-claims" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.fbi.gov/atlanta/press-releases/2013/c.r.-bard-inc.-to-pay-u.s.-48.26-million-to-resolve-false-claims-act-claims</a></span></div></li><li id="https://www.justice.gov/opa/pr/semler-scientific-inc-and-bard-peripheral-vascular-inc-pay-nearly-37m-resolve-false-claims" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.justice.gov/opa/pr/semler-scientific-inc-and-bard-peripheral-vascular-inc-pay-nearly-37m-resolve-false-claims" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.justice.gov/opa/pr/semler-scientific-inc-and-bard-peripheral-vascular-inc-pay-nearly-37m-resolve-false-claims</a></span></div></li><li id="https://www.classaction.com/transvaginal-mesh/settlement/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.classaction.com/transvaginal-mesh/settlement/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.classaction.com/transvaginal-mesh/settlement/</a></span></div></li><li id="https://www.forthepeople.com/blog/bard-avaulta-vaginal-mesh-complications-fda-warnings/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.forthepeople.com/blog/bard-avaulta-vaginal-mesh-complications-fda-warnings/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.forthepeople.com/blog/bard-avaulta-vaginal-mesh-complications-fda-warnings/</a></span></div></li><li id="https://www.youhavealawyer.com/mesh/avaulta/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.youhavealawyer.com/mesh/avaulta/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.youhavealawyer.com/mesh/avaulta/</a></span></div></li><li id="https://www.torhoermanlaw.com/vaginal-mesh-lawsuit/bard-vaginal-mesh-lawsuit/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.torhoermanlaw.com/vaginal-mesh-lawsuit/bard-vaginal-mesh-lawsuit/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.torhoermanlaw.com/vaginal-mesh-lawsuit/bard-vaginal-mesh-lawsuit/</a></span></div></li><li id="https://thesandersfirm.com/transvaginal-mesh-overview/transvaginal-mesh-settlements-verdicts/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://thesandersfirm.com/transvaginal-mesh-overview/transvaginal-mesh-settlements-verdicts/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://thesandersfirm.com/transvaginal-mesh-overview/transvaginal-mesh-settlements-verdicts/</a></span></div></li><li id="https://www.pmkm.com/bard-loses-millions-georgia-womans-vaginal-mesh-case/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.pmkm.com/bard-loses-millions-georgia-womans-vaginal-mesh-case/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.pmkm.com/bard-loses-millions-georgia-womans-vaginal-mesh-case/</a></span></div></li><li id="https://www.torhoermanlaw.com/vaginal-mesh-lawsuit/transvaginal-mesh-settlement-amounts/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.torhoermanlaw.com/vaginal-mesh-lawsuit/transvaginal-mesh-settlement-amounts/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.torhoermanlaw.com/vaginal-mesh-lawsuit/transvaginal-mesh-settlement-amounts/</a></span></div></li><li id="https://www.brownlawoffice.com/blog/bard-settles-3000-vaginal-mesh-cases-with-200m-settlement-sources-say/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.brownlawoffice.com/blog/bard-settles-3000-vaginal-mesh-cases-with-200m-settlement-sources-say/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.brownlawoffice.com/blog/bard-settles-3000-vaginal-mesh-cases-with-200m-settlement-sources-say/</a></span></div></li><li id="https://www.expertinstitute.com/resources/insights/plaintiff-awarded-68-million-in-c-r-bard-pelvic-repair-mesh-trial/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.expertinstitute.com/resources/insights/plaintiff-awarded-68-million-in-c-r-bard-pelvic-repair-mesh-trial/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.expertinstitute.com/resources/insights/plaintiff-awarded-68-million-in-c-r-bard-pelvic-repair-mesh-trial/</a></span></div></li><li id="https://www.drugwatch.com/transvaginal-mesh/recall/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.drugwatch.com/transvaginal-mesh/recall/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.drugwatch.com/transvaginal-mesh/recall/</a></span></div></li><li id="https://www.drugwatch.com/ivc-filters/lawsuits/bard/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.drugwatch.com/ivc-filters/lawsuits/bard/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.drugwatch.com/ivc-filters/lawsuits/bard/</a></span></div></li><li id="https://www.jvir.org/article/S1051-0443%2822%2901066-1/fulltext" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.jvir.org/article/S1051-0443%2822%2901066-1/fulltext" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.jvir.org/article/S1051-0443%2822%2901066-1/fulltext</a></span></div></li><li id="https://www.drugwatch.com/ivc-filters/lawsuits/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.drugwatch.com/ivc-filters/lawsuits/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.drugwatch.com/ivc-filters/lawsuits/</a></span></div></li><li id="https://www.wisnerbaum.com/defective-medical-device-injuries/ivc-filter-lawsuit/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.wisnerbaum.com/defective-medical-device-injuries/ivc-filter-lawsuit/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.wisnerbaum.com/defective-medical-device-injuries/ivc-filter-lawsuit/</a></span></div></li><li id="https://www.bencmartin.com/news/category/ivc-filters/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.bencmartin.com/news/category/ivc-filters/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.bencmartin.com/news/category/ivc-filters/</a></span></div></li><li id="https://www.millerandzois.com/products-liability/medical-device-lawsuits/ivc-filters/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.millerandzois.com/products-liability/medical-device-lawsuits/ivc-filters/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.millerandzois.com/products-liability/medical-device-lawsuits/ivc-filters/</a></span></div></li><li id="https://www.dallasnews.com/business/local-companies/2021/07/26/dallas-law-firms-combined-verdicts-top-7-million-in-series-of-blood-clot-filter-lawsuits/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.dallasnews.com/business/local-companies/2021/07/26/dallas-law-firms-combined-verdicts-top-7-million-in-series-of-blood-clot-filter-lawsuits/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.dallasnews.com/business/local-companies/2021/07/26/dallas-law-firms-combined-verdicts-top-7-million-in-series-of-blood-clot-filter-lawsuits/</a></span></div></li><li id="https://www.consumernotice.org/legal/ivc-filter-lawsuits/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.consumernotice.org/legal/ivc-filter-lawsuits/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.consumernotice.org/legal/ivc-filter-lawsuits/</a></span></div></li><li id="https://www.lawsuit-information-center.com/bard-hernia-mesh-lawsuits.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.lawsuit-information-center.com/bard-hernia-mesh-lawsuits.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.lawsuit-information-center.com/bard-hernia-mesh-lawsuits.html</a></span></div></li><li id="https://www.sokolovelaw.com/product-liability/medical-devices/hernia-mesh/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.sokolovelaw.com/product-liability/medical-devices/hernia-mesh/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.sokolovelaw.com/product-liability/medical-devices/hernia-mesh/</a></span></div></li><li id="https://www.medtechdive.com/news/BD-settlement-hernia-mesh-lawsuit/728829/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.medtechdive.com/news/BD-settlement-hernia-mesh-lawsuit/728829/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.medtechdive.com/news/BD-settlement-hernia-mesh-lawsuit/728829/</a></span></div></li><li id="https://federal-lawyer.com/injury-lawsuit/hernia-mesh/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://federal-lawyer.com/injury-lawsuit/hernia-mesh/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://federal-lawyer.com/injury-lawsuit/hernia-mesh/</a></span></div></li><li id="https://www.robertkinglawfirm.com/personal-injury/hernia-mesh-lawsuit/hernia-mesh-settlements/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.robertkinglawfirm.com/personal-injury/hernia-mesh-lawsuit/hernia-mesh-settlements/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.robertkinglawfirm.com/personal-injury/hernia-mesh-lawsuit/hernia-mesh-settlements/</a></span></div></li><li id="https://www.consumernotice.org/legal/hernia-mesh-lawsuits/settlements/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.consumernotice.org/legal/hernia-mesh-lawsuits/settlements/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.consumernotice.org/legal/hernia-mesh-lawsuits/settlements/</a></span></div></li><li id="https://nighgoldenberg.com/ventralex-hernia-mesh-lawsuit/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://nighgoldenberg.com/ventralex-hernia-mesh-lawsuit/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://nighgoldenberg.com/ventralex-hernia-mesh-lawsuit/</a></span></div></li><li id="https://www.kugelherniameshclassaction.com/composix-e-x-and-l-p/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.kugelherniameshclassaction.com/composix-e-x-and-l-p/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.kugelherniameshclassaction.com/composix-e-x-and-l-p/</a></span></div></li><li id="https://www.motleyrice.com/medical-devices/hernia-mesh" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.motleyrice.com/medical-devices/hernia-mesh" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.motleyrice.com/medical-devices/hernia-mesh</a></span></div></li><li id="https://www.lawsuit-information-center.com/how-much-compensation-can-you-expect-for-a-hernia-mesh-lawsuit.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.lawsuit-information-center.com/how-much-compensation-can-you-expect-for-a-hernia-mesh-lawsuit.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.lawsuit-information-center.com/how-much-compensation-can-you-expect-for-a-hernia-mesh-lawsuit.html</a></span></div></li><li id="https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfres/res.cfm?id=49722" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfres/res.cfm?id=49722" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfres/res.cfm?id=49722</a></span></div></li><li id="https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfres/res.cfm?start_search=1&amp;event_id=34393" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfres/res.cfm?start_search=1&amp;event_id=34393" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfres/res.cfm?start_search=1&amp;event_id=34393</a></span></div></li><li id="https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfres/res.cfm?id=213347" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfres/res.cfm?id=213347" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfres/res.cfm?id=213347</a></span></div></li><li id="https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/esophagogastric-tube-recall-bd-issues-correction-esophagogastric-balloon-tamponade-tubes-due" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/esophagogastric-tube-recall-bd-issues-correction-esophagogastric-balloon-tamponade-tubes-due" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/esophagogastric-tube-recall-bd-issues-correction-esophagogastric-balloon-tamponade-tubes-due</a></span></div></li><li id="https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfres/res.cfm?id=205286" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfres/res.cfm?id=205286" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfres/res.cfm?id=205286</a></span></div></li><li id="https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfres/res.cfm?id=104352" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfres/res.cfm?id=104352" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfres/res.cfm?id=104352</a></span></div></li><li id="https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/update-alert-atherectomy-catheter-system-issue-bard-peripheral-vascular" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/update-alert-atherectomy-catheter-system-issue-bard-peripheral-vascular" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/update-alert-atherectomy-catheter-system-issue-bard-peripheral-vascular</a></span></div></li><li id="https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/early-alert-intravascular-picc-catheter-issue-bd" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/early-alert-intravascular-picc-catheter-issue-bd" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/early-alert-intravascular-picc-catheter-issue-bd</a></span></div></li><li id="https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfres/res.cfm?start_search=1&amp;event_id=93679" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfres/res.cfm?start_search=1&amp;event_id=93679" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfres/res.cfm?start_search=1&amp;event_id=93679</a></span></div></li></ol></div></div></div><div class="hidden min-[1400px]:block"></div></div></div><!--$--><!--/$--><div role="region" aria-label="Notifications (F8)" tabindex="-1" style="pointer-events:none"><ol tabindex="-1" class="pointer-events-none fixed top-0 z-[100] flex max-h-screen w-full flex-col-reverse p-4 max-sm:left-0 sm:bottom-0 sm:right-0 sm:top-auto sm:max-w-[420px] sm:flex-col pl-16 pr-2 pt-16 sm:px-4"></ol></div><script type="application/json" id="server-client-data-experimentation">{"status":"uninitialized"}</script><script src="/_next/static/chunks/webpack-e121ed42680f327e.js" nonce="NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh" id="_R_" async=""></script><script nonce="NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh">(self.__next_f=self.__next_f||[]).push([0])</script><script nonce="NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh">self.__next_f.push([1,"1:\"$Sreact.fragment\"\n3:I[91363,[],\"\"]\n4:I[23775,[],\"\"]\n5:I[57654,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"3699\",\"static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js\"],\"PageHeaderProvider\"]\n6:I[17618,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"3699\",\"static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js\"],\"HeaderContent\"]\n7:I[25529,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"6751\",\"static/chunks/app/page/%5Bslug%5D/not-found-69a3edc7db5749d6.js\"],\"default\"]\n9:I[6666,[],\"OutletBoundary\"]\nb:I[80415,[],\"AsyncMetadataOutlet\"]\nd:I[6666,[],\"ViewportBoundary\"]\nf:I[6666,[],\"MetadataBoundary\"]\n10:\"$Sreact.suspense\"\n12:I[95909,[\"4219\",\"static/chunks/app/global-error-4d07d20223cd4b4c.js\"],\"default\"]\n"])</script><script nonce="NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh">self.__next_f.push([1,"13:I[51498,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"ConstantsProvider\"]\n"])</script><script nonce="NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh">self.__next_f.push([1,"14:I[91073,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh">self.__next_f.push([1,"15:I[38642,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh">self.__next_f.push([1,"16:I[99648,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"default\"]\n"])</script><script nonce="NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh">self.__next_f.push([1,"17:I[78825,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh">self.__next_f.push([1,"18:I[8550,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"MixpanelProvider\"]\n"])</script><script nonce="NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh">self.__next_f.push([1,"19:I[12290,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"MobileTocProvider\"]\n"])</script><script nonce="NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh">self.__next_f.push([1,"1a:I[53947,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"NuqsAdapter\"]\n"])</script><script nonce="NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh">self.__next_f.push([1,"1b:I[91873,[\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8039\",\"static/chunks/app/error-4a29e9399afba038.js\"],\"default\"]\n1c:I[5091,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"4345\",\"static/chunks/app/not-found-dd95690acf732f18.js\"],\"default\"]\n"])</script><script nonce="NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh">self.__next_f.push([1,"1d:I[16091,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh">self.__next_f.push([1,":HL[\"/_next/static/media/1f2316909698f815.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/3d4419af2cf8609b.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/4dec29efcaeb336c.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/74452ea3ef0f9101.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/904ef0a86fe32a00.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/d886a03bcda7ad8f.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/e1447589d6f59c4b.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/f5a90156f8995c8c.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/css/62c4caba71dfda84.css\",\"style\",{\"nonce\":\"NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh\"}]\n:HL[\"/_next/static/css/eb3d87f98fe1565f.css\",\"style\",{\"nonce\":\"NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh\"}]\n:HL[\"/_next/static/css/1b5e561215938d4d.css\",\"style\",{\"nonce\":\"NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh\"}]\n:HL[\"/_next/static/css/0227d069a630d414.css\",\"style\",{\"nonce\":\"NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh\"}]\n:HL[\"/_next/static/css/f87fff2ab93d05a7.css\",\"style\",{\"nonce\":\"NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh\"}]\n"])</script><script nonce="NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh">self.__next_f.push([1,"0:{\"P\":null,\"b\":\"BpM29AX4fmgcUxZ_6t0le\",\"p\":\"\",\"c\":[\"\",\"page\",\"Bard_(company)\"],\"i\":false,\"f\":[[[\"\",{\"children\":[\"page\",{\"children\":[[\"slug\",\"Bard_(company)\",\"d\"],{\"children\":[\"__PAGE__\",{}]}]}]},\"$undefined\",\"$undefined\",true],[\"\",[\"$\",\"$1\",\"c\",{\"children\":[[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/62c4caba71dfda84.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh\"}],[\"$\",\"link\",\"1\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/eb3d87f98fe1565f.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh\"}],[\"$\",\"link\",\"2\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/1b5e561215938d4d.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh\"}],[\"$\",\"link\",\"3\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/0227d069a630d414.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh\"}]],\"$L2\"]}],{\"children\":[\"page\",[\"$\",\"$1\",\"c\",{\"children\":[null,[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":\"$undefined\",\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]]}],{\"children\":[[\"slug\",\"Bard_(company)\",\"d\"],[\"$\",\"$1\",\"c\",{\"children\":[null,[\"$\",\"$L5\",null,{\"children\":[[\"$\",\"$L6\",null,{\"maxWidth\":\"full\",\"mobileOptions\":{\"right\":{\"showFixedIssues\":true,\"showThemeSwitcher\":true,\"showSearch\":true,\"showTableOfContents\":true}}}],[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[[\"$\",\"$L7\",null,{}],[]],\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]]}]]}],{\"children\":[\"__PAGE__\",[\"$\",\"$1\",\"c\",{\"children\":[\"$L8\",[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/f87fff2ab93d05a7.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh\"}]],[\"$\",\"$L9\",null,{\"children\":[\"$La\",[\"$\",\"$Lb\",null,{\"promise\":\"$@c\"}]]}]]}],{},null,false]},null,false]},null,false]},null,false],[\"$\",\"$1\",\"h\",{\"children\":[null,[[\"$\",\"$Ld\",null,{\"children\":\"$Le\"}],[\"$\",\"meta\",null,{\"name\":\"next-size-adjust\",\"content\":\"\"}]],[\"$\",\"$Lf\",null,{\"children\":[\"$\",\"div\",null,{\"hidden\":true,\"children\":[\"$\",\"$10\",null,{\"fallback\":null,\"children\":\"$L11\"}]}]}]]}],false]],\"m\":\"$undefined\",\"G\":[\"$12\",[]],\"s\":false,\"S\":false}\n"])</script><script nonce="NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh">self.__next_f.push([1,"2:[\"$\",\"html\",null,{\"lang\":\"en\",\"className\":\"bg-surface-base antialiased\",\"suppressHydrationWarning\":true,\"children\":[[\"$\",\"head\",null,{\"children\":[[\"$\",\"title\",null,{\"children\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"type\":\"image/x-icon\",\"href\":\"/favicon.ico\",\"sizes\":\"48x48\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"href\":\"/images/icon-dark.png\",\"media\":\"(prefers-color-scheme: light)\",\"type\":\"image/png\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"href\":\"/images/icon-light.png\",\"media\":\"(prefers-color-scheme: dark)\",\"type\":\"image/png\"}],[\"$\",\"link\",null,{\"rel\":\"apple-touch-icon\",\"href\":\"/icon-192x192.png\"}],[\"$\",\"link\",null,{\"rel\":\"manifest\",\"href\":\"/manifest.webmanifest\"}],[\"$\",\"meta\",null,{\"name\":\"robots\",\"content\":\"index, follow\"}],[\"$\",\"meta\",null,{\"name\":\"googlebot\",\"content\":\"index, follow, max-snippet:-1\"}],[\"$\",\"meta\",null,{\"property\":\"og:title\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"property\":\"og:description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"meta\",null,{\"property\":\"og:url\",\"content\":\"https://grokipedia.com\"}],[\"$\",\"meta\",null,{\"property\":\"og:site_name\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"property\":\"og:locale\",\"content\":\"en_US\"}],[\"$\",\"meta\",null,{\"property\":\"og:type\",\"content\":\"website\"}],[\"$\",\"meta\",null,{\"property\":\"og:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:width\",\"content\":\"512\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:height\",\"content\":\"512\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:alt\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:card\",\"content\":\"summary\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:creator\",\"content\":\"@Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:title\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}]]}],[\"$\",\"body\",null,{\"className\":\"flex h-[100svh] w-full flex-col __variable_13c637 __variable_8a0ba0 __variable_779740 __variable_2484fd __variable_525cc3 __variable_13486b\",\"children\":[[\"$\",\"$L13\",null,{\"children\":[\"$\",\"$L14\",null,{\"children\":[\"$\",\"$L15\",null,{\"defaultTheme\":\"dark\",\"nonce\":\"NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh\",\"children\":[\"$\",\"$L16\",null,{\"children\":[\"$\",\"$L17\",null,{\"children\":[\"$\",\"$L18\",null,{\"children\":[\"$\",\"$L19\",null,{\"children\":[\"$\",\"$L1a\",null,{\"children\":[[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$1b\",\"errorStyles\":[],\"errorScripts\":[],\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[[\"$\",\"$L1c\",null,{}],[]],\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}],[\"$\",\"$L1d\",null,{}]]}]}]}]}]}]}]}]}],[\"$\",\"script\",null,{\"type\":\"application/json\",\"id\":\"server-client-data-experimentation\",\"children\":\"{\\\"status\\\":\\\"uninitialized\\\"}\"}]]}]]}]\n"])</script><script nonce="NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh">self.__next_f.push([1,"e:[[\"$\",\"meta\",\"0\",{\"charSet\":\"utf-8\"}],[\"$\",\"meta\",\"1\",{\"name\":\"viewport\",\"content\":\"width=device-width, initial-scale=1, interactive-widget=resizes-content\"}]]\na:null\n"])</script><script nonce="NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh">self.__next_f.push([1,"1e:I[42712,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"HydrationBoundary\"]\n"])</script><script nonce="NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh">self.__next_f.push([1,"21:I[6367,[],\"IconMark\"]\n1f:Tc6fd,"])</script><script nonce="NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh">self.__next_f.push([1,"# Bard (company)\n\n![C. R. Bard logo](./_assets_/Bard_logo.gif)\n\nC. R. Bard, Inc. was a medical technology company specializing in the development, manufacture, and marketing of devices for vascular, urology, oncology, and surgical applications.[](https://www.sec.gov/Archives/edgar/data/9892/000119312505038606/d10k1.pdf) Founded in 1907 in Covington, Georgia, the company grew to become a leader in products such as catheters, stents, and soft tissue repair meshes, serving hospitals and healthcare professionals worldwide.[](https://www.bd.com/en-us/about-bd/our-company) Headquartered in Murray Hill, New Jersey, Bard employed over 14,000 people and generated significant revenue from its specialized medical solutions prior to its acquisition.[](https://www.companieshistory.com/cr-bard/)\n\nIn 2017, Becton, Dickinson and Company (BD) completed the acquisition of C. R. Bard for approximately $24 billion, integrating Bard's portfolio into BD's broader offerings in diagnostics, medical devices, and biosciences, thereby creating a combined entity with enhanced capabilities in peripheral vascular disease, urology, and hernia repair.[](https://news.bd.com/2017-12-29-BD-Completes-Bard-Acquisition-Creating-New-Global-Health-Care-Leader%2C1)[](https://investors.bd.com/news-events/press-releases/detail/403/bd-to-acquire-bard-for-24-billion) Bard's innovations, including its BardÂ® Mesh for tension-free hernia repairs with over 50 years of clinical use, underscored its contributions to minimally invasive procedures.[](https://www.bd.com/en-us/products-and-solutions/products/product-families/bard-mesh) However, the company encountered major controversies involving product liability lawsuits, particularly over transvaginal mesh and hernia mesh devices alleged to cause injuries, resulting in multibillion-dollar settlements and highlighting risks in implantable medical technologies.[](https://www.drugwatch.com/manufacturers/bard/)[](https://www.rxinjuryhelp.com/manufacturers/c-r-bard/)\n\n## History\n\n### Founding and Early Development\n\nCharles Russell Bard established the company in New York City in 1907, initially focusing on the U.S. distribution of a urethral catheter developed by the French firm J. Eynard.[](https://www.company-histories.com/CR-Bard-Inc-Company-History.html) This venture marked the beginnings of what would become a specialized medical device enterprise, emphasizing urological products imported from Europe.[](https://www.companieshistory.com/cr-bard/)\n\nIn 1915, Bard partnered with inventor Morgan Parker to form Bard-Parker Co. Inc., which produced detachable-blade scalpels, expanding into surgical instruments.[](https://www.company-histories.com/CR-Bard-Inc-Company-History.html) Bard incorporated his primary business as C.R. Bard, Inc. in 1923, hiring James Vassar as its first full-time salesperson, though he sold his interest in the scalpel partnership to Parker that year for $23,000.[](https://www.company-histories.com/CR-Bard-Inc-Company-History.html) By 1926, facing operational challenges, Bard sold the incorporated company to John Frederick Willits and Edson L. Outwin for $18,000, with Willits assuming the role of president and Outwin serving as vice-president and treasurer.[](https://www.company-histories.com/CR-Bard-Inc-Company-History.html)[](https://www.companieshistory.com/cr-bard/)\n\nUnder new ownership, C.R. Bard continued importing European catheters while beginning to distribute the Foley catheter in 1934, a significant advancement in urological drainage technology invented by Frederic Foley.[](https://www.company-histories.com/CR-Bard-Inc-Company-History.html) The company's early growth relied on these imported and distributed devices, serving hospitals and medical professionals, though World War II disruptions in 1940 prompted a shift toward U.S.-sourced alternatives through partnerships like U.S. Catheter and Instrument Corporation (USCI).[](https://www.company-histories.com/CR-Bard-Inc-Company-History.html) This period laid the foundation for Bard's focus on minimally invasive medical solutions, establishing its reputation in urology prior to broader diversification.[](https://www.companieshistory.com/cr-bard/)\n\n### Mid-20th Century Growth and Diversification\n\nFollowing World War II disruptions in European imports, C.R. Bard partnered with the United States Catheter and Instrument Corporation (USCI) in 1944 to distribute the first American-manufactured woven catheters, shifting production to domestic synthetics like nylon.[](https://www.company-histories.com/CR-Bard-Inc-Company-History.html)[](https://www.rxinjuryhelp.com/manufacturers/c-r-bard/) By 1945, net sales had risen 150% from 1935 levels, reflecting postwar demand for urological products.[](https://www.company-histories.com/CR-Bard-Inc-Company-History.html) In 1948, the company relocated its headquarters to a 5,400-square-foot facility in Summit, New Jersey, surpassing $1 million in annual sales and adding 18 employees.[](https://www.company-histories.com/CR-Bard-Inc-Company-History.html)\n\nThe 1950s marked accelerated growth, with net sales expanding over 400% and workforce reaching 200 employees; by decade's end, all products were manufactured in the United States, eliminating reliance on foreign suppliers.[](https://www.company-histories.com/CR-Bard-Inc-Company-History.html)[](https://www.rxinjuryhelp.com/manufacturers/c-r-bard/) A key innovation came in 1957â€“1958, when Bard introduced pre-sterilized, packaged Foley catheters, which reduced hospital preparation costs and infection risks by enabling direct use from packaging.[](https://www.company-histories.com/CR-Bard-Inc-Company-History.html)[](https://www.rxinjuryhelp.com/manufacturers/c-r-bard/)\n\nEntering the 1960s, Bard diversified beyond urology into cardiology, radiology, and anesthesiology, beginning manufacturing of additional medical devices in 1961.[](https://www.rxinjuryhelp.com/manufacturers/c-r-bard/) Net sales climbed to $51 million by 1969, supported by workforce expansion to 2,200 employees and a new 50,000-square-foot headquarters in Murray Hill, New Jersey.[](https://www.company-histories.com/CR-Bard-Inc-Company-History.html) The company went public on the over-the-counter market in 1963 and initiated in-house production of medical plastic tubing in 1964, alongside establishing C.R. Bard Limited in Toronto to serve the Canadian market.[](https://www.company-histories.com/CR-Bard-Inc-Company-History.html)[](https://www.rxinjuryhelp.com/manufacturers/c-r-bard/) Diversification accelerated through the 1966 acquisition of USCI, which broadened offerings in urological and cardiovascular products.[](https://www.company-histories.com/CR-Bard-Inc-Company-History.html)[](https://www.rxinjuryhelp.com/manufacturers/c-r-bard/) By 1968, Bard's stock listed on the New York Stock Exchange, coinciding with a 172,000-square-foot manufacturing plant opening in Murray Hill.[](https://www.company-histories.com/CR-Bard-Inc-Company-History.html)\n\n### Late 20th and Early 21st Century Acquisitions\n\nIn the 1980s, C.R. Bard expanded its urology and vascular product lines through strategic purchases. In 1980, the company acquired Davol Inc. and its international subsidiary from International Paper Company, gaining control over the production of Foley catheters and other latex-based urinary products that had previously been supplied under a long-term relationship.[](https://www.company-histories.com/CR-Bard-Inc-Company-History.html) This move integrated manufacturing in-house and bolstered Bard's position in disposable urological devices. Later in the decade, in 1989, Bard purchased Catheter Technology Corporation, adding specialized vascular access catheters to its portfolio.[](https://www.rxinjuryhelp.com/manufacturers/c-r-bard/)\n\nThe 1990s saw Bard pursue acquisitions to enter oncology diagnostics and advanced vascular interventions. In 1993, it acquired Bainbridge Sciences Inc., which provided diagnostic tests for early detection of prostate, bladder, cervical, and lung cancers, enhancing Bard's oncology offerings.[](https://www.company-histories.com/CR-Bard-Inc-Company-History.html) The 1994 acquisition of Angiomed AG introduced self-expanding vascular stents and biliary stents, expanding Bard's endovascular capabilities.[](https://www.company-histories.com/CR-Bard-Inc-Company-History.html)[](https://www.rxinjuryhelp.com/manufacturers/c-r-bard/) In 1995, Bard acquired MedChem Products, Inc. in a stock swap valued at approximately $100 million, incorporating neonatal and adult catheters along with surgical drainage products.[](https://www.company-histories.com/CR-Bard-Inc-Company-History.html) The decade closed with the 1996 purchase of Impra, Inc. for about $143 million, securing vascular grafts used in blood vessel replacement surgeries, and the acquisition of Dymax, Inc., which added ultrasound guidance technology for catheter insertions.[](https://www.company-histories.com/CR-Bard-Inc-Company-History.html)[](https://www.rxinjuryhelp.com/manufacturers/c-r-bard/)\n\nEntering the 2000s, Bard focused on surgical repair and biopsy technologies amid growing demand for minimally invasive procedures. In 2001, it acquired Surgical Sense, Inc., obtaining the Kugel Hernia Patch, a composite mesh device for hernia repairs that later faced regulatory scrutiny for defects.[](https://www.company-histories.com/CR-Bard-Inc-Company-History.html)[](https://www.rxinjuryhelp.com/manufacturers/c-r-bard/) By 2003, Bard bought assets from Source Tech Medical, LLC for iodine-125 seeds used in prostate brachytherapy, as well as select assets from Prostate Services of America, Inc. and Imagyn Medical Technologies, Inc., strengthening its radiation therapy and women's health segments.[](https://www.sec.gov/Archives/edgar/data/9892/000119312505038606/d10k1.pdf) In 2004, the acquisition of Onux Medical, Inc. brought the Salute fixation system for securing prosthetic patches during hernia surgeries.[](https://www.company-histories.com/CR-Bard-Inc-Company-History.html) Additional early 21st-century deals included Biomedical Instruments and Products GmbH for vacuum-assisted breast biopsy devices and the LifeStent product line from Edwards Lifesciences for peripheral vascular stenting.[](https://www.rxinjuryhelp.com/manufacturers/c-r-bard/) These moves diversified Bard's technologies but also introduced products linked to subsequent litigation over safety issues.[](https://www.rxinjuryhelp.com/manufacturers/c-r-bard/)\n\n### Acquisition by Becton Dickinson\n\nOn April 23, 2017, Becton, Dickinson and Company (BD) announced its agreement to acquire C. R. Bard, Inc. for approximately $24 billion in a cash-and-stock transaction, representing a 25% premium over Bard's closing share price on April 21, 2017.[](https://investors.bd.com/news-events/press-releases/detail/403/bd-to-acquire-bard-for-24-billion)[](https://www.reuters.com/article/business/becton-dickinson-to-acquire-bard-for-24-billion-idUSKBN17P0ZR/) Under the terms, Bard shareholders received $222.93 in cash and 0.5077 shares of BD common stock per Bard share, valuing each Bard share at $317.[](https://www.reuters.com/article/business/becton-dickinson-to-acquire-bard-for-24-billion-idUSKBN17P0ZR/)[](https://www.sec.gov/Archives/edgar/data/9892/000119312517220263/d420627ddefm14a.htm) The deal aimed to combine BD's expertise in medication delivery and diagnostics with Bard's strengths in vascular, urology, and oncology devices, projecting $300 million in annual pre-tax cost synergies by fiscal year 2020.[](https://investors.bd.com/news-events/press-releases/detail/403/bd-to-acquire-bard-for-24-billion)\n\nBard shareholders approved the merger on August 8, 2017, with approximately 99% of votes cast in favor.[](https://investors.bd.com/news-events/press-releases/detail/379/bard-shareholders-approve-proposed-merger-with-becton-dickinson) Regulatory scrutiny followed, including second requests from the U.S. Federal Trade Commission (FTC) in June 2017 under the Hart-Scott-Rodino Act, European Commission clearance on October 18, 2017, and final approval from China's Ministry of Commerce (MOFCOM) on December 28, 2017.[](https://investors.bd.com/news-events/press-releases/detail/388/bd-and-bard-receive-second-requests-from-ftc-under-hsr-act)[](https://ec.europa.eu/competition/mergers/cases/decisions/m8523_1133_3.pdf)[](https://investors.bd.com/news-events/press-releases/detail/355/bd-statement-on-mofcom-clearance-of-bard-acquisition) The acquisition closed on December 29, 2017, after satisfying all customary closing conditions, resulting in Bard's common stock ceasing to trade and being delisted from the New York Stock Exchange.[](https://news.bd.com/2017-12-29-BD-Completes-Bard-Acquisition-Creating-New-Global-Health-Care-Leader%2C1)[](https://www.sec.gov/Archives/edgar/data/10795/000119312517383523/d517273d8k.htm)\n\nThe merger created a combined entity with approximately $16 billion in annualized revenue, positioning BD as a leading global provider of medical technology solutions across vascular access, urological care, oncology interventions, and surgical devices.[](https://news.bd.com/2017-12-29-BD-Completes-Bard-Acquisition-Creating-New-Global-Health-Care-Leader%2C1)[](https://www.prnewswire.com/news-releases/bd-completes-bard-acquisition-creating-new-global-health-care-leader-300576098.html) Vincent A. Forlenza, then BD's chairman and CEO, described the integration as enhancing BD's ability to address complex health care challenges through expanded innovation and scale.[](https://investors.bd.com/news-events/press-releases/detail/355/bd-statement-on-mofcom-clearance-of-bard-acquisition) Post-acquisition, BD reorganized its structure to incorporate Bard's operations, focusing on realizing operational efficiencies while maintaining distinct product portfolios.[](https://investors.bd.com/news-events/press-releases/detail/403/bd-to-acquire-bard-for-24-billion)\n\n## Products and Technologies\n\n### Urology and Urological Devices\n\nC.R. Bard's urology division, now integrated into Becton Dickinson's (BD) Acute Urology portfolio following the 2017 acquisition, specializes in devices for bladder management, urinary drainage, and endourological procedures. The company's foundational contribution to urology was the introduction of the Foley indwelling catheter in 1934, which enabled continuous bladder drainage and marked a significant advancement in managing urinary retention and incontinence.[](https://www.bd.com/en-us/products-and-solutions/solutions/bd-acute-urology) By the 1950s, Bard had shifted to U.S.-based manufacturing of its urological products, and in 1958, it pioneered pre-sterilized, packaged Foley catheters to reduce infection risks associated with preparation.[](https://www.rxinjuryhelp.com/manufacturers/c-r-bard/)\n\nKey urological devices include a broad array of catheters designed to minimize complications such as catheter-associated urinary tract infections (CAUTIs). Indwelling options feature silicone-based Foley catheters, which are latex-free and provide enhanced patient comfort for long-term use, available in 2-way and 3-way configurations with balloon capacities from 3-30 cc.[](https://pdf.medicalexpo.com/pdf/bard-medical/urological-catheters/78646-131364.html) Intermittent catheters, such as the Bard Magic3, incorporate coatings like Micro-Hole Zone Technology for reduced friction and improved drainage.[](https://www.bd.com/en-us/products-and-solutions/products) External catheters, including male and female variants like the PureWick system, offer non-invasive urine collection alternatives, supporting CAUTI prevention protocols.[](https://www.bd.com/en-us/products-and-solutions/solutions/bd-acute-urology)\n\nIn endourology, Bard developed ureteral stents and catheters for upper urinary tract drainage. The Bard Inlay and Inlay VerSaFit ureteral stents facilitate urine flow from the kidney to the bladder, with features like dual-durometer construction for flexibility and radiopaque markers for imaging guidance. The Urinary Diversion Stent supports drainage in uretero-intestinal diversion procedures post-surgery.[](https://www.bd.com/en-us/products-and-solutions/products/product-families/urinary-diversion-stent) Accessory products encompass urinary drainage bags, leg bags, and stabilization devices like the STATLOCK Foley Stabilization Device, which secure catheters to prevent migration and trauma.[](https://www.bd.com/en-us/products-and-solutions/products)\n\nBard also innovated in infection-resistant technologies, with FDA approval in 1994 for urinary catheters incorporating hydrophilic coatings, such as those from Bactiguard partnerships, to lower bacterial adhesion.[](https://www.bactiguard.com/about-us/history/) These devices collectively address acute and chronic urological needs, with Bard's portfolio emphasizing biocompatibility, ease of insertion, and reduced healthcare-associated infections through material advancements like silicone and antimicrobial surfaces.[](https://www.bd.com/en-us/products-and-solutions/solutions/bd-acute-urology)\n\n### Vascular Access and Intervention Devices\n\nC.R. Bard's vascular access portfolio encompassed devices for short- and long-term intravenous access, including peripherally inserted central catheters (PICCs), midline catheters, central venous catheters, and implantable ports. These products facilitated the delivery of medications, fluids, nutrition, and contrast agents while aiming to minimize complications such as infection and thrombosis. The GroshongÂ® catheter, introduced with a slit valve mechanism at the distal tip, allowed passive flow control to reduce the need for heparin flushes and limit blood reflux, thereby potentially lowering occlusion rates compared to open-ended designs.[](https://www.bd.com/en-us/products-and-solutions/solutions/vascular-access-management) Similarly, Bard's PowerPICCÂ® catheters supported power injection for CT imaging, enabling rates up to 5 mL/second with pressures up to 300 psi, which expanded their utility in diagnostic procedures.[](https://www.bardaccess.com/catalog)\n\nImplantable vascular access devices from Bard, such as the PowerPortÂ® implantable port, featured titanium construction and silicone septums rated for high-pressure power injection, accommodating up to 5 mL/second flows for contrast-enhanced imaging. This design addressed limitations of earlier ports by supporting radiopaque identification and catheter securement to prevent migration. Bard also developed guidance technologies, including the Site-RiteÂ® ultrasound systems with needle guides, to enhance first-insertion success rates and reduce arterial punctures during catheter placement.[](https://www.bd.com/en-us/products-and-solutions/solutions/vascular-access-management) Care and maintenance products, like antimicrobial dressings and securement devices, complemented the access portfolio to extend dwell times and mitigate central line-associated bloodstream infections.[](https://www.bardaccess.com/catalog)\n\nIn vascular intervention, Bard's Peripheral Vascular division produced stents and delivery systems for treating peripheral artery disease and other occlusive conditions. The LifeStentÂ® Vascular Stent System, a flexible nitinol self-expanding stent, was indicated for improving luminal diameter in symptomatic de novo or restenotic lesions up to 240 mm long in the superficial femoral and proximal popliteal arteries, with FDA approval granted in 2009 and subsequent expansions.[](https://www.accessdata.fda.gov/cdrh_docs/pdf7/P070014S037d.pdf) The COVERAâ„¢ Vascular Covered Stent, featuring ePTFE encapsulation over a nitinol frame, provided barrier properties against tissue ingrowth while maintaining flexibility for deployment in iliac and superficial femoral arteries. Bard further offered vascular access grafts, such as the V. AscendÂ® series, constructed from expanded polytetrafluoroethylene (ePTFE) for hemodialysis arteriovenous access, emphasizing kink resistance and reduced infection profiles through tissue ingrowth promotion.[](http://www.micromed.no/Userfiles/Sites/files/2014_Product_List_S120082_Rev2.pdf) These intervention devices integrated with Bard's introducer sets and sheaths to support minimally invasive endovascular procedures.[](https://pdf.medicalexpo.com/pdf/bard-access-systems/introducer-sets/78824-181932.html)\n\n### Oncology and Radiation Therapy Products\n\nC.R. Bard developed brachytherapy seeds for localized radiation delivery in prostate cancer treatment, utilizing iodine-125 (I-125) isotopes permanently implanted via needles to target tumor cells directly while sparing adjacent healthy tissue.[](https://www.justice.gov/archives/opa/pr/cr-bard-inc-pay-us-4826-million-resolve-false-claims-act-claims) The BrachySourceâ„¢ I-125 Seed Implant incorporates a polymer coating and embedded gold markers for radiopaque visualization under fluoroscopy, facilitating precise dosimetry and post-implant verification.[](https://www.bd.com/en-us/products-and-solutions/products/product-page.ps1251l) These seeds, typically 4.5 mm in length and 0.8 mm in diameter, emit low-energy gamma radiation over a half-life of approximately 59.4 days, with indications for early-stage prostate cancer as monotherapy or adjunct to external beam radiation for residual or recurrent tumors.[](https://eu.bd.com/emea-peripheral-interventions/lib/asset/227.pdf)\n\nBard also produced implantable vascular access devices compatible with radiation therapy protocols, including the M.R.I.â„¢ Dual-Lumen Implantable Port, featuring large silicone septa and plastic construction to minimize imaging artifacts during MRI or radiotherapy sessions.[](https://www.bd.com/en-us/products-and-solutions/products/product-families/mri-dual-lumen-implantable-port) The PowerPortâ„¢ ClearVUEâ„¢ ports employ a metal-free, clear silicone dome for power injection up to 5 mL/second at 300 psi, reducing radiation scatter in CT or fluoroscopy-guided procedures common in oncology.[](https://www.bd.com/en-us/products-and-solutions/products/product-families/powerport-clearvue-implantable-ports)\n\nFor intraoperative oncology applications, Bard's Gamma FinderÂ® III wireless gamma probe detects emissions in the 20-512 keV range from technetium-99m radiotracers, enabling sentinel lymph node localization in breast cancer and melanoma surgeries with directional sensitivity and audio/visual feedback.[](https://www.bd.com/en-us/products-and-solutions/products/product-families/gamma-finder-iii-wireless-gamma-detector) The 2010 acquisition of SenoRx for $213 million integrated vacuum-assisted biopsy systems like EnCor Enspireâ„¢, which support stereotactic, ultrasound, and MRI-guided tissue sampling for breast oncology diagnostics prior to radiation planning.[](https://www.itnonline.com/content/c-r-bard-acquire-senorx-213-million)[](https://www.bd.com/en-us/products-and-solutions/products/product-families/encor-enspire-breast-biopsy-system)\n\n### Surgical and Hernia Repair Devices\n\nC.R. Bard developed and marketed a range of synthetic mesh implants and fixation devices for hernia repair, primarily targeting inguinal, ventral, incisional, and umbilical hernias. These products emphasized tension-free surgical techniques, utilizing materials such as monofilament polypropylene to reinforce abdominal walls while facilitating tissue integration and reducing recurrence risks. Bard's hernia portfolio, managed through its Davol subsidiary, included both flat sheets and pre-shaped implants designed for open and laparoscopic procedures.[](https://www.bd.com/en-us/products-and-solutions/products/product-families/bard-mesh)[](https://www.drugwatch.com/hernia-mesh/manufacturers/)\n\nKey offerings encompassed Bard Mesh, a lightweight monofilament polypropylene sheet introduced as the standard for tension-free repairs, which promotes rapid tissue ingrowth due to its large pore structure and has been in clinical use for over 40 years.[](https://www.bd.com/en-us/products-and-solutions/products/product-families/bard-mesh) The Ventralex ST Hernia Patch, cleared by the FDA for umbilical and epigastric hernias as well as trocar site closure, incorporates an absorbable hydrogel barrier on the visceral side to prevent unintended adhesions to bowel tissue during the critical healing phase.[](https://www.bd.com/en-us/products-and-solutions/products/product-families/ventralex-st-hernia-patch) Plug-style devices like the PerFix Plug Mesh provided cone-shaped polypropylene implants for inguinal hernia occlusion, often combined with overlying patches for layered reinforcement in open repairs.[](https://akinglobal.com.tr/uploads/subdir-182-4/BARD_catalogue.pdf)\n\nBard also produced anatomically contoured meshes, such as the 3DMax Mesh and 3DMax Light variants, featuring macroporous polypropylene with pre-formed shapes to conform to pelvic anatomy, minimizing folding and improving fit in minimally invasive inguinal repairs.[](https://www.drugwatch.com/hernia-mesh/manufacturers/) Composite products like Composix L/P Mesh integrated a low-profile polypropylene layer with an ePTFE barrier to reduce visceral attachments in ventral applications.[](https://akinglobal.com.tr/uploads/subdir-182-4/BARD_catalogue.pdf) These designs addressed biomechanical needs by balancing strength, flexibility, and porosity, with weights typically ranging from light (under 50 g/mÂ²) to standard grades for varying defect sizes.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC10672379/)\n\nIn terms of technological advancements, Bard focused on enhancing deployment precision and biocompatibility. By 2019, the company secured FDA 510(k) clearance for a laparoscopic delivery system enabling tetherless mesh placement, which preclinical testing demonstrated improved accuracy and reduced operative time in minimally invasive hernia repairs compared to traditional methods.[](https://idataresearch.com/c-r-bard-hernia-repair-device-fda-cleared/) Earlier innovations included soft, large-pore variants like Bard Soft Mesh, engineered for reduced foreign body reaction through minimized material density while maintaining tensile strength exceeding 16 N/cm in both warp and weft directions.[](https://eu.bd.com/your-surgery/wp-content/uploads/2025/04/BD-107468-BDI-Surgery-Catalogue-October-2024.pdf) Following Bard's acquisition by Becton Dickinson in December 2017, these products integrated into BD's broader soft tissue repair lineup, sustaining emphasis on durable, non-absorbable synthetics over bioresorbable alternatives for long-term reinforcement.[](https://www.drugwatch.com/hernia-mesh/manufacturers/)\n\n## Innovations and Contributions\n\n### Key Technological Breakthroughs\n\nC. R. Bard's early advancements in urological devices centered on the commercialization of the indwelling Foley catheter in 1934, which provided a self-retaining mechanism for continuous urinary drainage, significantly improving patient management for conditions requiring prolonged catheterization compared to prior intermittent methods.[](https://www.bd.com/en-us/products-and-solutions/solutions/bd-acute-urology) This innovation, originally designed by Frederic Foley, was scaled for market distribution by Bard, marking a pivotal shift toward reliable, balloon-retained catheters that reduced procedural frequency and complications like bladder spasms.[](https://activelifemed.com/catheter-resource/bard-catheters-facts-history-usage/)\n\nIn the mid-20th century, Bard advanced catheter materials and designs to address infection risks and biocompatibility issues inherent in early latex models. By the late 1960s, the company introduced Teflon-coated latex catheters, which facilitated smoother insertion and limited bacterial adhesion, thereby decreasing urinary tract infection rates associated with indwelling devices.[](https://www.liebertpub.com/doi/pdfplus/10.1089/end.2000.14.5) Concurrently, Bard pioneered in-house production of medical plastic tubing in 1964, enabling customized intravenous and drainage lines that enhanced sterility and precision in fluid management.[](https://www.company-histories.com/CR-Bard-Inc-Company-History.html) These developments laid the groundwork for disposable, single-patient-use products, a hallmark of Bard's approach to minimizing cross-contamination in hospital settings.[](https://www.mpo-mag.com/top-company-profile/c-r-bard/)\n\nIn vascular access, Bard contributed to breakthroughs in central venous catheterization, particularly through the evolution of peripherally inserted central catheters (PICCs) optimized for power injection. The PowerPICC catheter, cleared by the FDA in 2016 for high-flow rates up to 5 mL/second, allowed safe administration of CT contrast media directly via peripheral insertion, reducing the need for more invasive central lines and improving imaging diagnostics for vascular and oncological conditions.[](https://www.accessdata.fda.gov/cdrh_docs/pdf16/K162443.pdf) This built on Bard's broader expertise in antimicrobial coatings for PICCs, which incorporated technologies like chlorhexidine to combat catheter-related bloodstream infections, a leading cause of hospital-acquired morbidity.[](https://www.prnewswire.com/news-releases/cr-bard-and-teleflex-benefit-from-new-antimicrobial-catheter-power-picc-and-tip-location-technologies-in-3-billion-vascular-access-market-119681574.html)\n\n### Clinical Impact and Patient Outcomes Data\n\nBard's silver-alloy hydrogel-coated urinary catheters have shown significant reductions in catheter-associated urinary tract infections (CAUTIs) in clinical settings. In a multicenter before-after cohort study involving adult patients across seven acute care hospitals, implementation of these catheters resulted in a 47% relative reduction in symptomatic CAUTI rates (0.945 to 0.498 per 1000 patient days; odds ratio 0.53, P \u003c .0001) and a 58% reduction in National Healthcare Safety Network-defined CAUTIs (0.60 to 0.25 per 1000 patient days; odds ratio 0.42, P \u003c .0001), alongside decreased antimicrobial use for CAUTIs (1165 to 406 days).[](https://pubmed.ncbi.nlm.nih.gov/24922561/)\n\nIn vascular access, Bard's COVERAâ„¢ arteriovenous stent graft demonstrated high target lesion primary patency and safety in treating venous outflow stenoses in dialysis access circuits. The AVeNEW PAS prospective multicenter study reported 82.2% target lesion primary patency at 6 months (Kaplan-Meier estimate) among 93 patients, with 60.0% access circuit primary patency, 100% acute technical success, and 94.9% freedom from primary safety events at 30 days; complications were minimal, including no device-related deaths.[](https://link.springer.com/article/10.1007/s00270-024-03930-7)\n\nBard stent grafts, such as the Fluencyâ„¢ system, have improved patency outcomes in dialysis circuits compared to percutaneous transluminal angioplasty (PTA). Randomized trials including FLAIR showed 51% treatment area patency at 6 months versus 23% with PTA (P \u003c .001) and 38% access circuit patency versus 20% (P = 0.008); RENOVA reported 47.6% versus 24.8% at 12 months (P \u003c .001); and RESCUE found 66.4% treatment area patency versus 12.3% at 6 months (P \u003c .001), with overall reductions in reintervention rates but no differences in complications or survival.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC8856768/)\n\n| Trial | Device Comparison | 6-Month Treatment Area Patency | Clinical Impact |\n|-------|-------------------|--------------------------------|-----------------|\n| FLAIR | Bard Fluency Stent Graft vs. PTA | 51% vs. 23% (P \u003c .001) | Reduced reinterventions; lower costs in some scenarios |\n| RESCUE | Stent Graft vs. PTA | 66.4% vs. 12.3% (P \u003c .001) | Extended time to next intervention |\n| RENOVA | Stent Graft vs. PTA | Sustained benefits to 24 months (26.9% vs. 13.5%, P \u003c .001) | Improved durability in high-risk grafts |[](https://pmc.ncbi.nlm.nih.gov/articles/PMC8856768/)\n\nFor surgical hernia repair, Bard's Phasixâ„¢ poly-4-hydroxybutyrate (P4HB) mesh has been associated with low complication rates and durable repairs in high-risk patients. A prospective multicenter study of ventral or incisional hernia repair with Phasix mesh reported favorable 3-year outcomes, including low recurrence and surgical site occurrences in cohorts at risk for complications, with improvements in quality of life metrics.[](https://pmc.ncbi.nlm.nih.gov/articles/PMC7750179/)[](https://www.researchgate.net/publication/347977018_Prospective_multicenter_study_of_P4HB_Phasix_mesh_for_hernia_repair_in_cohort_at_risk_for_complications_3-Year_follow-up)\n\n## Legal and Regulatory Issues\n\n### Anti-Kickback Settlements\n\nIn January 2025, C.R. Bard, Inc., along with affiliates Liberator Medical Supply, Inc., Liberator Holdings, LLC, and Rochester Medical Corporation, agreed to pay $17 million to resolve allegations under the False Claims Act stemming from violations of the Anti-Kickback Statute.[](https://www.justice.gov/usao-ndga/pr/cr-bard-inc-and-affiliates-pay-17-million-resolve-allegations-healthcare-kickbacks) The U.S. Department of Justice claimed that from approximately 2016 to 2022, the companies provided unlawful remuneration, including free supplies, volume-based discounts, and other incentives, to urology practices to induce purchases and prescriptions of Bard's intermittent catheters reimbursable by Medicare, Medicaid, and other federal healthcare programs.[](https://oig.hhs.gov/fraud/enforcement/cr-bard-inc-and-affiliates-pay-17-million-to-resolve-allegations-of-healthcare-kickbacks/) Bard did not admit liability in the settlement, which was initiated by a whistleblower qui tam action under the False Claims Act.[](https://www.justice.gov/usao-ndga/pr/cr-bard-inc-and-affiliates-pay-17-million-resolve-allegations-healthcare-kickbacks)\n\nEarlier, in May 2013, C.R. Bard, Inc. settled False Claims Act allegations for $48.26 million related to Anti-Kickback Statute violations occurring between 1998 and 2006.[](https://www.justice.gov/archives/opa/pr/cr-bard-inc-pay-us-4826-million-resolve-false-claims-act-claims) The government alleged that Bard offered physicians and hospitals inducements such as unrestricted grant money, rebates, advertising support, and free equipment to encourage purchases of Bard's products, including brachytherapy seeds used in prostate cancer treatment and other medical devices reimbursable by federal programs.[](https://www.fbi.gov/atlanta/press-releases/2013/c.r.-bard-inc.-to-pay-u.s.-48.26-million-to-resolve-false-claims-act-claims) These practices purportedly generated false claims submitted to Medicare and other programs; Bard again denied wrongdoing in the resolution.[](https://www.justice.gov/archives/opa/pr/cr-bard-inc-pay-us-4826-million-resolve-false-claims-act-claims)\n\nIn September 2025, Bard Peripheral Vascular, Inc.â€”a Bard subsidiaryâ€”and related entities settled for approximately $7.25 million as part of a broader $37 million False Claims Act resolution involving Semler Scientific, Inc., over kickback allegations tied to diagnostic testing devices.[](https://www.justice.gov/opa/pr/semler-scientific-inc-and-bard-peripheral-vascular-inc-pay-nearly-37m-resolve-false-claims) The claims centered on remuneration provided to physicians from 2017 to 2023 to promote orders of Bard-distributed FloChec and EverFlow tests for peripheral artery disease, leading to reimbursable claims under federal healthcare programs.[](https://www.justice.gov/opa/pr/semler-scientific-inc-and-bard-peripheral-vascular-inc-pay-nearly-37m-resolve-false-claims) No admission of liability occurred, and the settlement addressed inducements like speaker fees and consulting payments lacking fair market value.[](https://www.justice.gov/opa/pr/semler-scientific-inc-and-bard-peripheral-vascular-inc-pay-nearly-37m-resolve-false-claims)\n\n### Transvaginal Mesh Litigation\n\nC.R. Bard, Inc. faced thousands of lawsuits alleging that its transvaginal mesh products, particularly the Avaulta Solo and Avaulta Forte systems introduced in the mid-2000s for treating pelvic organ prolapse and stress urinary incontinence, caused severe complications including mesh erosion, chronic pain, organ perforation, and recurrent infections requiring multiple revision surgeries.[](https://www.classaction.com/transvaginal-mesh/settlement/)[](https://www.forthepeople.com/blog/bard-avaulta-vaginal-mesh-complications-fda-warnings/) Plaintiffs claimed the polypropylene mesh was defectively designed and inadequately tested, with Bard failing to warn adequately about risks despite internal knowledge of issues.[](https://www.youhavealawyer.com/mesh/avaulta/)\n\nLitigation consolidated into multidistrict proceedings in the U.S. District Court for the Southern District of West Virginia, where bellwether trials tested claims; Bard defended by arguing the devices' benefits outweighed disclosed risks and that complications stemmed from surgical technique or patient factors rather than inherent defects.[](https://www.torhoermanlaw.com/vaginal-mesh-lawsuit/bard-vaginal-mesh-lawsuit/) Early verdicts included a $5.5 million award in 2012 to a California plaintiff who underwent eight revision surgeries after Avaulta implantation, and a $2 million compensatory damages ruling in a Georgia state court case against Bard.[](https://thesandersfirm.com/transvaginal-mesh-overview/transvaginal-mesh-settlements-verdicts/)[](https://www.pmkm.com/bard-loses-millions-georgia-womans-vaginal-mesh-case/)\n\nTo resolve mounting claims, Bard reached settlements totaling hundreds of millions; in October 2014, it agreed to pay over $21 million to resolve more than 500 Avaulta cases, averaging approximately $43,000 per claimant without admitting liability.[](https://www.classaction.com/transvaginal-mesh/settlement/) This was followed by a $200 million global settlement in August 2015 covering about 3,000 additional pelvic mesh lawsuits, including Avaulta-related claims, amid ongoing trials and FDA scrutiny of transvaginal mesh risks.[](https://www.torhoermanlaw.com/vaginal-mesh-lawsuit/transvaginal-mesh-settlement-amounts/)[](https://www.brownlawoffice.com/blog/bard-settles-3000-vaginal-mesh-cases-with-200m-settlement-sources-say/)\n\nDespite these resolutions, over 10,000 cases remained unresolved as of mid-decade, with some later trials yielding large plaintiff verdicts, such as $68 million in compensatory and punitive damages from a New Jersey jury in 2014 (upheld on appeal in part).[](https://www.expertinstitute.com/resources/insights/plaintiff-awarded-68-million-in-c-r-bard-pelvic-repair-mesh-trial/) Bard discontinued U.S. sales of its transvaginal mesh for prolapse in 2016, aligning with FDA reclassification of such devices as high-risk Class III requiring premarket approval, though no Bard-specific recall occurred.[](https://www.torhoermanlaw.com/vaginal-mesh-lawsuit/bard-vaginal-mesh-lawsuit/) The litigation contributed to broader industry shifts, including the FDA's 2019 order halting sales of transvaginal mesh for prolapse repair due to disproportionate risks versus benefits.[](https://www.drugwatch.com/transvaginal-mesh/recall/)\n\n### Inferior Vena Cava (IVC) Filter Cases\n\nThe Inferior Vena Cava (IVC) filter products manufactured by C.R. Bard, including the Recovery, G2, G2X, Eclipse, and Meridian models, were designed to prevent pulmonary embolisms by capturing blood clots in patients at high risk for deep vein thrombosis.[](https://www.drugwatch.com/ivc-filters/lawsuits/bard/) These retrievable filters faced allegations in lawsuits that they exhibited higher rates of complications such as strut fracture, migration, tilting, and perforation of the IVC wall or adjacent organs compared to predicate devices, leading to risks of embolization, hemorrhage, and death.[](https://www.jvir.org/article/S1051-0443%2822%2901066-1/fulltext) Plaintiffs claimed Bard failed to adequately warn of these risks and continued marketing despite internal awareness of elevated adverse event reports, including data from the FDA's MAUDE database showing Bard filters linked to 39 deaths as reported by NBC investigations.[](https://www.drugwatch.com/ivc-filters/lawsuits/)\n\nLitigation consolidated into multidistrict proceedings (MDL No. 2185) in the U.S. District Court for the District of Arizona, where thousands of cases alleged design defects, manufacturing flaws, and inadequate testing under theories of strict liability, negligence, and failure to warn.[](https://www.drugwatch.com/ivc-filters/lawsuits/bard/) Bellwether trials tested key issues: In October 2018, a jury awarded $3.6 million ($1.6 million compensatory and $2 million punitive) to a plaintiff injured by a fracturing G2 filter that migrated and perforated organs.[](https://www.wisnerbaum.com/defective-medical-device-injuries/ivc-filter-lawsuit/) A subsequent verdict in 2019 granted $926,000 to another plaintiff for similar G2 complications.[](https://www.drugwatch.com/ivc-filters/lawsuits/bard/) In July 2021, verdicts included $386,250 for Recovery filter fracture causing embolization and $3.3 million (upheld on appeal) for a Meridian filter leg that embolized to the heart, as awarded to Natalie Johnson in Wisconsin federal court.[](https://www.bencmartin.com/news/category/ivc-filters/)[](https://www.millerandzois.com/products-liability/medical-device-lawsuits/ivc-filters/)\n\nBard defended the filters as safe and effective when used per instructions for short-term implantation in appropriately selected patients, arguing that complications often stemmed from off-label permanent use or patient factors rather than inherent defects, and citing FDA approval via 510(k) clearance.[](https://www.drugwatch.com/ivc-filters/lawsuits/bard/) However, juries in multiple bellwether cases found Bard liable for defective design and punitive damages, with one Dallas firm securing verdicts totaling over $7 million across several Recovery and G2 filter injury claims by July 2021.[](https://www.dallasnews.com/business/local-companies/2021/07/26/dallas-law-firms-combined-verdicts-top-7-million-in-series-of-blood-clot-filter-lawsuits/)\n\nBy March 2024, the MDL remained active with ongoing settlements, though most cases had resolved confidentially, and lawyers continued filing new claims.[](https://www.drugwatch.com/ivc-filters/lawsuits/bard/) As of October 2025, the Bard IVC filter MDL closed following agreements on major settlement terms, resolving remaining inventory cases without public disclosure of total amounts, while emphasizing Bard's (now BD's) position that the devices prevented countless emboli.[](https://www.consumernotice.org/legal/ivc-filter-lawsuits/) An analysis of 557 Bard IVC filter cases in litigation reported common complications including 30% IVC penetration, 30% migration, and 26% fracture rates, with 45% requiring intervention.[](https://www.jvir.org/article/S1051-0443%2822%2901066-1/fulltext)\n\n### Hernia Mesh Disputes\n\nC.R. Bard, Inc., through its Davol subsidiary, produced polypropylene-based hernia mesh devices such as the Ventralex, Ventralex ST, Composix, and PerFix Plug, intended for ventral and inguinal hernia repairs by providing tissue reinforcement and promoting integration.[](https://www.lawsuit-information-center.com/bard-hernia-mesh-lawsuits.html) These products faced allegations in multidistrict litigation (MDL No. 2846) in the U.S. District Court for the Southern District of Ohio, where plaintiffs claimed defects including mesh contraction, degradation, and excessive inflammatory response caused complications like chronic pain, infections, adhesions, bowel obstructions, and recurrent hernias necessitating revision surgeries.[](https://www.sokolovelaw.com/product-liability/medical-devices/hernia-mesh/)[](https://www.medtechdive.com/news/BD-settlement-hernia-mesh-lawsuit/728829/)\n\nBy mid-2025, over 25,000 federal lawsuits were pending against Bard in the MDL, with additional state claims, primarily asserting failure to warn of risks and inadequate pre-market testing despite known issues with polypropylene meshes eroding or migrating post-implantation.[](https://federal-lawyer.com/injury-lawsuit/hernia-mesh/) Bard defended by arguing that individual surgeon technique and patient factors contributed more to adverse outcomes than device design, and that clinical data supported efficacy in most cases.[](https://www.robertkinglawfirm.com/personal-injury/hernia-mesh-lawsuit/hernia-mesh-settlements/) Key bellwether trials highlighted disputes: in 2022, a Rhode Island jury awarded $4.8 million to a plaintiff alleging severe injuries from Ventralex mesh, including multiple corrective procedures; a subsequent Ohio verdict in 2023 reached $500,000 for PerFix Plug complications.[](https://www.sokolovelaw.com/product-liability/medical-devices/hernia-mesh/)[](https://www.medtechdive.com/news/BD-settlement-hernia-mesh-lawsuit/728829/)\n\nThe Kugel Hernia Patch, an earlier Bard product recalled in 2005 and 2007 due to ring breakage risks causing bowel perforations and deaths in rare instances, prompted a 2011 settlement of 2,600 claims for $184 million, resolving allegations of manufacturing flaws and inadequate disclosures.[](https://www.lawsuit-information-center.com/bard-hernia-mesh-lawsuits.html)[](https://www.consumernotice.org/legal/hernia-mesh-lawsuits/settlements/) For non-recalled products like Ventralex and Composix, approximately 2,500 and thousands of suits respectively alleged similar polypropylene-related failures, though the FDA classified most as Class II devices with no broad recall, issuing only general safety communications on mesh risks in 2011 and 2018.[](https://nighgoldenberg.com/ventralex-hernia-mesh-lawsuit/)[](https://www.kugelherniameshclassaction.com/composix-e-x-and-l-p/)\n\nIn October 2024, Becton Dickinson (Bardâ€™s parent) approved a global resolution for roughly 38,000 claims across federal and state courts, with projected average payouts of $60,000â€“$100,000 per qualifying case based on injury severity, though weaker claims offered quick-pay options as low as $25,000; total value exceeded $1 billion in estimates, reflecting Bard's strategy to avoid prolonged jury risks amid mounting evidence of revision rates up to 20% in some studies.[](https://www.motleyrice.com/medical-devices/hernia-mesh)[](https://www.lawsuit-information-center.com/how-much-compensation-can-you-expect-for-a-hernia-mesh-lawsuit.html) This settlement did not admit liability, and remaining outlier cases continued, underscoring ongoing debates over mesh innovation benefits versus complication causality, with plaintiff experts citing peer-reviewed data on foreign body reactions while Bard referenced long-term success in population-level hernia recurrence reductions.[](https://www.robertkinglawfirm.com/personal-injury/hernia-mesh-lawsuit/hernia-mesh-settlements/)[](https://www.medtechdive.com/news/BD-settlement-hernia-mesh-lawsuit/728829/)\n\n### FDA Warnings, Recalls, and Compliance\n\nIn July 2015, the FDA issued a warning letter to C.R. Bard, Inc., citing multiple violations of the Federal Food, Drug, and Cosmetic Act and FDA regulations at its facilities in Tempe, Arizona, and Queensbury, New York. The letter identified marketing of the Recovery Cone Removal System (Model RC 15) and Model FBRC without required premarket approval or 510(k) clearance, inadequate complaint handling procedures that misclassified events such as patient deaths and serious injuries related to inferior vena cava (IVC) filters as mere malfunctions, failures to submit timely Medical Device Reports (MDRs) for events posing risks of death or serious injury, unvalidated manufacturing processes for IVC filter cleaning and dimensioning, and improper acceptance of incoming products without full inspection. Bard was required to respond within 15 business days outlining corrective actions, with the FDA warning of potential regulatory actions including seizures or injunctions if deficiencies persisted.\n\nC.R. Bard has initiated or been subject to numerous device recalls classified by the FDA, often Class II for potential temporary or reversible health risks, though some escalated to Class I indicating a reasonable probability of serious adverse health consequences or death. A prominent example is the 2005â€“2007 recalls of Composix Kugel hernia patch meshes, including large circle and oval models, classified as Class I in 2007 due to reports of the internal polypropylene ring breaking, which could lead to bowel perforation, abscesses, or other complications requiring surgical intervention.[](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfres/res.cfm?id=49722) Initial recalls began in December 2005 after post-market complaints, expanding to affect thousands of units distributed domestically and internationally.[](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfres/res.cfm?start_search=1\u0026event_id=34393)\n\nMore recent actions include a Class I recall in April 2025 for Bard Blakemore Esophageal-Nasogastric Tubes (adult size), prompted by risks of balloon deflation failure during esophagogastric tamponade for bleeding control, potentially causing life-threatening hemorrhage; BD (Bardâ€™s parent) updated instructions but did not remove devices from use.[](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfres/res.cfm?id=213347) [](https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/esophagogastric-tube-recall-bd-issues-correction-esophagogastric-balloon-tamponade-tubes-due) Class II recalls have addressed issues such as mislabeling in Ventralex ST hernia patches (2011), reduced flow in NG Sump Tubes with ENFit connectors (January 2024), and manufacturing defects in Magic3 GO catheters (2023).[](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfres/res.cfm?id=205286) [](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfres/res.cfm?id=104352) Additionally, FDA early alerts in 2025 highlighted risks with Bard Peripheral Vascular atherectomy catheters (potential for tip detachment) and BD PICC catheters (hub separation), urging immediate mitigation.[](https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/update-alert-atherectomy-catheter-system-issue-bard-peripheral-vascular) [](https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/early-alert-intravascular-picc-catheter-issue-bd)\n\nCompliance efforts following these actions have included process validations, enhanced reporting, and facility corrections, though FDA inspections have repeatedly uncovered persistent quality system gaps, particularly in high-risk vascular and surgical devices. No further enforcement like import alerts or facility shutdowns have been publicly documented post-2015, but ongoing recalls suggest continued scrutiny of Bard's (now BD's) manufacturing and post-market surveillance.[](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfres/res.cfm?start_search=1\u0026event_id=93679)"])</script><script nonce="NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh">self.__next_f.push([1,"8:[\"$\",\"$L1e\",null,{\"state\":{\"mutations\":[],\"queries\":[{\"dehydratedAt\":1761885866793,\"state\":{\"data\":{\"page\":{\"citations\":[{\"id\":\"1\",\"title\":\"[PDF] C. R. BARD, INC. - SEC.gov\",\"description\":\"In 2003, Bard acquired the assets of Source Tech Medical, LLC and certain assets of Prostate Services of America, Inc. and Imagyn Medical. Technologies, Inc.\",\"url\":\"https://www.sec.gov/Archives/edgar/data/9892/000119312505038606/d10k1.pdf\",\"favicon\":\"\"},{\"id\":\"2\",\"title\":\"Our Company - BD\",\"description\":\"2017 BD acquired C. R. Bard, a medical device company founded in 1907 in Covington, Georgia. 2015 BD became the first to integrate IV pumps with electronicÂ ...\",\"url\":\"https://www.bd.com/en-us/about-bd/our-company\",\"favicon\":\"\"},{\"id\":\"3\",\"title\":\"C.R. Bard - Companies History\",\"description\":\"Sep 13, 2014 Â· In 2012, Bard acquired Lutonix. In 2017, Bard was acquired by Becton Dickinson. With more than1 4.000 employees, C. R. Bard, Inc. wasÂ ...\",\"url\":\"https://www.companieshistory.com/cr-bard/\",\"favicon\":\"\"},{\"id\":\"4\",\"title\":\"BD Completes Bard Acquisition, Creating New Global Health Care ...\",\"description\":\"Dec 29, 2017 Â· It has completed the acquisition of CR Bard, Inc. (NYSE: BCR), creating a new health care industry leader with approximately $16 billion in annualized revenue.\",\"url\":\"https://news.bd.com/2017-12-29-BD-Completes-Bard-Acquisition-Creating-New-Global-Health-Care-Leader%2C1\",\"favicon\":\"\"},{\"id\":\"5\",\"title\":\"BD To Acquire Bard For $24 Billion - Investors\",\"description\":\"Apr 23, 2017 Â· Bard will expand BD's focus on the treatment of disease states beyond diabetes to include peripheral vascular disease, urology, hernia andÂ ...\",\"url\":\"https://investors.bd.com/news-events/press-releases/detail/403/bd-to-acquire-bard-for-24-billion\",\"favicon\":\"\"},{\"id\":\"6\",\"title\":\"Bard Mesh | BD\",\"description\":\"With more than 50 years of clinical experience, BardÂ® Mesh is the Gold Standard product to be used in a \\\"tension-free\\\" hernia repair.\",\"url\":\"https://www.bd.com/en-us/products-and-solutions/products/product-families/bard-mesh\",\"favicon\":\"\"},{\"id\":\"7\",\"title\":\"C.R. Bard: Devices, Recalls \u0026 Lawsuits - Drugwatch.com\",\"description\":\"C.R. Bard is a medical technology company specializing in vascular, urology, surgery and oncology devices. Becton, Dickinson \u0026 Co. acquired C.R. Bard Inc.\u003c|separator|\u003e\",\"url\":\"https://www.drugwatch.com/manufacturers/bard/\",\"favicon\":\"\"},{\"id\":\"8\",\"title\":\"C.R. Bard History, Products \u0026 Lawsuits\",\"description\":\"Feb 14, 2017 Â· Bard's acquisitions in the 21st Century included Surgical Sense, Inc. and its Kugel patch product line; vacuum-assisted biopsy deviceÂ ...\",\"url\":\"https://www.rxinjuryhelp.com/manufacturers/c-r-bard/\",\"favicon\":\"\"},{\"id\":\"9\",\"title\":\"C.R. Bard, Inc. - Company-Histories.com\",\"description\":\"1998: Company sells its coronary catheter laboratory business, including its angioplasty operations. 2001: C.R. Bard agrees to be acquired by Tyco InternationalÂ ...\",\"url\":\"https://www.company-histories.com/CR-Bard-Inc-Company-History.html\",\"favicon\":\"\"},{\"id\":\"10\",\"title\":\"Becton Dickinson to acquire Bard for $24 billion | Reuters\",\"description\":\"Apr 24, 2017 Â· The deal values Bard at $317 per share, a 25 percent premium over Friday's close of trading. Bard shareholders stand to receive $222.93 in cashÂ ...\",\"url\":\"https://www.reuters.com/article/business/becton-dickinson-to-acquire-bard-for-24-billion-idUSKBN17P0ZR/\",\"favicon\":\"\"},{\"id\":\"11\",\"title\":\"DEFM14A - SEC.gov\",\"description\":\"If the merger is completed, you will be entitled to receive for each share of Bard common stock $222.93 in cash, without interest, and 0.5077 of a share of BDÂ ...\",\"url\":\"https://www.sec.gov/Archives/edgar/data/9892/000119312517220263/d420627ddefm14a.htm\",\"favicon\":\"\"},{\"id\":\"12\",\"title\":\"Bard Shareholders Approve Proposed Merger With Becton, Dickinson\",\"description\":\"Aug 8, 2017 Â· Bard shareholders approved the definitive merger agreement, with approximately 99% of shares voting cast in favor of the proposal.\",\"url\":\"https://investors.bd.com/news-events/press-releases/detail/379/bard-shareholders-approve-proposed-merger-with-becton-dickinson\",\"favicon\":\"\"},{\"id\":\"13\",\"title\":\"BD and Bard Receive Second Requests from FTC under HSR Act\",\"description\":\"Jun 9, 2017 Â· The transaction, which was announced on April 23, 2017, is subject to regulatory and Bard shareholder approvals and customary closing conditionsÂ ...\",\"url\":\"https://investors.bd.com/news-events/press-releases/detail/388/bd-and-bard-receive-second-requests-from-ftc-under-hsr-act\",\"favicon\":\"\"},{\"id\":\"14\",\"title\":\"Case M.8523 - BD / BARD REGULATION (EC) No 139/2004 ...\",\"description\":\"Oct 18, 2017 Â· 4 Therefore, the Transaction consists in the acquisition by BD of sole control over Bard. (5). In the light of the above, the TransactionÂ ...\",\"url\":\"https://ec.europa.eu/competition/mergers/cases/decisions/m8523_1133_3.pdf\",\"favicon\":\"\"},{\"id\":\"15\",\"title\":\"BD Statement On MOFCOM Clearance Of Bard Acquisition - Investors\",\"description\":\"Dec 28, 2017 Â· \\\"MOFCOM clearance was the final regulatory approval needed to complete the Bard acquisition,\\\" said Vincent A. Forlenza, chairman and CEO of BD.\",\"url\":\"https://investors.bd.com/news-events/press-releases/detail/355/bd-statement-on-mofcom-clearance-of-bard-acquisition\",\"favicon\":\"\"},{\"id\":\"16\",\"title\":\"Form 8-K - SEC.gov\",\"description\":\"Dec 29, 2017 Â· On December 29, 2017, BD completed the acquisition of C. R. ... Agreement and Plan of Merger, dated April 23, 2017, among Becton, Dickinson andÂ ...\",\"url\":\"https://www.sec.gov/Archives/edgar/data/10795/000119312517383523/d517273d8k.htm\",\"favicon\":\"\"},{\"id\":\"17\",\"title\":\"BD Completes Bard Acquisition, Creating New Global Health Care ...\",\"description\":\"Dec 29, 2017 Â· It has completed the acquisition of CR Bard, Inc. (NYSE: BCR), creating a new health care industry leader with approximately $16 billion in annualized revenue.\",\"url\":\"https://www.prnewswire.com/news-releases/bd-completes-bard-acquisition-creating-new-global-health-care-leader-300576098.html\",\"favicon\":\"\"},{\"id\":\"18\",\"title\":\"BDÂ® Acute Urology\",\"description\":\"BD Acute Urology provides products for managing catheter-associated UTIs, including indwelling, external, and intermittent catheters, and bladder scanners.Missing:  CR | Show results with:CR\",\"url\":\"https://www.bd.com/en-us/products-and-solutions/solutions/bd-acute-urology\",\"favicon\":\"\"},{\"id\":\"19\",\"title\":\"Urological Catheters - Bard Medical - PDF Catalogs\",\"description\":\"The Bard Advantage n rovides the widest portfolio of urological catheter system components in the industry, P including the widest assortment of specialtyÂ ...\",\"url\":\"https://pdf.medicalexpo.com/pdf/bard-medical/urological-catheters/78646-131364.html\",\"favicon\":\"\"},{\"id\":\"20\",\"title\":\"Products - BD\",\"description\":\"HemoSphere Altaâ„¢ Monitor is designed to help you detect hemodynamic instability before it occursâ€”so you can stay ahead of critical momentsÂ ...\",\"url\":\"https://www.bd.com/en-us/products-and-solutions/products\",\"favicon\":\"\"},{\"id\":\"21\",\"title\":\"Urinary Diversion Stent - BD\",\"description\":\"The BD Urinary Diversion Stent is intended for use in drainage of urine from the kidney to the external stoma following any uretero-intestinal diversionÂ ...\",\"url\":\"https://www.bd.com/en-us/products-and-solutions/products/product-families/urinary-diversion-stent\",\"favicon\":\"\"},{\"id\":\"22\",\"title\":\"The history of Bactiguard - A Swedish innovation\",\"description\":\"In 1994, the US Food and Drug Administration (FDA) approves Bard's urinary catheters Bardex IC and Lubrisil IC with Bactiguard coating (FDA 510k approval). TheÂ ...Missing:  urological | Show results with:urological\",\"url\":\"https://www.bactiguard.com/about-us/history/\",\"favicon\":\"\"},{\"id\":\"23\",\"title\":\"Vascular access management - BD\",\"description\":\"Our extensive portfolio of vascular access devices, paired with product training and education, can help you address the vascular access needs of all patients.\",\"url\":\"https://www.bd.com/en-us/products-and-solutions/solutions/vascular-access-management\",\"favicon\":\"\"},{\"id\":\"24\",\"title\":\"Product Catalog | BD\",\"description\":\"Choose from our product lines below to view our online product catalog. Products. Guidance Technologies Â· Access Devices Â· Care \u0026 Maintenance. Bard Access.\",\"url\":\"https://www.bardaccess.com/catalog\",\"favicon\":\"\"},{\"id\":\"25\",\"title\":\"[PDF] BardÂ® LifeStentÂ® Vascular Stent System - accessdata.fda.gov\",\"description\":\"The LIFESTENTÂ® Vascular Stent System is intended to improve luminal diameter in the treatment of symptomatic de novo or restenotic lesions up to 240 mm inÂ ...\",\"url\":\"https://www.accessdata.fda.gov/cdrh_docs/pdf7/P070014S037d.pdf\",\"favicon\":\"\"},{\"id\":\"26\",\"title\":\"[PDF] Bard Peripheral Vascular PRODUCT LIST - MicroMed AS\",\"description\":\"V Â® Vascular Access Grafts . ... BARDÂ® Button Device Feeding Tube Bolus with Straight Adaptor (Non-Sterile). 000257. 18 F. 10\\\". Non-Balloon. 12/case. 000259. 24 F.\",\"url\":\"http://www.micromed.no/Userfiles/Sites/files/2014_Product_List_S120082_Rev2.pdf\",\"favicon\":\"\"},{\"id\":\"27\",\"title\":\"INTRODUCER SETS - Bard Access Systems - Catalogs Medicalexpo\",\"description\":\"Bard Access Systems offers an exclusive line of needle guides designed for Site-RiteÂ® Ultrasound Systems to help clinicians guide needles to vascularÂ ...\u003c|separator|\u003e\",\"url\":\"https://pdf.medicalexpo.com/pdf/bard-access-systems/introducer-sets/78824-181932.html\",\"favicon\":\"\"},{\"id\":\"28\",\"title\":\"C.R. Bard Inc. to Pay U.S. $48.26 Million to Resolve False Claims ...\",\"description\":\"May 13, 2013 Â· The settlement requires that Bard pay $48.26 million and it resolves claims relating to Bard's sale of brachytherapy seeds, a form of radiationÂ ...Missing:  oncology | Show results with:oncology\",\"url\":\"https://www.justice.gov/archives/opa/pr/cr-bard-inc-pay-us-4826-million-resolve-false-claims-act-claims\",\"favicon\":\"\"},{\"id\":\"29\",\"title\":\"Brachytherapy, BrachySourceâ„¢ I-125 Seed, Seed Implants, Loose\",\"description\":\"The BrachySourceâ„¢ I-125 Seed Implant has an innovative design and provides radiopaque visibility that makes BrachySourceâ„¢ I-125 Seed Implant an ideal choiceÂ ...\",\"url\":\"https://www.bd.com/en-us/products-and-solutions/products/product-page.ps1251l\",\"favicon\":\"\"},{\"id\":\"30\",\"title\":\"[PDF] Your Total Prostate Brachytherapy Solutions - BD\",\"description\":\"BrachySourceâ„¢ Seed Implants are indicated to treat residual tumors following completion of a course of external radiation therapy and for recurrent tumors.\",\"url\":\"https://eu.bd.com/emea-peripheral-interventions/lib/asset/227.pdf\",\"favicon\":\"\"},{\"id\":\"31\",\"title\":\"M.R.I.â„¢ Dual-Lumen Implantable Port - BD\",\"description\":\"M.R.I.â„¢ Dual-Lumen Implantable Port Â· Large dual silicone septa Â· Ideal for M.R.I. or radiation therapy Â· Plastic construction Â· Exclusive Septum-Finderâ„¢ ridge.\",\"url\":\"https://www.bd.com/en-us/products-and-solutions/products/product-families/mri-dual-lumen-implantable-port\",\"favicon\":\"\"},{\"id\":\"32\",\"title\":\"PowerPortâ„¢ ClearVUEâ„¢ Implantable Ports\",\"description\":\"PowerPortâ„¢ ClearVUEâ„¢ ports are metal-free, MR safe, power-injectable, enable clear imaging, minimize radiation, and are designed for easy placement.\",\"url\":\"https://www.bd.com/en-us/products-and-solutions/products/product-families/powerport-clearvue-implantable-ports\",\"favicon\":\"\"},{\"id\":\"33\",\"title\":\"Gamma FinderÂ® III Wireless Gamma Detector - BD\",\"description\":\"The Gamma Finder III is a self-contained probe for detecting gamma radiation (20-512 keV) in breast cancer and melanoma, with a single probe for lymphaticÂ ...\",\"url\":\"https://www.bd.com/en-us/products-and-solutions/products/product-families/gamma-finder-iii-wireless-gamma-detector\",\"favicon\":\"\"},{\"id\":\"34\",\"title\":\"C. R. Bard to Acquire SenoRx for $213 Million\",\"description\":\"A new study finds that brachytherapy, a common procedure that delivers radiation directly to cancer cells ... Time May 19, 2021.\",\"url\":\"https://www.itnonline.com/content/c-r-bard-acquire-senorx-213-million\",\"favicon\":\"\"},{\"id\":\"35\",\"title\":\"EnCor Enspireâ„¢ Breast Biopsy System - BD\",\"description\":\"A smart breast biopsy system features a sleek, streamlined console, a simple touch monitor, and versatile performance in multiple modalities.Missing:  CR | Show results with:CR\",\"url\":\"https://www.bd.com/en-us/products-and-solutions/products/product-families/encor-enspire-breast-biopsy-system\",\"favicon\":\"\"},{\"id\":\"36\",\"title\":\"Major Hernia Mesh Manufacturers \u0026 Popular Mesh Brands\",\"description\":\"Bard Davol specializes in disease management. It also makes more than a dozen hernia mesh products. Becton, Dickinson and Company acquired Bard Davol in 2017.\",\"url\":\"https://www.drugwatch.com/hernia-mesh/manufacturers/\",\"favicon\":\"\"},{\"id\":\"37\",\"title\":\"Ventralexâ„¢ ST Hernia Patch for Surgery \u0026 Repair - BD\",\"description\":\"A clinically proven umbilical hernia repair solution designed for ventral, incisional, umbilical and epigastric hernia repair as well as trocar site closure.\",\"url\":\"https://www.bd.com/en-us/products-and-solutions/products/product-families/ventralex-st-hernia-patch\",\"favicon\":\"\"},{\"id\":\"38\",\"title\":\"[PDF] Product Catalogue - Hernia Repair\",\"description\":\"The BARDÂ® COMPOSIXâ„¢ L/P Mesh is a light-weight, low-profile implant, which could easily introduced through a trocar and which offers an adhesion barrier.\",\"url\":\"https://akinglobal.com.tr/uploads/subdir-182-4/BARD_catalogue.pdf\",\"favicon\":\"\"},{\"id\":\"39\",\"title\":\"A Review of Abdominal Meshes for Hernia Repairâ€”Current Status ...\",\"description\":\"Despite the wide range of currently available mesh options, there is still room for improvement toward optimizing hernia repair management.\u003c|separator|\u003e\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC10672379/\",\"favicon\":\"\"},{\"id\":\"40\",\"title\":\"C.R. Bard Hernia Repair Device FDA Cleared - iData Research\",\"description\":\"May 12, 2019 Â· This system allows for a more accurate and reliable mesh placement for minimally invasive hernia repairs. Through preclinical tests, it wasÂ ...\",\"url\":\"https://idataresearch.com/c-r-bard-hernia-repair-device-fda-cleared/\",\"favicon\":\"\"},{\"id\":\"41\",\"title\":\"[PDF] BD Surgical Product Catalogue\",\"description\":\"Monofilament polypropylene mesh for use in ventral or inguinal hernia repair. BardÂ® Soft Mesh. Large pore monofilament polypropylene mesh that has a soft,.\",\"url\":\"https://eu.bd.com/your-surgery/wp-content/uploads/2025/04/BD-107468-BDI-Surgery-Catalogue-October-2024.pdf\",\"favicon\":\"\"},{\"id\":\"42\",\"title\":\"Bard Catheters: Facts, History \u0026 Usage - Active Life Medical Products\",\"description\":\"Dec 20, 2021 Â· Charles BARD founded the company in 1907 in New York City following his first import of urinary discomfort treatment, Gomenol. Over the years,Â ...Missing:  innovations | Show results with:innovations\",\"url\":\"https://activelifemed.com/catheter-resource/bard-catheters-facts-history-usage/\",\"favicon\":\"\"},{\"id\":\"43\",\"title\":\"A Short History of the Foley Catheter - Mary Ann Liebert, Inc.\",\"description\":\"urinary tract infections. In the late 1960s, CR Bard introduced Teflon-coated latex catheters designed to improve the ease and comfort of inser- tion. InÂ ...Missing:  innovations | Show results with:innovations\",\"url\":\"https://www.liebertpub.com/doi/pdfplus/10.1089/end.2000.14.5\",\"favicon\":\"\"},{\"id\":\"44\",\"title\":\"C.R. Bard - Medical Product Outsourcing\",\"description\":\"Bard's Vascular business performed near the top of its guidance range in 2016 (year ended Dec. 31) due to strong global demand for the Lutonix 035 DCB, a drug-Â ...Missing:  timeline | Show results with:timeline\",\"url\":\"https://www.mpo-mag.com/top-company-profile/c-r-bard/\",\"favicon\":\"\"},{\"id\":\"45\",\"title\":\"[PDF] October 25, 2016 C.R. Bard, Inc. Mr. Bryan Stone Regulatory Affairs ...\",\"description\":\"Oct 25, 2016 Â· The PowerPICC Provena Catheters are indicated for short or long-term peripheral access to the central venous system for intravenous therapy,Â ...\",\"url\":\"https://www.accessdata.fda.gov/cdrh_docs/pdf16/K162443.pdf\",\"favicon\":\"\"},{\"id\":\"46\",\"title\":\"C.R. Bard and Teleflex Benefit from New Antimicrobial Catheter ...\",\"description\":\"Apr 12, 2011 Â· Companies such as Teleflex, Cook and C.R. Bard have leveraged antimicrobial technology to develop antimicrobial CVCs, PICCs, and dialysisÂ ...Missing:  innovations | Show results with:innovations\",\"url\":\"https://www.prnewswire.com/news-releases/cr-bard-and-teleflex-benefit-from-new-antimicrobial-catheter-power-picc-and-tip-location-technologies-in-3-billion-vascular-access-market-119681574.html\",\"favicon\":\"\"},{\"id\":\"47\",\"title\":\"Multicenter cohort study to assess the impact of a silver-alloy and ...\",\"description\":\"Use of a silver-alloy hydrogel urinary catheter reduced symptomatic CAUTI occurrences as defined by both NHSN and clinical criteria.Missing:  outcomes | Show results with:outcomes\",\"url\":\"https://pubmed.ncbi.nlm.nih.gov/24922561/\",\"favicon\":\"\"},{\"id\":\"48\",\"title\":\"Six-Month Outcomes from the Prospective, Multi-Center, Non ...\",\"description\":\"Jan 9, 2025 Â· We recently published results from the randomized, prospective, multi-center trial comparing the Coveraâ„¢ Vascular Covered Stent (CS) to PTA forÂ ...\",\"url\":\"https://link.springer.com/article/10.1007/s00270-024-03930-7\",\"favicon\":\"\"},{\"id\":\"49\",\"title\":\"Stent Graft Outcomes in Dialysis Circuits: A Review of Clinical Trials ...\",\"description\":\"Stent grafts appear to offer increased primary patency over balloon angioplasty in the treatment of dialysis circuit stenosis.\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC8856768/\",\"favicon\":\"\"},{\"id\":\"50\",\"title\":\"Prospective, multicenter study of P4HB (Phasixâ„¢) mesh for hernia ...\",\"description\":\"Dec 15, 2020 Â· This study was funded by CR Bard/Becton Dickinsone. Authors were reimbursed for expenses related to the conduct of the study. Provenance andÂ ...\",\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC7750179/\",\"favicon\":\"\"},{\"id\":\"51\",\"title\":\"Prospective, multicenter study of P4HB (Phasixâ„¢) mesh for hernia ...\",\"description\":\"... C.R. Bard, Inc., Warwick, RI) for primary ventral or incisional or. multiply ... Conclusions: P4HB mesh for complex VHR is associated with favorable 2-yearÂ ...\",\"url\":\"https://www.researchgate.net/publication/347977018_Prospective_multicenter_study_of_P4HB_Phasix_mesh_for_hernia_repair_in_cohort_at_risk_for_complications_3-Year_follow-up\",\"favicon\":\"\"},{\"id\":\"52\",\"title\":\"C.R. Bard, Inc. and Affiliates Pay $17 Million to Resolve Allegations ...\",\"description\":\"Jan 23, 2025 Â· The Liberator Defendants have agreed to pay $17 million to resolve allegations that they violated the False Claims Act and various state false claims actÂ ...\",\"url\":\"https://www.justice.gov/usao-ndga/pr/cr-bard-inc-and-affiliates-pay-17-million-resolve-allegations-healthcare-kickbacks\",\"favicon\":\"\"},{\"id\":\"53\",\"title\":\"C.R. Bard, Inc. and Affiliates Pay $17 Million to Resolve Allegations ...\",\"description\":\"Jan 23, 2025 Â· The â€œLiberator Defendantsâ€), have agreed to pay $17 million to resolve allegations that they violated the False Claims Act and various state false claims actÂ ...\",\"url\":\"https://oig.hhs.gov/fraud/enforcement/cr-bard-inc-and-affiliates-pay-17-million-to-resolve-allegations-of-healthcare-kickbacks/\",\"favicon\":\"\"},{\"id\":\"54\",\"title\":\"C.R. Bard Inc. to Pay U.S. $48.26 Million to Resolve False Claims ...\",\"description\":\"May 13, 2013 Â· WASHINGTONâ€”C.R. Bard Inc. has agreed to pay the United States $48.26 million to resolve claims that it knowingly caused false claims to beÂ ...\",\"url\":\"https://www.fbi.gov/atlanta/press-releases/2013/c.r.-bard-inc.-to-pay-u.s.-48.26-million-to-resolve-false-claims-act-claims\",\"favicon\":\"\"},{\"id\":\"55\",\"title\":\"Semler Scientific Inc. and Bard Peripheral Vascular Inc. to Pay ...\",\"description\":\"Sep 26, 2025 Â· Semler Scientific Inc. has agreed to pay $29.75 million and its former distributor, Bard Peripheral Vascular Inc. and its related companies,Â ...Missing:  scheme | Show results with:scheme\",\"url\":\"https://www.justice.gov/opa/pr/semler-scientific-inc-and-bard-peripheral-vascular-inc-pay-nearly-37m-resolve-false-claims\",\"favicon\":\"\"},{\"id\":\"56\",\"title\":\"Transvaginal Mesh Settlement - Pelvic Mesh Verdicts and Payouts\",\"description\":\"Bard agreed to pay more than $21 million to settle over 500 mesh lawsuits in October 2014 (an average payout of $43,000 per claim). It was the company' firstÂ ...C.R. Bard Â· Endo/american Medical... Â· Boston Scientific\",\"url\":\"https://www.classaction.com/transvaginal-mesh/settlement/\",\"favicon\":\"\"},{\"id\":\"57\",\"title\":\"Bard Avaulta Vaginal Mesh: Complications \u0026 FDA Warnings\",\"description\":\"Bard Avaulta mesh complications include infection, pain, bowel/bladder perforation, mesh erosion, internal bleeding, urinary problems, and nerve damage. FDAÂ ...\",\"url\":\"https://www.forthepeople.com/blog/bard-avaulta-vaginal-mesh-complications-fda-warnings/\",\"favicon\":\"\"},{\"id\":\"58\",\"title\":\"Bard Avaulta Lawsuit - Saiontz \u0026 Kirk\",\"description\":\"Bard Avaulta lawsuits allege that C.R. Bard was negligent in the design and sale of the Avault system. Since the vaginal mesh was introduced, the manufacturerÂ ...Bard Avaulta Lawsuit Â· Contact Our Lawyers About A... Â· Bard Avaulta Cases\",\"url\":\"https://www.youhavealawyer.com/mesh/avaulta/\",\"favicon\":\"\"},{\"id\":\"59\",\"title\":\"Bard Vaginal Mesh Lawsuit | 2025 Update - TorHoerman Law\",\"description\":\"The Bard Vaginal Mesh Lawsuit involves legal claims against C.R. Bard, Inc., a manufacturer of vaginal mesh products, by women who suffered complications afterÂ ...\",\"url\":\"https://www.torhoermanlaw.com/vaginal-mesh-lawsuit/bard-vaginal-mesh-lawsuit/\",\"favicon\":\"\"},{\"id\":\"60\",\"title\":\"Transvaginal Mesh Settlements \u0026 Verdicts - The Sanders Law Firm\",\"description\":\"$$5.5 million â€“ Christine Scott and her husband won a 2012 C.R. Bard transvaginal mesh lawsuit. The women underwent eight revision surgeries when the AvaultaÂ ...Transvaginal Mesh Verdicts Â· How To File A Transvaginal... Â· Call Our Transvaginal Mesh...\",\"url\":\"https://thesandersfirm.com/transvaginal-mesh-overview/transvaginal-mesh-settlements-verdicts/\",\"favicon\":\"\"},{\"id\":\"61\",\"title\":\"Bard Loses Millions In Georgia Woman's Vaginal Mesh Case\",\"description\":\"Just this week C.R. Bard, a maker of vaginal mesh implants, was ordered to pay a Georgia woman $2 million after the jury decided the medical device makerÂ ...\u003c|separator|\u003e\",\"url\":\"https://www.pmkm.com/bard-loses-millions-georgia-womans-vaginal-mesh-case/\",\"favicon\":\"\"},{\"id\":\"62\",\"title\":\"Transvaginal Mesh Settlement Amounts | 2025 Update\",\"description\":\"C.R. Bard: This mesh producer consented to a $21 million payout in October 2014 to settle more than 500 cases, and by August 2015, they addressed another 3,000Â ...\",\"url\":\"https://www.torhoermanlaw.com/vaginal-mesh-lawsuit/transvaginal-mesh-settlement-amounts/\",\"favicon\":\"\"},{\"id\":\"63\",\"title\":\"Bard Settles 3,000 Vaginal Mesh Cases with $200M Settlement\",\"description\":\"Rating  4.4  (353) Bard agrees to a $200M settlement for 3000 vaginal mesh lawsuits, addressing patient concerns and legal challenges. Read more here!\",\"url\":\"https://www.brownlawoffice.com/blog/bard-settles-3000-vaginal-mesh-cases-with-200m-settlement-sources-say/\",\"favicon\":\"\"},{\"id\":\"64\",\"title\":\"Plaintiff Awarded $68 Million in C.R. Bard Pelvic Repair Mesh Trial\",\"description\":\"Aug 31, 2021 Â· C.R. Bard suffered a major legal defeat as a New Jersey jury awarded $68 million in a pelvic mesh lawsuit, a pivotal case in ongoing massÂ ...\",\"url\":\"https://www.expertinstitute.com/resources/insights/plaintiff-awarded-68-million-in-c-r-bard-pelvic-repair-mesh-trial/\",\"favicon\":\"\"},{\"id\":\"65\",\"title\":\"Transvaginal Mesh Recalls \u0026 Discontinued Products - Drugwatch.com\",\"description\":\"Despite thousands of reports of serious injuries leading to lawsuits being filed, only one transvaginal mesh device has been recalled.ProteGen Mesh Recall Â· FDA Actions\",\"url\":\"https://www.drugwatch.com/transvaginal-mesh/recall/\",\"favicon\":\"\"},{\"id\":\"66\",\"title\":\"Bard IVC Filter Lawsuit: 2025 Updates \u0026 Average Suit Payout\",\"description\":\"$$3.6 million awarded to the plaintiff in the first Bard IVC filter bellwether trial prior to the MDL beginning. $926,000 awarded to plaintiff by jury.Lawsuit Updates Â· Why People Are Suing Â· Do I Qualify Â· Verdicts and Settlements\",\"url\":\"https://www.drugwatch.com/ivc-filters/lawsuits/bard/\",\"favicon\":\"\"},{\"id\":\"67\",\"title\":\"Inferior Vena Cava Filter Litigation Review: An Analysis of ... - JVIR\",\"description\":\"Jul 18, 2022 Â· The most common complications included IVC wall penetration (30%), filter migration (30%), and filter fracture (26%). â€¢. Forty-five percent ofÂ ...\",\"url\":\"https://www.jvir.org/article/S1051-0443%2822%2901066-1/fulltext\",\"favicon\":\"\"},{\"id\":\"68\",\"title\":\"IVC Filter Lawsuit: October 2025 Updates - Drugwatch.com\",\"description\":\"NBC linked Bard IVC filters to 39 deaths. Bard's IVC Filter Lawsuits. Jury verdicts in Bard IVC lawsuits have found in favor of plaintiffs, awardingÂ ...Lawsuit Updates Â· Why Are People Filing IVC... Â· Manufacturers and Brands...\",\"url\":\"https://www.drugwatch.com/ivc-filters/lawsuits/\",\"favicon\":\"\"},{\"id\":\"69\",\"title\":\"IVC Filter Lawsuits | Recalls, Deadlines, \u0026 Settlements - Wisner Baum\",\"description\":\"In 2018, a federal jury awarded $3.6 million to a plaintiff injured by Bard's G2 filter, which included compensatory and punitive damages. This verdict markedÂ ...Seeking Fair Compensation... Â· Ivc Filter Complications Â· C.R Bard Ivc Filters\u003c|separator|\u003e\",\"url\":\"https://www.wisnerbaum.com/defective-medical-device-injuries/ivc-filter-lawsuit/\",\"favicon\":\"\"},{\"id\":\"70\",\"title\":\"IVC Filter Complications Archives - Ben Martin Law Group\",\"description\":\"4th Successful IVC Filter Verdict for Ben Martin Law Group Awards Plaintiff $386,250. A federal jury on July 21, 2021 found that C.R. Bard Inc.'s IVC blood clotÂ ...\",\"url\":\"https://www.bencmartin.com/news/category/ivc-filters/\",\"favicon\":\"\"},{\"id\":\"71\",\"title\":\"IVC Filter Lawsuit Settlements | August 2023 Update - Miller \u0026 Zois\",\"description\":\"The Seventh Circuit upheld last week a $3.3 million verdict in favor of Natalie Johnson, who alleged that a shard from a Meridian filter, made by C.R. Bard,Â ...\",\"url\":\"https://www.millerandzois.com/products-liability/medical-device-lawsuits/ivc-filters/\",\"favicon\":\"\"},{\"id\":\"72\",\"title\":\"Dallas law firm's combined verdicts top $7 million in series of blood ...\",\"description\":\"Jul 26, 2021 Â· In the latest case, decided July 21, jurors found that Bard's Recovery IVC filter caused serious complications when the device fractured afterÂ ...\u003c|separator|\u003e\",\"url\":\"https://www.dallasnews.com/business/local-companies/2021/07/26/dallas-law-firms-combined-verdicts-top-7-million-in-series-of-blood-clot-filter-lawsuits/\",\"favicon\":\"\"},{\"id\":\"73\",\"title\":\"IVC Filter Lawsuit: Status Updates \u0026 Settlement Amounts\",\"description\":\"IVC Filter Settlements and Verdicts Â· June 2021: A Wisconsin plaintiff received a $3.3 million verdict against C.R. Bard. Â· October 2019: Courts awarded TracyÂ ...\",\"url\":\"https://www.consumernotice.org/legal/ivc-filter-lawsuits/\",\"favicon\":\"\"},{\"id\":\"74\",\"title\":\"Bard Hernia Mesh Lawsuit | Settlement Amounts | Oct 2025\",\"description\":\"Oct 2, 2025 Â· C.R. Bard is defending over 18,000 hernia mesh lawsuits, which allege that its mesh devices were defective, resulting in injuries andÂ ...\",\"url\":\"https://www.lawsuit-information-center.com/bard-hernia-mesh-lawsuits.html\",\"favicon\":\"\"},{\"id\":\"75\",\"title\":\"Hernia Mesh Lawsuit Settlements \u0026 Litigation Updates | 2025\",\"description\":\"Oct 18, 2025 Â· A Davol Inc. and C.R. Bard hernia mesh lawsuit led to a $4.8 Million verdict for a Rhode Island man who underwent corrective surgeries forÂ ...\",\"url\":\"https://www.sokolovelaw.com/product-liability/medical-devices/hernia-mesh/\",\"favicon\":\"\"},{\"id\":\"76\",\"title\":\"BD agrees to settle most of its hernia mesh litigation | MedTech Dive\",\"description\":\"Oct 3, 2024 Â· In 2022, a jury ordered BD's C.R. Bard subsidiary to pay $4.8 million to a patient who alleged severe injuries from the company's VentralexÂ ...\",\"url\":\"https://www.medtechdive.com/news/BD-settlement-hernia-mesh-lawsuit/728829/\",\"favicon\":\"\"},{\"id\":\"77\",\"title\":\"Hernia Mesh Lawsuit Attorney (October Update) - Oberheiden P.C.\",\"description\":\"June 6, 2025 â€“ The Bard hernia mesh multidistrict litigation (MDL) added nearly 1,000 lawsuits in May, bringing the total number of pending lawsuits to 25,015Â ...\",\"url\":\"https://federal-lawyer.com/injury-lawsuit/hernia-mesh/\",\"favicon\":\"\"},{\"id\":\"78\",\"title\":\"Hernia Mesh Settlements [2025 Update] - King Law\",\"description\":\"Rating  4.9  (159) Oct 17, 2025 Â· We believe the average Bard hernia mesh settlement amount could be $60,000 to $100,000 in some cases. This amount could be lower or higherÂ ...Hernia Mesh Lawsuit Average... Â· Who Will Pay Out the...\",\"url\":\"https://www.robertkinglawfirm.com/personal-injury/hernia-mesh-lawsuit/hernia-mesh-settlements/\",\"favicon\":\"\"},{\"id\":\"79\",\"title\":\"Hernia Mesh Settlements | Payouts, Updates \u0026 Eligibility\",\"description\":\"In 2011, C.R. Bard agreed to pay $184 million to settle 2,600 state and federal suits over its hernia mesh patches. Legal experts specializing in hernia meshÂ ...\",\"url\":\"https://www.consumernotice.org/legal/hernia-mesh-lawsuits/settlements/\",\"favicon\":\"\"},{\"id\":\"80\",\"title\":\"Ventralex Hernia Mesh Lawsuit | Nigh Goldenberg Raso \u0026 Vaughn\",\"description\":\"Jun 26, 2023 Â· Approximately 2,500 Ventralex hernia mesh lawsuits have been filed against Bard in MDL 2846. The Ventralex is the third most common hernia meshÂ ...\",\"url\":\"https://nighgoldenberg.com/ventralex-hernia-mesh-lawsuit/\",\"favicon\":\"\"},{\"id\":\"81\",\"title\":\"Bard Composix Hernia Mesh Lawsuit | Composix E/X \u0026 L/P\",\"description\":\"Currently, Composix is one of the hernia mesh products that have sparked thousands of lawsuits against Bard Medical that are were pending as part of two massiveÂ ...\",\"url\":\"https://www.kugelherniameshclassaction.com/composix-e-x-and-l-p/\",\"favicon\":\"\"},{\"id\":\"82\",\"title\":\"Hernia Mesh Lawsuit | Settlement Info \u0026 2025 Updates - Motley Rice\",\"description\":\"October 2024: C.R. Bard approved terms of a global settlement that could resolve around 38,000 federal and state lawsuits related to its hernia mesh products.\",\"url\":\"https://www.motleyrice.com/medical-devices/hernia-mesh\",\"favicon\":\"\"},{\"id\":\"83\",\"title\":\"Hernia Mesh Lawsuit | September 2025 Settlement Update\",\"description\":\"Sep 1, 2025 Â· Hernia mesh lawsuit update for class actions. Real talk about new Bard settlement in September 2025 and future of these lawsuits.Missing:  transvaginal | Show results with:transvaginal\u003c|separator|\u003e\",\"url\":\"https://www.lawsuit-information-center.com/how-much-compensation-can-you-expect-for-a-hernia-mesh-lawsuit.html\",\"favicon\":\"\"},{\"id\":\"84\",\"title\":\"Class 1 Device Recall Davol Composix Kugel Hernia Patch\",\"description\":\"Jan 30, 2007 Â· Date Initiated by Firm, January 10, 2007. Date Posted, January 30, 2007. Recall Status, Completed. Recall Number, Z-0360-2007.Missing:  details | Show results with:details\",\"url\":\"https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfres/res.cfm?id=49722\",\"favicon\":\"\"},{\"id\":\"85\",\"title\":\"\",\"description\":\"\",\"url\":\"https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfres/res.cfm?start_search=1\u0026event_id=34393\",\"favicon\":\"\"},{\"id\":\"86\",\"title\":\"Class 1 Device Recall Bard Blakemore EsophagealNasogastric ...\",\"description\":\"May 20, 2025 Â· Class 1 Device Recall Bard Blakemore EsophagealNasogastric Tube (Adult) ; Device Design Â· On April 17, 2025, BD (C.R. Bard) Urology and CriticalÂ ...Missing:  warnings | Show results with:warnings\",\"url\":\"https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfres/res.cfm?id=213347\",\"favicon\":\"\"},{\"id\":\"87\",\"title\":\"Esophagogastric Tube Recall: BD Issues Correction for ... - FDA\",\"description\":\"May 23, 2025 Â· This recall involves updating the Instructions for using these devices and does not involve removing them from where they are used or sold.\",\"url\":\"https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/esophagogastric-tube-recall-bd-issues-correction-esophagogastric-balloon-tamponade-tubes-due\",\"favicon\":\"\"},{\"id\":\"88\",\"title\":\"Class 2 Device Recall Bard - accessdata.fda.gov\",\"description\":\"Jan 25, 2024 Â· BD (C.R. Bard) has received user complaints reporting that during use of BD Bard NG Sump Tubes with ENFit Connectors, inadequate or reducedÂ ...Missing:  warnings | Show results with:warnings\",\"url\":\"https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfres/res.cfm?id=205286\",\"favicon\":\"\"},{\"id\":\"89\",\"title\":\"Class 2 Device Recall Bard Ventralex\\\" ST Medium Circle with Strap ...\",\"description\":\"Davol Inc. issued an Urgent; Medical Device Recall letter on 10/4/11 for the mislabeled Bard Ventralex ST Medium Circle. The letter identified the affectedÂ ...Missing:  warnings | Show results with:warnings\",\"url\":\"https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfres/res.cfm?id=104352\",\"favicon\":\"\"},{\"id\":\"90\",\"title\":\"Atherectomy Catheter System Issue from Bard Peripheral Vascular\",\"description\":\"Mar 20, 2025 Â· The FDA has identified this recall as the most serious type. This device may cause serious injury or death if you continue to use it withoutÂ ...\",\"url\":\"https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/update-alert-atherectomy-catheter-system-issue-bard-peripheral-vascular\",\"favicon\":\"\"},{\"id\":\"91\",\"title\":\"Early Alert: Intravascular PICC Catheter Issue from BD - FDA\",\"description\":\"Apr 18, 2025 Â· On March 11, 2025, BD sent all affected health care providers an Urgent Medical Device Product Recall notice recommending the following actions:.\",\"url\":\"https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/early-alert-intravascular-picc-catheter-issue-bd\",\"favicon\":\"\"},{\"id\":\"92\",\"title\":\"\",\"description\":\"\",\"url\":\"https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfres/res.cfm?start_search=1\u0026event_id=93679\",\"favicon\":\"\"}],\"images\":[{\"id\":\"3de1b3a7d9cc\",\"caption\":\"C. R. Bard logo\",\"url\":\"./_assets_/Bard_logo.gif\",\"position\":\"CENTER\",\"width\":0,\"height\":0}],\"fixedIssues\":[],\"slug\":\"Bard_(company)\",\"title\":\"Bard (company)\",\"content\":\"$1f\",\"description\":\"Bard (company)\\n\\nC. R. Bard logo\\n\\nC. R. Bard, Inc. was a medical technology company specializing in the development, manufacture, and marketing of devices for vascular, urology, oncology, and surgical...\",\"metadata\":{\"categories\":[\"C. R. Bard\",\"C.R. Bard, Inc.\",\"CR Bard\",\"Bard Inc.\"],\"lastModified\":\"1761584819\",\"contentLength\":\"50941\",\"version\":\"1.0\",\"lastEditor\":\"system\",\"language\":\"en\",\"isRedirect\":false,\"redirectTarget\":\"\",\"isWithheld\":false},\"stats\":{\"totalViews\":\"18757\",\"recentViews\":\"18757\",\"dailyAvgViews\":625.2333374023438,\"qualityScore\":1,\"lastViewed\":\"1761885866\"},\"linkedPages\":null},\"found\":true},\"dataUpdateCount\":1,\"dataUpdatedAt\":1761885866791,\"error\":null,\"errorUpdateCount\":0,\"errorUpdatedAt\":0,\"fetchFailureCount\":0,\"fetchFailureReason\":null,\"fetchMeta\":null,\"isInvalidated\":false,\"status\":\"success\",\"fetchStatus\":\"idle\"},\"queryKey\":[\"page\",\"Bard_(company)\"],\"queryHash\":\"[\\\"page\\\",\\\"Bard_(company)\\\"]\"}]},\"children\":\"$L20\"}]\n"])</script><script nonce="NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh">self.__next_f.push([1,"c:{\"metadata\":[[\"$\",\"title\",\"0\",{\"children\":\"Bard (company)\"}],[\"$\",\"meta\",\"1\",{\"name\":\"description\",\"content\":\"C. R. Bard, Inc. was a medical technology company specializing in the development, manufacture, and marketing of devices for vascular, urology, oncology, and surgical applications. Founded in 1907 in Covington, Georgia, the company grew to become a leader in products such as catheters, stents, and soft tissue repair meshes, serving hospitals and healthcare professionals worldwide. Headquartered in Murray Hill, New Jersey, Bard employed over 14,000 people and generated significant revenue from...\"}],[\"$\",\"meta\",\"2\",{\"name\":\"author\",\"content\":\"system\"}],[\"$\",\"link\",\"3\",{\"rel\":\"manifest\",\"href\":\"/manifest.webmanifest\",\"crossOrigin\":\"$undefined\"}],[\"$\",\"meta\",\"4\",{\"name\":\"keywords\",\"content\":\"C. R. Bard, C.R. Bard, Inc., CR Bard, Bard Inc.\"}],[\"$\",\"meta\",\"5\",{\"name\":\"robots\",\"content\":\"index, follow\"}],[\"$\",\"meta\",\"6\",{\"name\":\"googlebot\",\"content\":\"index, follow, max-snippet:-1\"}],[\"$\",\"link\",\"7\",{\"rel\":\"canonical\",\"href\":\"https://grokipedia.com/page/Bard_(company)\"}],[\"$\",\"meta\",\"8\",{\"property\":\"og:title\",\"content\":\"Bard (company)\"}],[\"$\",\"meta\",\"9\",{\"property\":\"og:description\",\"content\":\"C. R. Bard, Inc. was a medical technology company specializing in the development, manufacture, and marketing of devices for vascular, urology, oncology, and surgical applications. Founded in 1907 in Covington, Georgia, the company grew to become a leader in products such as catheters, stents, and soft tissue repair meshes, serving hospitals and healthcare professionals worldwide. Headquartered in Murray Hill, New Jersey, Bard employed over 14,000 people and generated significant revenue from...\"}],[\"$\",\"meta\",\"10\",{\"property\":\"og:url\",\"content\":\"https://grokipedia.com/page/Bard_(company)\"}],[\"$\",\"meta\",\"11\",{\"property\":\"og:site_name\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",\"12\",{\"property\":\"og:locale\",\"content\":\"en\"}],[\"$\",\"meta\",\"13\",{\"property\":\"og:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"meta\",\"14\",{\"property\":\"og:image:width\",\"content\":\"512\"}],[\"$\",\"meta\",\"15\",{\"property\":\"og:image:height\",\"content\":\"512\"}],[\"$\",\"meta\",\"16\",{\"property\":\"og:image:alt\",\"content\":\"Bard (company)\"}],[\"$\",\"meta\",\"17\",{\"property\":\"og:type\",\"content\":\"article\"}],[\"$\",\"meta\",\"18\",{\"property\":\"article:modified_time\",\"content\":\"1970-01-21T09:19:44.819Z\"}],[\"$\",\"meta\",\"19\",{\"name\":\"twitter:card\",\"content\":\"summary\"}],[\"$\",\"meta\",\"20\",{\"name\":\"twitter:creator\",\"content\":\"@Grokipedia\"}],[\"$\",\"meta\",\"21\",{\"name\":\"twitter:title\",\"content\":\"Bard (company)\"}],[\"$\",\"meta\",\"22\",{\"name\":\"twitter:description\",\"content\":\"C. R. Bard, Inc. was a medical technology company specializing in the development, manufacture, and marketing of devices for vascular, urology, oncology, and surgical applications. Founded in 1907 in Covington, Georgia, the company grew to become a leader in products such as catheters, stents, and soft tissue repair meshes, serving hospitals and healthcare professionals worldwide. Headquartered in Murray Hill, New Jersey, Bard employed over 14,000 people and generated significant revenue from...\"}],[\"$\",\"meta\",\"23\",{\"name\":\"twitter:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"link\",\"24\",{\"rel\":\"icon\",\"href\":\"/favicon.ico\",\"type\":\"image/x-icon\",\"sizes\":\"16x16\"}],[\"$\",\"$L21\",\"25\",{}]],\"error\":null,\"digest\":\"$undefined\"}\n"])</script><script nonce="NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh">self.__next_f.push([1,"11:\"$c:metadata\"\n"])</script><script nonce="NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh">self.__next_f.push([1,"22:I[61172,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"PageEditorProvider\"]\n"])</script><script nonce="NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh">self.__next_f.push([1,"23:I[63493,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"default\"]\n"])</script><script nonce="NzliMDI2Y2MtNThlMC00ZTBhLWE1MWMtMDJmNzcxYTBjZGFh">self.__next_f.push([1,"20:[\"$\",\"$L22\",null,{\"children\":[\"$\",\"$L23\",null,{\"slug\":\"Bard_(company)\"}]}]\n"])</script></body></html>